1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Disease Models, Animal in 1164 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine if the beneficial effects of transient desflurane application mitigates inflammation and decrease associated signaling induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in mice." | 8.12 | Beneficial effect of transient desflurane inhalation on relieving inflammation and reducing signaling induced by MPTP in mice. ( Ge, Z; Li, W; Qin, G; Yu, Z, 2022) |
| " Specifically, we aimed to explore the mechanism by which puerarin prevents inflammation and apoptosis in neurocytes." | 7.83 | Puerarin prevents inflammation and apoptosis in the neurocytes of a murine Parkinson's disease model. ( Gao, Y; Jiang, M; Niu, G; Shi, F; Yu, S; Yun, Q, 2016) |
| "To investigate the use of diffusion-tensor imaging (DTI) to detect denervation of the nigrostriatal pathway in a nonhuman primate model of Parkinson disease (PD) after treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 7.81 | Parkinson Disease: Diffusion MR Imaging to Detect Nigrostriatal Pathway Loss in a Marmoset Model Treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. ( Ando, K; Hikishima, K; Inoue, T; Itoh, T; Kawai, K; Komaki, Y; Momoshima, S; Okano, H; Okano, HJ; Yamada, M; Yano, R, 2015) |
| "The angiogenic factor, angiogenin, has been recently linked to both Amyotrophic Lateral Sclerosis (ALS) and Parkinson Disease (PD)." | 7.79 | Angiogenin in Parkinson disease models: role of Akt phosphorylation and evaluation of AAV-mediated angiogenin expression in MPTP treated mice. ( Ding, H; Slone, SR; Standaert, DG; Steidinger, TU; Yacoubian, TA, 2013) |
| "The purported alpha 2-adrenergic agonist clonidine was found to inhibit rest tremor at doses of 0." | 7.68 | Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B, 1991) |
| "In the murine model of early Parkinson's disease, the balance between dopamine and 5-hydroxytryptamine systems varied among brain regions." | 5.91 | Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease. ( He, L; Huang, H; Shi, J; Xie, S; Yang, R; Yang, Y; Ye, S; Zhang, S; Zhang, Y, 2023) |
| "However, the mechanisms and treatment of pain in PD have not been well studied." | 5.72 | Dexmedetomidine alleviates pain in MPTP-treated mice by activating the AMPK/mTOR/NF-κB pathways in astrocytes. ( Chen, Y; Cheng, O; Cui, J; Li, C; Li, Y; Zhu, D, 2022) |
| "Brain bioavailability of drugs developed to address central nervous system diseases is classically documented through cerebrospinal fluid collected in normal animals, i." | 5.43 | Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease. ( Bezard, E; Contamin, H; Li, Q; Thiollier, T; Wu, C; Zhang, J, 2016) |
| "Neuroinflammation is one of the critical pathological mechanisms influencing various neurodegenerative disorders." | 5.42 | Anti-neuroinflammatory effects of DPTP, a novel synthetic clovamide derivative in in vitro and in vivo model of neuroinflammation. ( Choi, DK; Jeon, SB; Kim, BW; Lim, HW; More, SV; Park, EJ; Park, JI; Park, JY; Yoon, SH; Yun, YS, 2015) |
| "A levodopa-responsive parkinsonism emerged in all MPTP-treated monkeys." | 5.31 | Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys. ( Bioulac, B; Fernagut, PO; Ghorayeb, I; Stefanova, N; Tison, F; Wenning, GK, 2002) |
| " Using a chronic regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and probenecid (MPTP/p) in mice, dopamine cell loss exceeds 60%, extracellular glutamate is elevated, cytoplasmic inclusions are formed and inflammation is chronic." | 4.84 | Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. ( Meredith, GE; Potashkin, JA; Surmeier, DJ; Totterdell, S, 2008) |
| "To determine if the beneficial effects of transient desflurane application mitigates inflammation and decrease associated signaling induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in mice." | 4.12 | Beneficial effect of transient desflurane inhalation on relieving inflammation and reducing signaling induced by MPTP in mice. ( Ge, Z; Li, W; Qin, G; Yu, Z, 2022) |
| " The aim of this study was to investigate the effect of chronic cerebral hypoperfusion (CCH) on cognitive dysfunction, structural abnormalities of the hippocampus and white matter (WM), and levels of inflammatory cytokines in control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mouse models." | 3.91 | Hippocampal damage and white matter lesions contribute to cognitive impairment in MPTP-lesioned mice with chronic cerebral hypoperfusion. ( Feng, S; Gao, L; Gao, Y; Huang, Z; Nie, K; Tang, H; Wang, L; Zhang, Y; Zhao, J; Zhu, R, 2019) |
| " In our previous study, we have shown that brain-specific microRNA-124 (miR-124) is significantly down-regulated in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD and that it can also inhibit neuroinflammation during the development of PD." | 3.91 | MicroRNA-124 regulates the expression of p62/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinson's disease. ( Lu, G; Qian, C; Sun, X; Wang, B; Wu, J; Xie, L; Yao, L; Zhang, H; Zhang, S; Zhang, Y; Zhu, Z, 2019) |
| "The present study is to investigate the neuroprotective effect of ibuprofen by intranasal administration of mucoadhesive microemulsion (MMEI) against inflammation-mediated by dopaminergic neurodegeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease (PD)." | 3.83 | Design and evaluation of mucoadhesive microemulsion for neuroprotective effect of ibuprofen following intranasal route in the MPTP mice model. ( Chuttani, K; Mandal, S; Mandal, SD; Sawant, KK; Subudhi, BB, 2016) |
| " Specifically, we aimed to explore the mechanism by which puerarin prevents inflammation and apoptosis in neurocytes." | 3.83 | Puerarin prevents inflammation and apoptosis in the neurocytes of a murine Parkinson's disease model. ( Gao, Y; Jiang, M; Niu, G; Shi, F; Yu, S; Yun, Q, 2016) |
| "To investigate the use of diffusion-tensor imaging (DTI) to detect denervation of the nigrostriatal pathway in a nonhuman primate model of Parkinson disease (PD) after treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 3.81 | Parkinson Disease: Diffusion MR Imaging to Detect Nigrostriatal Pathway Loss in a Marmoset Model Treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. ( Ando, K; Hikishima, K; Inoue, T; Itoh, T; Kawai, K; Komaki, Y; Momoshima, S; Okano, H; Okano, HJ; Yamada, M; Yano, R, 2015) |
| "The angiogenic factor, angiogenin, has been recently linked to both Amyotrophic Lateral Sclerosis (ALS) and Parkinson Disease (PD)." | 3.79 | Angiogenin in Parkinson disease models: role of Akt phosphorylation and evaluation of AAV-mediated angiogenin expression in MPTP treated mice. ( Ding, H; Slone, SR; Standaert, DG; Steidinger, TU; Yacoubian, TA, 2013) |
| "As an index of terminal serotonin innervation density, we measured radioligand binding to the plasma membrane serotonin transporter (SERT) in levodopa-treated dyskinetic and nondyskinetic subjects, using brain tissue from both rat and monkey models of Parkinson disease as well as parkinsonian patients." | 3.76 | Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. ( Bezard, E; Cenci, MA; Descarries, L; Dovero, S; Lees, AJ; O'Sullivan, SS; Parent, M; Rylander, D, 2010) |
| "Current evidence suggests a role of neuroinflammation in the pathogenesis of Parkinson's disease (PD) and in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of basal ganglia injury." | 3.76 | Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. ( Caniglia, S; Impagnatiello, F; L'Episcopo, F; Marchetti, B; Morale, MC; Serra, PA; Testa, N; Tirolo, C, 2010) |
| " In this study, we investigated the effect as well as the molecular mechanism of geldanamycin (GA), an inhibitor of Hsp90, on 1-methyl-4-pheny-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity, a mouse model of Parkinson disease." | 3.73 | Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. ( Chen, JF; He, JC; Huang, QY; Shen, HY; Wang, Y, 2005) |
| "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is commonly used to create animal models of Parkinson disease." | 3.73 | Evidence of apoptosis in the subventricular zone and rostral migratory stream in the MPTP mouse model of Parkinson disease. ( Doi, K; Dong, M; He, XJ; Nakayama, H; Ueno, M; Uetsuka, K; Yamauchi, H, 2006) |
| "To investigate the role of the basal ganglia in parkinsonian tremor, we recorded hand tremor and simultaneous activity of several neurons in the external and internal segments of the globus pallidus (GPe and GPi) in two vervet monkeys, before and after systemic treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and development of parkinsonism with tremor of 5 and 11 Hz." | 3.70 | Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism. ( Bergman, H; Raz, A; Vaadia, E, 2000) |
| " Acidic FGF was injected stereotaxically into the striatum of young (2-month-old) and aging (12-month-old) C57BL/6 mice that were treated 1 week before with systemic injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 3.68 | MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF). ( Date, I; Felten, DL; Felten, SY; Notter, MF, 1990) |
| "The purported alpha 2-adrenergic agonist clonidine was found to inhibit rest tremor at doses of 0." | 3.68 | Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B, 1991) |
| "The long-term effect of the parkinsonism-inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central monoaminergic neurons in young (2-3 months) and aging (12 months) C57BL/6 mice has been studied using neurochemical and immunocytochemical techniques." | 3.68 | Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. ( Date, I; Felten, DL; Felten, SY, 1990) |
| "Among the popular animal models of Parkinson's disease (PD) commonly used in research are those that employ neurotoxins, especially 1-methyl- 4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)." | 2.72 | MPTP-induced mouse model of Parkinson's disease: A promising direction of therapeutic strategies. ( Mat Taib, CN; Mustapha, M, 2021) |
| "Parkinson's disease (PD) and Alzheimer's disease (AD) are the most common chronic neurodegenerative disorders, characterized by motoric dysfunction or cognitive decline in the early stage, respectively, but often by both symptoms in the advanced stage." | 2.66 | Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease. ( Barilar, JO; Homolak, J; Knezovic, A; Perhoc, AB; Riederer, P; Salkovic-Petrisic, M, 2020) |
| "Models of Parkinson's disease (PD) can be produced in several non-human primate (NHP) species by applying neurotoxic lesions to the nigrostriatal dopamine pathway." | 2.52 | Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates. ( Fox, SH; Johnston, TM, 2015) |
| "Animal models of Parkinson's disease (PD) have been widely used in the past four decades to investigate the pathogenesis and pathophysiology of this neurodegenerative disorder." | 2.48 | Animal models of Parkinson's disease. ( Armentero, MT; Blandini, F, 2012) |
| "The classical animal models of Parkinson's disease (PD) rely on the use of neurotoxins, including 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine and, more recently, the agricultural chemicals paraquat and rotenone, to deplete dopamine (DA)." | 2.46 | alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach. ( Bazzu, G; Calia, G; Debetto, P; Desole, MS; Grigoletto, J; Miele, E; Migheli, R; Puggioni, G; Rocchitta, G; Serra, PA; Spissu, Y; Zusso, M, 2010) |
| "The sex difference in Parkinson's disease, with a higher susceptibility in men, suggests a modulatory effect of sex steroids in the brain." | 2.45 | Neuroprotective actions of sex steroids in Parkinson's disease. ( Bourque, M; Di Paolo, T; Dluzen, DE, 2009) |
| "Functional models of Parkinson's disease (PD) have led to effective treatment for the motor symptoms." | 2.44 | Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. ( Jenner, P, 2008) |
| "Nonhuman primate models of Parkinson's disease (PD) have been invaluable to our understanding of the human disease and in the advancement of novel therapies for its treatment." | 2.43 | Neural repair strategies for Parkinson's disease: insights from primate models. ( Kordower, JH; O'Malley, J; Soderstrom, K; Steece-Collier, K, 2006) |
| "Current research into Parkinson's disease (PD) is directed at developing novel agents and strategies for improved symptomatic management." | 2.42 | The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. ( Jenner, P, 2003) |
| "The development of animal models of Parkinson's disease is of great importance in order to test substitutive or neuroprotective strategies for Parkinson's disease." | 2.42 | Animal models of Parkinson's disease in rodents induced by toxins: an update. ( Breidert, T; Cohen-Salmon, C; Feger, J; Hirsch, EC; Höglinger, G; Launay, JM; Parain, K; Prigent, A; Rousselet, E; Ruberg, M, 2003) |
| "One major goal of current research in Parkinson's disease (PD) is the discovery of novel agents to improve symptomatic management." | 2.42 | Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. ( Linazasoro, G, 2004) |
| "Recent genetic studies in familial Parkinson's disease and parkinsonism show several gene mutations." | 2.41 | The parkinsonian models: invertebrates to mammals. ( Akaike, A; Kitamura, Y; Shimohama, S; Taniguchi, T, 2000) |
| "The "MPTP story" hypothesizes that Parkinson's disease may be initiated or percipitated by environmental and/or endogenous toxins by a mechanism similar to that of MPTP in genetically-predisposed individuals." | 2.40 | [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease]. ( Matsubara, K, 1998) |
| "The cause of Parkinson's disease (PD) is unknown, but reduced activity of complex I of the electron-transport chain has been implicated in the pathogenesis of both mitochondrial permeability transition pore-induced Parkinsonism and idiopathic PD." | 2.40 | Mitochondrial dysfunction in Parkinson's disease. ( Greenamyre, JT; MacKenzie, G; Peng, TI; Stephans, SE, 1999) |
| "Parkinsonism was induced by injections of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.91 | Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model. ( Huang, CW; Ker, MD; Lin, HC; Wu, YH, 2023) |
| "Cordycepin has been reported to alleviate cognitive impairments in neurodegenerative diseases." | 1.91 | Cordycepin improved the cognitive function through regulating adenosine A ( Han, YY; Huang, SY; Li, CH; Liu, L; Mai, ZF; Shang, YJ; Su, ZY; Zeng, ZW, 2023) |
| "Causes of dopaminergic neuronal loss in Parkinson's disease (PD) are subject of investigation and the common use of models of acute neurodegeneration induced by neurotoxins 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine, and rotenone contributed to advances in the study of PD." | 1.91 | Protective Effects of Flavonoid Rutin Against Aminochrome Neurotoxicity. ( Costa, ACS; Costa, SL; Cuenca-Bermejo, L; De Araújo, FM; de Fatima Dias Costa, M; de Jesus, LB; Farias, AA; Ferreira, KMS; Frota, AF; Herrero, MT; Menezes-Filho, JA; Munoz, P; Sanches, FS; Santos, CC; Segura-Aguilar, J; Silva, VDA; Soares, EN; Souza, JT, 2023) |
| "Methods: To create a cell model of Parkinson's disease, MPTP (2500 μmol/L) was administered to rat adrenal pheochromocytoma cells (PC-12) to produce an MPTP group." | 1.91 | Effect of Eleutheroside E on an MPTP-Induced Parkinson's Disease Cell Model and Its Mechanism. ( Liang, L; Liao, C; Meng, F; Qiu, H; Wu, L; Yao, Y; Zheng, W, 2023) |
| "Morin is a flavonoid that can be isolated from fruits like mulberry." | 1.91 | Morin exhibits a neuroprotective effect in MPTP-induced Parkinson's disease model via TFEB/AMPK-mediated mitophagy. ( Chen, G; Cui, J; Huang, J; Li, D; Ran, S; Wang, Z, 2023) |
| "The effects of FGF21 on Parkinson's disease (PD) and its relationship with gut microbiota have not been elucidated." | 1.91 | Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis. ( Deng, P; Gao, H; Li, C; Wang, W; Wang, X; Yang, C; Zhao, L; Zhu, L, 2023) |
| "In the murine model of early Parkinson's disease, the balance between dopamine and 5-hydroxytryptamine systems varied among brain regions." | 1.91 | Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease. ( He, L; Huang, H; Shi, J; Xie, S; Yang, R; Yang, Y; Ye, S; Zhang, S; Zhang, Y, 2023) |
| "Chlorogenic acid (CGA) is a phenolic compound appearing in coffee, honeysuckle, and eucommia that showed their potential as antioxidants and neuroprotectors." | 1.91 | Neuroprotective effect of chlorogenic acid on Parkinson's disease like symptoms through boosting the autophagy in zebrafish. ( Finiuk, N; Gao, X; Jin, M; Liu, K; Liu, X; Rostyslav, P; Sik, A; Stoika, R; Zhang, B; Zheng, Y, 2023) |
| "Our primate model of parkinsonism recapitulates important pathologic features in nature PD and provides an unbiased view of the axis of neuronal vulnerability and resistance." | 1.91 | A primate nigrostriatal atlas of neuronal vulnerability and resilience in a model of Parkinson's disease. ( Hao, ZZ; Huang, M; Li, Y; Liu, R; Liu, S; Liu, X; Sang, X; Shao, M; Shen, Y; Tang, L; Xu, C; Xu, N; Yi, W; Yue, F, 2023) |
| "Although the etiology of Parkinson's disease (PD) is poorly understood, studies in animal models revealed loss of dopamine and the dopaminergic neurons harbouring the neurotransmitter to be the principal cause behind this neuro-motor disorder." | 1.72 | Garcinol blocks motor behavioural deficits by providing dopaminergic neuroprotection in MPTP mouse model of Parkinson's disease: involvement of anti-inflammatory response. ( Bhattacharya, P; Borah, A; Chetia Phukan, B; Deb, S; Dutta, A; Mazumder, MK; Paul, R; Saikia, R; Sandhir, R, 2022) |
| "In addition to motor dysfunction, cognitive impairments have been reported to occur in patients with early-stage Parkinson's disease (PD)." | 1.72 | Asparagine endopeptidase deletion ameliorates cognitive impairments by inhibiting proinflammatory microglial activation in MPTP mouse model of Parkinson disease. ( Chai, X; Gao, J; Tan, X; Yang, Z; Zhang, W, 2022) |
| "Atractylon treatment increased the eGFP expression in dose-dependent manner in piggyBac-TANGO assay, decreased cAMP production, and enhanced the levels of p-CREB and BDNF in DRD2 highly expresseding SY-SY5Y cells." | 1.72 | Atractylon, a novel dopamine 2 receptor agonist, ameliorates Parkinsonian like motor dysfunctions in MPTP-induced mice. ( Fan, S; Feng, Y; Huang, C; Jiang, X; Li, F; Li, H; Liu, C; Wang, F; Wu, X; Zhang, Y; Zhou, Z, 2022) |
| "Current stem cell therapies for Parkinson's disease (PD) focus on a neurorestorative approach that aims to repair the CNS during the symptomatic phase." | 1.72 | Reduced dopaminergic neuron degeneration and global transcriptional changes in Parkinson's disease mouse brains engrafted with human neural stems during the early disease stage. ( Boese, AC; Hamblin, MH; Lee, JP; Murad, R; Pereira, MCL; Yin, J, 2022) |
| "Animal models of Parkinson's disease were built according to MPTP administration." | 1.72 | Effect of Different MPTP Administration Intervals on Mouse Models of Parkinson's Disease. ( Ma, Y; Rong, Q, 2022) |
| " Chronic administration of CP690550 (3 and 10 mg/kg, po) for 7 days significantly reversed the behavioural, biochemical and histological alterations induced by MPTP." | 1.72 | Protective Effect of CP690550 in MPTP-Induced Parkinson's Like Behavioural, Biochemical and Histological Alterations in Mice. ( Albekairi, NA; Albekairi, TH; Alharbi, M; Alharbi, OO; Alshammari, A; Singh, S; Yeapuri, P, 2022) |
| "The incidence of Parkinson's disease (PD) has increased tremendously, especially in the aged population and people with metabolic dysfunction; however, its underlying molecular mechanisms remain unclear." | 1.72 | Neuronal SH2B1 attenuates apoptosis in an MPTP mouse model of Parkinson's disease via promoting PLIN4 degradation. ( Dai, Y; Han, X; Hu, G; Hu, J; Hu, Q; Liu, Y; Rui, L; Xu, T; Yi, X, 2022) |
| "In the context of Parkinson's disease (PD), the sensitivity of dopaminergic neurons in the substantia nigra pars compacta to oxidative stress is considered a key factor of PD pathogenesis." | 1.72 | Human IPSC 3D brain model as a tool to study chemical-induced dopaminergic neuronal toxicity. ( Burtscher, J; Harris, G; Hartung, T; Hogberg, HT; Katt, ME; Pamies, D; Searson, PC; Smirnova, L; Wiersma, D; Zhao, L, 2022) |
| "Mangiferin (MGF) is a glucosyl xanthone mainly derived from Mangifera indica L." | 1.72 | Mangiferin, a natural glucoxilxanthone, inhibits mitochondrial dynamin-related protein 1 and relieves aberrant mitophagic proteins in mice model of Parkinson's disease. ( Chen, NH; Feng, ST; Guo, ZY; Wang, XL; Wang, YT; Wang, ZZ; Yan, X; Yuan, YH; Zhang, NN; Zhang, Y, 2022) |
| "Inflammasome involvement in Parkinson's disease (PD) has been intensively investigated." | 1.72 | Microglial AIM2 alleviates antiviral-related neuro-inflammation in mouse models of Parkinson's disease. ( Fan, Y; Hu, YC; Li, S; Liu, Y; Ma, CM; Rui, WJ; Shi, JP; Wang, BW; Yang, L, 2022) |
| "Curcumin (CUR) has been reported to provide neuroprotective effects on neurological disorders and modulate the gut flora in intestinal-related diseases." | 1.72 | Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease. ( Cui, C; Han, Y; Li, G; Li, H; Yu, H; Zhang, B, 2022) |
| "Shikonin plays protective roles in age-associated diseases." | 1.72 | Shikonin ameliorates oxidative stress and neuroinflammation via the Akt/ERK/JNK/NF-κB signalling pathways in a model of Parkinson's disease. ( Du, J; Guo, L; Li, W; Li, Y; Qiu, J; Wang, L; Zhang, T, 2022) |
| "Neurodegenerative diseases such as Parkinson's disease (PD) are known to be related to oxidative stress and neuroinflammation, and thus, modulating neuroinflammation offers a possible means of treating PD-associated pathologies." | 1.72 | Anti-Inflammatory and Neuroprotective Effects of Morin in an MPTP-Induced Parkinson's Disease Model. ( Ahn, J; Chang, SC; Ha, NC; Hong, DG; Kim, J; Lee, H; Lee, J; Lee, M; Lee, S; Yang, S, 2022) |
| " We administered a single dosage of MPTP (200μg/g bw) via intraperitoneal injection (i/p) and assessed the locomotor activity and swimming pattern at 0h, 24h, and 96h post-injection through an open field test." | 1.72 | Characterization of neurobehavioral pattern in a zebrafish 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model: A 96-hour behavioral study. ( Doolaanea, AA; Kumar, J; Mohamed, WMY; Mohd Nasir, MH; Nabeel Ibrahim, W; Othman, N; Razali, K, 2022) |
| "Research has connected Parkinson's disease (PD) with impaired intestinal barrier." | 1.72 | Neuroprotective Effects of Sodium Butyrate and Monomethyl Fumarate Treatment through GPR109A Modulation and Intestinal Barrier Restoration on PD Mice. ( Ding, ST; Jian, YX; Lei, YH; Liu, HD; Liu, MR; Miao, WT; Xu, JY; Xu, RC; Xu, WX; Yan, N, 2022) |
| "However, the mechanisms and treatment of pain in PD have not been well studied." | 1.72 | Dexmedetomidine alleviates pain in MPTP-treated mice by activating the AMPK/mTOR/NF-κB pathways in astrocytes. ( Chen, Y; Cheng, O; Cui, J; Li, C; Li, Y; Zhu, D, 2022) |
| "We first confirmed that synucleinopathies existed in the stomachs of chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/probenecid (MPTP/p)-induced PD mice, as indicated by the significant increase in abnormal aggregated and nitrated α-synuclein in the TH-positive neurons and enteric glial cells (EGCs) of the gastric myenteric plexus." | 1.72 | Gastric Enteric Glial Cells: A New Contributor to the Synucleinopathies in the MPTP-Induced Parkinsonism Mouse. ( Chen, NH; Heng, Y; Li, YY; Wen, L; Yan, JQ; Yuan, YH, 2022) |
| "Epimedin B treatment ameliorated MPTP-induced motor dysfunction and alleviated the decreased contents of DA with its metabolites in the striatum and the loss of tyrosine hydroxylase-immunoreactive (TH-IR) neurons in the substantial nigra pars compacta (SNpc)." | 1.72 | Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target. ( Chen, WF; Dong, XL; Hu, ZF; Zhang, M, 2022) |
| "Morphine is an opioid pain killer and a strong analgesic that is used to treat chronic pain." | 1.72 | Morphine attenuates neurotoxic effects of MPTP in zebrafish embryos by regulating oxidant/antioxidant balance and acetylcholinesterase activity. ( Alturfan, AA; Cansız, D; Emekli-Alturfan, E; Unal, I; Ustundag, UV, 2022) |
| "The main neuropathological feature of Parkinson's disease (PD) is degeneration of dopamine (DA) neurons in the substantia nigra (SN); PD prevalence is higher in men, suggesting a role of sex hormones in neuroprotection." | 1.62 | Effect of sex and gonadectomy on brain MPTP toxicity and response to dutasteride treatment in mice. ( Bourque, M; Coulombe, K; Di Paolo, T; Isenbrandt, A; Lamontagne-Proulx, J; Morissette, M; Soulet, D, 2021) |
| "Heterogenous diseases such as Parkinson's disease (PD) needs an efficient animal model to enhance understanding of the underlying mechanisms and to develop therapeutics." | 1.62 | Impaired mitochondrial functions and energy metabolism in MPTP-induced Parkinson's disease: comparison of mice strains and dose regimens. ( Garg, P; Pathania, A; Sandhir, R, 2021) |
| "Depression was induced by a 14-day chronic unpredictable mild stress (CUMS), and PD was induced by 1-day acute injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.62 | Depression Induced by Chronic Unpredictable Mild Stress Increases Susceptibility to Parkinson's Disease in Mice via Neuroinflammation Mediated by P2X7 Receptor. ( Dong, AQ; Hu, H; Li, LX; Liu, CF; Mao, CJ; Ren, C; Wang, F; Zhang, YT, 2021) |
| "Simvastatin has been touted as a potential neuroprotective agent for neurologic disorders such as PD, but the specific underlying mechanism remains unclear." | 1.62 | Simvastatin Prevents Neurodegeneration in the MPTP Mouse Model of Parkinson's Disease via Inhibition of A1 Reactive Astrocytes. ( Bu, WG; Du, RW, 2021) |
| "Prucalopride treatment also ameliorated intestinal barrier impairment and increased IL-6 release in PD model mice." | 1.62 | Protective effects of prucalopride in MPTP-induced Parkinson's disease mice: Neurochemistry, motor function and gut barrier. ( Cui, C; Hong, H; Huang, SB; Jia, XB; Qiao, CM; Shen, YQ; Shi, Y; Wu, J; Yao, L; Zhao, WJ; Zhou, Y, 2021) |
| "The aetiology of PD psychosis is multifactorial and likely arises from the complex interaction between dopamine replacement therapy and disease state." | 1.62 | Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset. ( Gourdon, JC; Huot, P; Kwan, C; Nuara, SG, 2021) |
| "Parkinson's disease is the second most common neurodegenerative disease." | 1.62 | The neuroprotective effects of isoquercitrin purified from apple pomace by high-speed countercurrent chromatography in the MPTP acute mouse model of Parkinson's disease. ( Cheng, Y; Hu, Y; Li, H; Liu, C; Liu, J; Qin, X; Wang, W; Wei, Y; Zhang, P, 2021) |
| "(R)-ketamine has greater and longer-lasting antidepressant effects than (S)-ketamine in animal models of depression." | 1.56 | MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling. ( Chang, L; Fujita, A; Fujita, Y; Hashimoto, K; Pu, Y, 2020) |
| "A moving tremor was also observed by visual inspection during this period." | 1.56 | Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious precl ( Ando, K; Hikishima, K; Inoue, R; Inoue, T; Kawai, K; Komaki, Y; Nishime, C; Nishinaka, E; Okano, H; Urano, K, 2020) |
| "Dopaminergic cell loss in Parkinson's disease (PD) leads to NMDAR dysregulation in the cortico-striato-pallidal-thalmo-cortical network and altered plasticity in brain regions important to cognitive function." | 1.56 | NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model. ( Barth, AL; Brotchie, JM; Cearley, CN; Hill, MP; Johnston, TH; Moskal, JR; Schneider, JS, 2020) |
| "Simvastatin can play a positive role in Parkinson's disease." | 1.56 | Simvastatin Improves Behavioral Disorders and Hippocampal Inflammatory Reaction by NMDA-Mediated Anti-inflammatory Function in MPTP-Treated Mice. ( Fan, H; Huang, J; Lai, X; Liu, A; Qiao, L; Shen, M; Wu, J; Yan, J, 2020) |
| " The results indicated that the chronic administration of either DHM or PRE-084 attenuated the Dicer cKO-induced loss of DA neurons and motor impairments, although the two drugs acted through different mechanisms." | 1.56 | Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin. ( Cao, T; Guo, CH; Waddington, JL; Zhen, XC; Zheng, LT, 2020) |
| "The main symptom of Parkinson's disease (PD) is motor dysfunction and remarkably approximately 30-40% of PD patients exhibit cognitive impairments." | 1.56 | Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice. ( Fukunaga, K; Haga, H; Izumi, H; Kawahata, I; Miyachi, H; Shinoda, Y; Yamada, R, 2020) |
| "Clioquinol (CQ) has been shown to have therapeutic benefits in rodent models of neurodegenerative disorders." | 1.56 | Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson's disease through AKT/mTOR pathway. ( Cheng, A; Huang, C; Liu, W; Luo, Q; Shi, L; Shi, R; Xia, Y; Zeng, W; Zhengli, C, 2020) |
| "Moclobemide significantly reversed parkinsonism (by 39%, P < 0." | 1.56 | Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset. ( Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG, 2020) |
| "This reduction of parkinsonism was not accompanied by an exacerbation of dyskinesia or PLBs." | 1.56 | Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset. ( Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG, 2020) |
| "Evidence suggests that the Parkinson's disease (PD) pathogenesis is strongly associated with bidirectional pathways in the microbiota-gut-brain axis (MGBA), and psychobiotics may inhibit PD progression." | 1.56 | Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models of Parkinson's disease. ( Cheng, YF; Chiou, JJ; Hsieh-Li, HM; Hsu, CC; Huang, CW; Kuo, WC; Liao, JF; Tsai, YC; Wang, S; You, ST, 2020) |
| "Genetic susceptibility is a strong risk factor for PD." | 1.56 | Functional validation of a human GLUD2 variant in a murine model of Parkinson's disease. ( Chen, X; Ding, L; Gao, F; Gong, J; Guo, W; Li, Y; Lin, Y; Pan, X; Peng, G; Sun, X; Wang, S; Xu, P; Xuan, A; Yang, X; Zhang, W; Zhang, X; Zhang, Y; Zhang, Z; Zhu, X, 2020) |
| " Mice were put on the subacute dosing regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), producing bilateral degeneration of the nigrostriatal pathway consistent with early-stage PD." | 1.51 | Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson's disease mouse model. ( Jackson-Lewis, V; Ji, R; Karakatsani, ME; Konofagou, EE; Murillo, MF; Niimi, Y; Przedborski, S; Smith, M, 2019) |
| "A major hallmark of Parkinson's disease (PD) is the degeneration of dopaminergic neurons in the substantia nigra, and the causative mechanism is thought to be the activation of programmed neuronal death." | 1.51 | miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson's disease. ( Chen, HZ; Cheng, Q; Cui, HL; Hu, YB; Huang, WY; Ren, RJ; Wang, G; Wang, H; Zhang, YF, 2019) |
| "More than 90% of the cases of Parkinson's disease have unknown etiology." | 1.48 | Targeted deletion of the aquaglyceroporin AQP9 is protective in a mouse model of Parkinson's disease. ( Amiry-Moghaddam, M; Berg, T; Leergaard, TB; MacAulay, N; Mylonakou, MN; Ottersen, OP; Paulsen, RE; Prydz, A; Rahmani, S; Skare, Ø; Skauli, N; Stahl, K; Torp, R, 2018) |
| "Amplified inflammation is important for the progression of Parkinson's disease (PD)." | 1.48 | JNK-mediated microglial DICER degradation potentiates inflammatory responses to induce dopaminergic neuron loss. ( Chen, Y; He, Q; Shao, W; Wang, Q; Wang, Y; Yuan, C, 2018) |
| "The nonhuman primate model of Parkinson's disease emulates the cardinal symptoms of the disease, including tremor, rigidity, bradykinesia, postural instability, freezing and cognitive impairment." | 1.48 | Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson's disease. ( Choudhury, GR; Daadi, MM, 2018) |
| "Patients with Parkinson's disease (PD) often have non-motor symptoms related to gastrointestinal (GI) dysfunction, such as constipation and delayed gastric emptying, which manifest prior to the motor symptoms of PD." | 1.48 | Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease. ( Bai, Q; Gao, J; Jia, Y; Jiang, R; Lai, F; Liu, X; Tang, Y; Xiao, H; Xie, W, 2018) |
| "The pathological alterations of Parkinson's disease (PD) predominantly manifest as a loss of dopaminergic neurons in the substantia nigra, which may be caused by oxidative stress damage." | 1.48 | Proanthocyanidins exert a neuroprotective effect via ROS/JNK signaling in MPTP‑induced Parkinson's disease models in vitro and in vivo. ( Chen, H; He, P; Jiao, J; Li, S; Liu, C; Lv, Y; Mao, X; Xu, J; Xue, X, 2018) |
| "Parkinson's disease is characterized by progressive death of dopaminergic neurons, leading to motor and cognitive dysfunction." | 1.48 | Nicotine promotes neuron survival and partially protects from Parkinson's disease by suppressing SIRT6. ( Bender, CA; Francisco, AB; Glorioso, C; Libert, S; Lugay, FJ; Nicholatos, JW; Salazar, JE; Yeh, T, 2018) |
| " Daily therapeutic dosing of these metalloporphyrins were well tolerated without accumulation of brain manganese levels or behavioral alterations assessed by open field and rotarod tests." | 1.46 | Pre-clinical therapeutic development of a series of metalloporphyrins for Parkinson's disease. ( Day, BJ; Fulton, R; Huang, J; Liang, LP; Patel, M; Pearson-Smith, JN, 2017) |
| "Cognitive impairment often occurs in Parkinson's disease (PD), but the mechanism of onset remains unknown." | 1.46 | Rolipram improves facilitation of contextual fear extinction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. ( Ishii, T; Kinoshita, KI; Muroi, Y; Unno, T, 2017) |
| "Treatment with isradipine prevented against MPP+-induced iron influx in the MES23." | 1.46 | Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice. ( Liu, S; Ma, ZG; Wang, QM; Xu, YY, 2017) |
| "Melanoma is strongly tied to red hair/fair skin, a phenotype of loss-of-function polymorphisms in the MC1R (melanocortin 1 receptor) gene." | 1.46 | The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival. ( Cai, W; Chen, H; Chen, X; Fisher, DE; Li, H; Logan, R; Maguire, M; Robinson, K; Schwarzschild, MA; Vanderburg, CR; Wang, Y; Ya, B; Yu, Y; Zuo, F, 2017) |
| " We recently demonstrated 30-40% neuronal loss in the LC, A5 and A6 NE cell groups of rhesus monkeys rendered parkinsonian by chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.46 | Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys. ( Groover, O; Masilamoni, GJ; Smith, Y, 2017) |
| "Isobavachalcone is a main component of Chinese herb medicine Psoralea corylifolia, which function includes immunoregulation, anti-oxidation and the regulation of β-amyloid (Aβ42) deposited in hippocampus in Alzheimer's patients." | 1.46 | Isobavachalcone Attenuates MPTP-Induced Parkinson's Disease in Mice by Inhibition of Microglial Activation through NF-κB Pathway. ( Fu, W; Jing, H; Wang, M; Wang, S; Xu, D; Zhang, C, 2017) |
| "Hypercholesterolemia is a known contributor to the pathogenesis of Alzheimer's disease while its role in the occurrence of Parkinson's disease (PD) is only conjecture and far from conclusive." | 1.46 | Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress. ( Borah, A; Choudhury, A; Giri, A; Kumar, S; Paul, R; Sandhir, R, 2017) |
| "Icariin pretreatment could ameliorate the decreased striatum DA content and the loss of TH-IR neurons in the SNpc induced by MPTP." | 1.46 | Neuroprotective properties of icariin in MPTP-induced mouse model of Parkinson's disease: Involvement of PI3K/Akt and MEK/ERK signaling pathways. ( Chen, L; Chen, WF; Chen, XH; Du, ZR; Teng, JJ; Wong, MS; Wu, L; Xu, AL, 2017) |
| " Mice were treated with four intraperitoneal injections for every 2 h with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) at the dosage of 14 mg/kg b." | 1.43 | Effect of monocrotophos, an organophosphorus insecticide, on the striatal dopaminergic system in a mouse model of Parkinson's disease. ( Ali, SJ; Rajini, PS, 2016) |
| "Brain bioavailability of drugs developed to address central nervous system diseases is classically documented through cerebrospinal fluid collected in normal animals, i." | 1.43 | Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease. ( Bezard, E; Contamin, H; Li, Q; Thiollier, T; Wu, C; Zhang, J, 2016) |
| "Although the initial events of sporadic Parkinson's disease (PD) are not known, consistent evidence supports the hypothesis that the disease results from the combined effect of genetic and environmental risk factors." | 1.43 | Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson's disease. ( Di Meco, A; Lauretti, E; Merali, S; Praticò, D, 2016) |
| "Neuroinflammation is implicated for dopaminergic neurodegeneration." | 1.43 | Inhibitory effect of thiacremonone on MPTP-induced dopaminergic neurodegeneration through inhibition of p38 activation. ( Choi, DY; Han, SB; Hong, JT; Hwang, CJ; Hwang, DY; Jeong, HS; Kim, SY; Kim, TH; Kim, YM; Lee, HJ; Lee, HP; Lee, TH; Moon, DB; Oh, KW; Park, SS, 2016) |
| "Paeonol treatment decreased MPTP/p‑induced oxidative stress, as determined by evaluating the activity levels of superoxide dismutase, catalase and glutathione." | 1.43 | Therapeutic effects of paeonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson's disease in mice. ( Chen, YH; Liu, H; Qu, HD; Shi, X, 2016) |
| "Neuroinflammation is one of the critical pathological mechanisms influencing various neurodegenerative disorders." | 1.42 | Anti-neuroinflammatory effects of DPTP, a novel synthetic clovamide derivative in in vitro and in vivo model of neuroinflammation. ( Choi, DK; Jeon, SB; Kim, BW; Lim, HW; More, SV; Park, EJ; Park, JI; Park, JY; Yoon, SH; Yun, YS, 2015) |
| "Tanshinone I could also inhibit LPS-induced NF-κB activation in microglia." | 1.42 | Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease. ( Chai, L; Guo, H; Hu, L; Jing, H; Liu, Z; Wang, S; Yang, H, 2015) |
| "Chronic Parkinsonism was induced in the PD group using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and probenecid (MPTP/p)." | 1.42 | Apoptotic Mediators are Upregulated in the Skeletal Muscle of Chronic/Progressive Mouse Model of Parkinson's Disease. ( Erekat, NS, 2015) |
| "Levodopa treatment increased the specific binding of NMDA receptors in the basal ganglia." | 1.42 | Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy. ( Di Paolo, T; Grégoire, L; Jourdain, VA; Morin, N; Morissette, M, 2015) |
| "Gaucher disease is an autosomal recessive disease, caused by a lack or functional deficiency of the lysosomal enzyme, glucocerebrosidase (GCase)." | 1.42 | Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease. ( Alvarez-Fischer, D; Andreas, H; Hirsch, EC; Höglinger, GU; Höllerhage, M; Lu, L; Noelker, C; Oertel, WH; Roscher, R; Sturn, A; Vulinovic, F, 2015) |
| "Geniposide treatment (100mg/kg ip." | 1.42 | Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease. ( Chen, Y; Hölscher, C; Li, L; Zhang, Y, 2015) |
| "Piperine (10 mg/kg) was administered orally for 15 days including 8 days of pretreatment." | 1.42 | Neuroprotective effects of piperine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease mouse model. ( Chen, YH; Liu, H; Qu, HD; Yang, W, 2015) |
| "Although anti-Parkinson's disease activity of puerarin was reported in both of in vivo and in vitro model, detailed mechanisms are not clarified." | 1.40 | Neuroprotective effects of puerarin on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease model in mice. ( Li, Q; Li, X; Wang, X; Wu, S; Zhu, G, 2014) |
| " Silymarin treatment showed a non-monotonic dose-response curve and only 50 and 100mg/kg doses preserved dopamine levels (62% and 69%, respectively) after MPTP intoxication." | 1.40 | Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease. ( Carrillo-S, C; Chavarría, A; García, E; Pérez-H, J; Pérez-Tamayo, R; Ruiz-Mar, G, 2014) |
| "In an MPTP-treated animal model of Parkinson's disease, MSC administration significantly increased final maturation of late autophagic vacuoles, fusion with lysosomes." | 1.40 | Neuroprotective effects of mesenchymal stem cells through autophagy modulation in a parkinsonian model. ( Kim, HN; Lee, PH; Oh, SH; Park, HJ; Shin, JY, 2014) |
| "Tetramethylpyrazine (TMP) is a biological component that has been extracted from Ligusticum wallichii Franchat (ChuanXiong), which exhibits anti-apoptotic and antioxidant roles." | 1.40 | Neuroprotective effects of tetramethylpyrazine against dopaminergic neuron injury in a rat model of Parkinson's disease induced by MPTP. ( Bi, L; Lu, C; Miao, Q; Miao, S; Shi, X; Wang, S; Xie, Y; Yang, Q; Zhang, J; Zhang, M; Zhang, S; Zhou, X, 2014) |
| "c-Abl is activated in the brain of Parkinson's disease (PD) patients and in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated mice where it inhibits parkin through tyrosine phosphorylation leading to the accumulation of parkin substrates, and neuronal cell death." | 1.40 | The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. ( Brahmachari, S; Dawson, TM; Dawson, VL; Karuppagounder, SS; Ko, HS; Lee, Y, 2014) |
| "Calpain-p25-mediated increase in cdk5 expression leading to dopaminergic neuronal death has been demonstrated in human PD and MPTP-PD models." | 1.40 | Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins. ( Beiping, H; Dheen, ST; Kanagaraj, N; Tay, SS, 2014) |
| "In this model, motor parkinsonism correlates well with the loss of nigral dopaminergic cell bodies but only correlates with in vitro measures of nigrostriatal terminal fields when nigral cell loss does not exceed 50%." | 1.40 | In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment. ( Brown, CA; Karimi, M; Loftin, SK; Perlmutter, JS; Tian, L, 2014) |
| "A goldfish (Carassius auratus) model of Parkinson's disease (PD) was constructed by a single dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) according to previously reported methods." | 1.40 | (1)H NMR-based metabolomics study on a goldfish model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Kong, L; Li, M; Liu, Q; Lu, Z; Wang, J; Wei, D; Yang, M, 2014) |
| " Intranasal drug administration may be useful for Parkinson's treatment because this route avoids first-pass metabolism and increases bioavailability in the brain." | 1.39 | Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice. ( Chen, JC; Hsieh, YT; Kuo, YH; Lao, CL, 2013) |
| " Three common dosing regimens of the MPTP-induced mice model of PD were compared on dopaminergic neurotransmission and serotonin levels in various brain regions." | 1.39 | Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease. ( Bodard, S; Chalon, S; Gochard, A; Gulhan, Z; Pain, S; Prunier-Aesch, C, 2013) |
| "The development of dyskinesias following chronic L-DOPA replacement therapy remains a major problem in the long-term treatment of Parkinson's disease." | 1.39 | IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. ( Aron Badin, R; Auguet, M; Bertrand, A; Boulet, S; Brouillet, E; Chabrier, PE; Dollé, F; Gaillard, MC; Guillermier, M; Hantraye, P; Jan, C; Malgorn, C; Savasta, M; Spinnewyn, B; Van Camp, N, 2013) |
| "Treatment with asiaticoside was found to protect dopaminergic neuron by antagonizing MPTP induced neurotoxicity and to improve locomotor dysfunction." | 1.38 | Asiaticoside: attenuation of neurotoxicity induced by MPTP in a rat model of Parkinsonism via maintaining redox balance and up-regulating the ratio of Bcl-2/Bax. ( Deng, JM; Li, LF; Li, XM; Ma, SP; Sun, LM; Wang, QZ; Xu, CL; Xu, R; Zhang, J, 2012) |
| "Thus, homologous parkinsonism-related metabolic networks are demonstrable in PD patients and in monkeys with experimental parkinsonism." | 1.38 | Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism. ( Doudet, DJ; Eidelberg, D; Ma, Y; Peng, S; Sossi, V; Spetsieris, PG, 2012) |
| "Neurodegenerative disorders such as Parkinson's disease (PD) often exhibit significant declines in PUFAs." | 1.38 | Docosahexaenoic acid provides protective mechanism in bilaterally MPTP-lesioned rat model of Parkinson's disease. ( Agar, A; Balkan, S; Hacioglu, G; Ozsoy, O; Saka-Topcuoglu, E; Seval-Celik, Y; Tanriover, G, 2012) |
| "The marmoset shows prominent Parkinson's disease (PD) signs due to dopaminergic neural degeneration." | 1.38 | PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease. ( Ando, K; Higuchi, M; Inoue, T; Itoh, T; Minamimoto, T; Nagai, Y; Obayashi, S; Oh-Nishi, A; Suhara, T, 2012) |
| "Parkinson's disease is a neurodegenerative disorder that can, at least partly, be mimicked by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine." | 1.38 | S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway. ( Berg, D; Fleckenstein, C; Itohara, S; Lang, JD; Maetzler, W; Martin, HL; Mounsey, RB; Mustafa, S; Sathe, K; Schulte, C; Synofzik, M; Teismann, P; Vukovic, Z, 2012) |
| "Parkinson's disease is characterized by motor deficits caused by loss of midbrain dopaminergic neurons." | 1.37 | Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease. ( Andersson, A; Dannaeus, K; Delfani, K; Di Monte, DA; Haegerstrand, A; Häggblad, J; Hill, MP; Isacson, R; Janson Lang, AM; McCormack, AL; Nielsen, E; Palmer, T; Patrone, C; Rönnholm, H; Wikstrom, L; Zachrisson, O; Zhao, M, 2011) |
| "Hydrogen sulfide (H(2)S) has been shown to protect neurons." | 1.37 | Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson's disease. ( Ichinose, F; Kakinohana, M; Kaneki, M; Kida, K; Marutani, E; Tokuda, K; Yamada, M, 2011) |
| "In a mouse model of MPTP-induced Parkinson's disease (PD), AQP4-deficient animals show more robust microglial inflammatory responses and more severe loss of dopaminergic neurons (DNs) compared with WT mice." | 1.37 | Novel role of aquaporin-4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson's disease. ( Chi, Y; Fan, Y; He, L; Hu, G; Kong, H; Li, CJ; Liu, W; Sonoda, L; Su, C; Tripathi, P; Wang, X; Wen, X; Yu, MS; Zhang, C; Zhou, S, 2011) |
| "Neuroinflammation is implicated in the progression of numerous disease states of the CNS, but early inflammatory signaling events in glial cells that may predispose neurons to injury are not easily characterized in vivo." | 1.37 | Low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor-κB reporter mice prior to loss of dopaminergic neurons. ( Bialecki, RA; Miller, JA; Roberts, RA; Sullivan, KA; Tjalkens, RB; Trout, BR, 2011) |
| "The clinical stage of Parkinson's disease begins after this period." | 1.37 | Experimental modeling of preclinical and clinical stages of Parkinson's disease. ( Bocharov, EV; Khaindrava, VG; Klodt, PD; Kozina, EA; Kryzhanovsky, GN; Kucheryanu, VG; Kudrin, VS; Nanaev, AK; Narkevich, VB; Raevskii, KS; Ugrumov, MV, 2011) |
| "Posttreatment with benzamide also attenuated MPTP neurotoxicity in mice." | 1.36 | Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. ( Araki, T; Kato, H; Kuroiwa, H; Tsukada, T; Uchida, H; Yokoyama, H, 2010) |
| "Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder of mature and older individuals." | 1.36 | Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. ( Charlton, CG; King, J; Mackey, V; Muthian, G, 2010) |
| "Depression is a frequently encountered non-motor feature of Parkinson's disease (PD) and it can have a significant impact on patient's quality of life." | 1.36 | Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. ( Andreatini, R; Barbieiro, J; Dombrowski, PA; Lima, MM; Santiago, RM; Vital, MA, 2010) |
| "In the mouse Parkinson's disease model, treatment with Yi-Gan San also significantly improved motor functioning and prevented dopaminergic loss related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine challenge." | 1.36 | Neuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxicity in vitro and in vivo. ( Cho, KH; Doo, AR; Eun-Kyung, K; Hong, J; Jung, JH; Jung, WS; Kim, SN; Lee, H; Moon, SK; Park, HJ; Park, JY, 2010) |
| "The tremor is intermittent and does not appear in all human patients." | 1.36 | Computational physiology of the basal ganglia in Parkinson's disease. ( Bergman, H; Elias, S; Heimer, G; Rivlin-Etzion, M, 2010) |
| " However, once dyskinesia has developed, dopamine agonists administered with l-dopa exacerbate involuntary movements." | 1.36 | The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. ( Jackson, MJ; Jenner, P; McCreary, AC; Rose, S; Tayarani-Binazir, K, 2010) |
| "The development of Parkinson's disease is accompanied by concurrent activation of caspase-3 and apoptosis of dopaminergic neurons of human patients and rodent models." | 1.36 | Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice. ( Amutuhaire, W; Ichinose, F; Kaneki, M; Kida, K; Yamada, M, 2010) |
| "Amiloride was found to protect substantia nigra (SNc) neurons from MPTP-induced degeneration, as determined by attenuated reductions in striatal tyrosine hydroxylase (TH) and dopamine transporter (DAT) immunohistochemistry, as well as smaller declines in striatal DAT radioligand binding and dopamine levels." | 1.35 | Amiloride is neuroprotective in an MPTP model of Parkinson's disease. ( Albinson, K; Arias, RL; Beyer, C; Bowlby, MR; Dunlop, J; Dwyer, JM; Kagan, N; Kubek, K; Lin, Q; Monaghan, M; Sung, ML; Vasylyev, D; Zaleska, MM; Zhang, MY, 2008) |
| ") injection of the neurotoxicant, 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine or 2'-CH(3)-MPTP, to postnatal day 4 (PD4) mice caused acute and transient gliosis in the brain, which can be noninvasively monitored during a course of 8 h immediately after the dosing [Ho, G." | 1.35 | Molecular imaging reveals a correlation between 2'-CH3-MPTP-induced neonatal neurotoxicity and dopaminergic neurodegeneration in adult transgenic mice. ( Ho, G; Kng, YL; Kumar, S; Zhang, C; Zhuo, L, 2008) |
| "When biperiden was combined with SKF-82958, contraversive circling also was enhanced and ipsiversive circling decreased." | 1.35 | Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions. ( Domino, EF; Ni, L, 2008) |
| " Furthermore, chronic administration of low doses of the 5-HT(1) agonists in combination was able to prevent development of dyskinesia, and reduce the up-regulation of FosB after daily treatment with l-DOPA in the rat 6-OHDA model." | 1.35 | Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. ( Bezard, E; Björklund, A; Carlsson, T; Carta, M; Di Luca, M; Gardoni, F; Kirik, D; Li, Q; Marcello, E; Muñoz, A; Qin, C, 2008) |
| "In most environmental models of Parkinson's disease (PD), a single neurodegenerative agent is introduced to cause nigrostriatal dopamine depletion." | 1.35 | Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice. ( Barth, TM; Boehm, GW; Byler, SL; Karp, JD; Kohman, RA; Schallert, T; Tarr, AJ, 2009) |
| "Animal models of Parkinson's disease have been widely used for investigating the mechanisms of neurodegenerative process and for discovering alternative strategies for treating the disease." | 1.35 | Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration. ( Kurz, MJ; Lau, YS; Pothakos, K, 2009) |
| "Nicotine pre-treatment attenuated behavioral deficits and lessened lesion-induced losses of the striatal dopamine transporter, and alpha6beta2* and alpha4beta2* nicotinic receptors (nAChRs)." | 1.35 | Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys. ( Bordia, T; Huang, LZ; Michael McIntosh, J; Parameswaran, N; Quik, M, 2009) |
| " Here, we show that drinking H(2)-containing water significantly reduced the loss of dopaminergic neurons in PD model mice using both acute and chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.35 | Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. ( Fujita, K; Katafuchi, T; Kido, MA; Nakabeppu, Y; Noda, M; Ohno, M; Sakumi, K; Seike, T; Takaki, A; Tanaka, Y; Yamada, H; Yamaguchi, H; Yamakawa, Y; Yutsudo, N, 2009) |
| " 30 C57BL/6J mice were randomly divided into six groups: control group, PD model group, QXT high dosage group, QXT middle dosage group, QXT low dosage group and trihexyphenidyl hydrochloride group." | 1.35 | [Effection of Qing-Xuan tablets on behavior pattern and striatal TNF-alpha of Parkinson model mice]. ( Huo, QL; Lin, XX; Liu, MN; Liu, SJ; Yang, L; Yang, XX, 2009) |
| "Different Parkinson's disease (PD) animal models reproduce the early phase of the disease, which deny the possible existence of a synergic effect of consecutive insults to the dopaminergic neurons." | 1.35 | Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease. ( Andersen, ML; Andreatini, R; Dombrowski, P; Lima, MM; Reksidler, AB; Tufik, S; Vital, MA; Zanata, SM, 2008) |
| "Coenzyme Q10 (CoQ10) is a promising agent for neuroprotection in neurodegenerative diseases." | 1.35 | Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. ( Beal, MF; Calingasan, NY; Cleren, C; Lorenzo, B; Schomer, A; Sireci, A; Wille, EJ; Yang, L, 2008) |
| "Nicotine or caffeine-treated animals showed significant restoration against most of the MPTP-induced alterations." | 1.35 | Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype in mouse. ( Nath, C; Patel, DK; Patel, S; Singh, C; Singh, K; Singh, MP; Singh, S, 2008) |
| "SUN N8075 is a novel antioxidant with neuroprotective properties." | 1.35 | Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease. ( Adachi, T; Hara, H; Izuta, H; Matsunaga, N; Oida, Y; Oyagi, A; Shimazawa, M, 2008) |
| "In reserpine-treated animals, specific delta opioid binding was increased in premotor cortex (+30%), sensorimotor striatum (+20%), and associative striatum (+17%) rostrally, but was not changed in caudal forebrain." | 1.34 | Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. ( Brotchie, JM; Hallett, PJ, 2007) |
| " The dosage of 1-methyl-4-phenyl pyridinium (MPP+) in the striatum by high-performance liquid chromatography indicated that fenofibrate did not affect MPTP metabolism." | 1.34 | Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. ( Bordet, R; Destée, A; Gelé, P; Kreisler, A; Lhermitte, M; Wiart, JF, 2007) |
| "Three monkeys were induced hemiparkinsonism by intracarotid (left) infusion of MPTP (0." | 1.34 | Changes in the rates of the tricarboxylic acid (TCA) cycle and glutamine synthesis in the monkey brain with hemiparkinsonism induced by intracarotid infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): studies by non-invasive 13C-magnetic reso ( Kanamatsu, T; Nambu, A; Okamoto, K; Otsuki, T; Takada, M; Tokuno, H; Tsukada, Y; Umeda, M; Watanabe, H, 2007) |
| " Here we extended the study and investigated TNF-alpha receptor 1 (-/-) (TNFR1) and TNF-alpha receptor 2 (-/-) (TNFR2) mice using a chronic MPTP dosing regimen (15 mg/kg MPTP on 8 consecutive days)." | 1.33 | Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease. ( Feldon, J; Ferger, B; Leng, A; Mura, A, 2005) |
| "The improvement of parkinsonism in all animals treated with l-Dopa alone was clearly displayed from the first day of treatment." | 1.33 | Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys. ( Bédard, PJ; Di Paolo, T; Grégoire, L; Hadj Tahar, A; Rouillard, C; Samadi, P, 2005) |
| "Pramipexole pretreatment also prevented degeneration of striatal dopamine terminals." | 1.33 | Pramipexole protects against MPTP toxicity in non-human primates. ( Cooper, JM; Haddon, CO; Iravani, MM; Jenner, P; Schapira, AH, 2006) |
| "Parkinson's disease is associated with a progressive loss of substantia nigra pars compacta dopaminergic neurons." | 1.33 | Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. ( Garris, BL; Garris, DR; Lau, YS; Novikova, L, 2006) |
| "The aetiology of idiopathic Parkinson's disease (PD) is poorly defined but environmental aggression may be relevant." | 1.33 | Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. ( Cavada, C; Close, RM; Cuadrado, A; de Sagarra, MR; Fernández-Ruiz, J; Jackson-Lewis, V; Montero, C; Rojo, AI; Salazar, M; Sánchez-González, MA, 2006) |
| "Pretreatment with pargyline attenuated the MPTP-induced clinical signs, MRI and MRS changes, and the histopathological and immunoreactivity alterations." | 1.32 | Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism. ( Hadjiconstantinou, M; Neff, NH; Podell, M; Smith, MA, 2003) |
| " These data indicate that differences in striatal glutamate function appear to be associated with the dosing interval of MPTP administration and the variable loss of striatal TH immunolabeling." | 1.32 | Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function. ( Freeman, P; Krentz, L; Meshul, CK; Moore, C; Robinson, S; Touchon, JC, 2003) |
| " Consistent with previous findings, 17beta-estradiol was found to inhibit MPTP-induced DA depletion under a dosing regimen (repeated daily administration) that mimicked physiological levels of the steroid." | 1.32 | Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. ( Liu, X; Menniti, FS; Ramirez, AD, 2003) |
| "Tolcapone treatment enhanced CSF DOPAC concentrations in unlesioned animals (by approximately four times) as well as monkeys rendered parkinsonian after severe nigrostriatal dopaminergic injury caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.32 | Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. ( Di Monte, DA; Langston, JW; Thiffault, C, 2003) |
| "Long-term treatment of Parkinson's disease with levodopa is compromised by the development of motor complications, including on-off fluctuations and involuntary movements termed dyskinesia." | 1.32 | Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. ( Brotchie, JM; Crossman, AR; Duty, S; Fox, SH; Henry, B, 2003) |
| " Chronic administration of low doses of MPTP resulted in animals with stable cognitive deficits without overt parkinsonian motor symptoms." | 1.32 | Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys. ( Kulak, JM; Schneider, JS, 2004) |
| "(3) Substance P distribution was 'reversed' in dopamine depleted striatum: striosomes, which normally express higher levels of substance P, showed decreased expression, whereas substance P expression was up-regulated in the matrix." | 1.32 | Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. ( Betarbet, R; Greenamyre, JT, 2004) |
| "These results support reactive gliosis as a means of striatal compensation for dopamine loss." | 1.32 | Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. ( Beales, M; Dervan, AG; McBean, GJ; Meredith, GE; Meshul, CK; Moore, C; Snyder, AK; Totterdell, S, 2004) |
| " In study 1, the authors examined the effect of V-10,367 (50 mg/kg x 2 per day, by mouth) on neurofilament M (NFM) protein levels and on alpha-spectrin breakdown products (SBDPs) when dosed for 2 days, starting 24 hours after TBI and killed on day 3." | 1.31 | Neuroimmunophilin ligand V-10,367 is neuroprotective after 24-hour delayed administration in a mouse model of diffuse traumatic brain injury. ( Detloff, MR; Dutta, S; Hall, ED; Kupina, NC, 2002) |
| "A levodopa-responsive parkinsonism emerged in all MPTP-treated monkeys." | 1.31 | Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys. ( Bioulac, B; Fernagut, PO; Ghorayeb, I; Stefanova, N; Tison, F; Wenning, GK, 2002) |
| "Riluzole, has previously been shown to be protective in animal models of Parkinson's disease in vivo." | 1.31 | The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. ( Boireau, A; Bordier, F; Dubedat, P; Imperato, A; Moussaoui, S, 2000) |
| " Selective adenosine A(2A) receptor antagonists, such as KW-6002, may be one means of reducing the dosage of L-DOPA used in treating Parkinson's disease and are potentially a novel approach to treating the illness both as monotherapy and in combination with dopaminergic drugs." | 1.31 | Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. ( Jackson, MJ; Jenner, P; Kanda, T; Kase, H; Kuwana, Y; Nakamura, J; Pearce, RK; Smith, LA, 2000) |
| "We developed a primate model of striatonigral degeneration (SND), the neuropathology underlying levodopa-unresponsive parkinsonism associated with multiple systemic atrophy (MSA-P), by sequential systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 3-nitropropionic acid (3NP) in a Macaca fascicularis monkey." | 1.31 | Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. ( Aubert, I; Bezard, E; Fernagut, PO; Ghorayeb, I; Poewe, W; Tison, F; Wenning, GK, 2000) |
| " The lower dosages of (+/-)-kavain (50 and 100 mg/kg) showed only a nonsignificant attenuation of MPTP-induced dopamine depletion, but a high dosage of (+/-)-kavain (200 mg/kg) significantly antagonized the dopamine depletion to 58." | 1.31 | Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease. ( Ferger, B; Schmidt, N, 2001) |
| "Clinical and experimental grafting in Parkinson's disease has shown the need for enhanced survival of dopamine neurons to obtain improved functional recovery." | 1.31 | Evidence for target-specific outgrowth from subpopulations of grafted human dopamine neurons. ( Almqvist, PM; Bygdeman, M; Johansson, S; Strömberg, I; Törnqvist, N, 2001) |
| " A significant reduction of the ligand-DATs binding was found in the mice treated with MPTP, but not with TIQ, under the dosage inducing behavioral abnormality and loss of tyrosine hydroxylase-positive cells in the substantia nigra." | 1.31 | Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum. ( Abe, K; Ishiwata, K; Kawamura, K; Koyanagi, Y; Saitoh, T; Sano, T; Senda, M; Taguchi, K; Toda, J, 2001) |
| "Murine model of Parkinson's disease uses a quite selective toxic effect of MPTP on nigrostriatal system." | 1.31 | [Treatment of neurodegenerative diseases: new perspectives]. ( Członkowska, A; Kurkowska-Jastrzebska, I, 2001) |
| "That thalidomide has activity in this model suggests that an inflammatory process may be involved in the induction of lesions by MPTP in DAergic neurons." | 1.30 | Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. ( Boireau, A; Bordier, F; Dubédat, P; Impérato, A; Pény, C, 1997) |
| "Lisuride was applied to 4 x 5 cm of skin of the abdomen of monkeys." | 1.30 | [Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease]. ( Fukuda, T; Irifune, M; Iwata, S; Kaseda, S; Nomoto, M; Osame, M, 1998) |
| " These results are consistent with previous work highlighting the importance of aberrant amine production in neurological disease and demonstrate that treatments that reduce endogenous melatonin bioavailability can ameliorate experimental PD." | 1.30 | A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. ( Armstrong, SM; Willis, GL, 1999) |
| "R-apomorphine is a potent radical scavenger and iron chelator." | 1.30 | Apomorphine protects against MPTP-induced neurotoxicity in mice. ( Berkuzki, T; Grünblatt, E; Mandel, S; Youdim, MB, 1999) |
| "We examined whether or not the antiparkinsonian activity of talipexole (B-HT 920, 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]-azepine) could be optimised by combination with L-3,4-dihydroxyphenylalanine (L-dopa)." | 1.29 | Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment. ( Fukuda, T; Irifune, M; Nomoto, M, 1994) |
| "The behavioural, biochemical and morphological effects of a chronic administration of low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were studied in the common marmoset." | 1.29 | Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. ( Albanese, A; Colosimo, C; Granata, R; Gregori, B; Piccardi, MP; Tonali, P, 1993) |
| " Twelve adult female Japanese monkeys weighing about 7kg were lesioned with systemic infusion of MPTP according to the following dosing schedules." | 1.29 | [Intrathecal infusion of brain-derived neurotrophic factor protects nigral dopaminergic neurons from degenerative changes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced monkey parkinsonian model]. ( Takeda, M, 1995) |
| " Thrice daily dosing at a 4-h interval with the short-acting agent SKF 82958 maintained the maximal antiparkinsonian response but some shortening in the duration of response was observed after several days." | 1.29 | Dopamine D1 receptor desensitization profile in MPTP-lesioned primates. ( Bédard, PJ; Blanchet, PJ; Britton, DR; Grondin, R; Shiosaki, K, 1996) |
| " We carried out an oral levodopa dose-response study in two rhesus monkeys whose left hemiparkinsonism was induced by intracarotid administration of MPTP." | 1.28 | Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. ( Gash, DM; Kim, MH; Kurlan, R, 1991) |
| "Although it is known that Parkinson's disease results from a loss of dopaminergic neurons in the substantia nigra, the resulting alterations in activity in the basal ganglia responsible for parkinsonian motor deficits are still poorly characterized." | 1.28 | Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. ( Bergman, H; DeLong, MR; Wichmann, T, 1990) |
| " Some dissimilarities between both the conditions noticed in earlier investigations have been dissolved by starting a well-prescribed chronic administration of subliminal dose of MPTP in old matured monkeys." | 1.27 | Similarity and dissimilarity of MPTP models to Parkinson's disease: importance of juvenile parkinsonism. ( Narabayashi, H, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 51 (4.38) | 18.7374 |
| 1990's | 108 (9.28) | 18.2507 |
| 2000's | 327 (28.09) | 29.6817 |
| 2010's | 435 (37.37) | 24.3611 |
| 2020's | 243 (20.88) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, X | 14 |
| Chen, W | 3 |
| Wang, C | 6 |
| Liu, W | 6 |
| Hayashi, T | 5 |
| Mizuno, K | 2 |
| Hattori, S | 2 |
| Fujisaki, H | 2 |
| Ikejima, T | 2 |
| Bai, X | 2 |
| Zhang, X | 23 |
| Fang, R | 2 |
| Wang, J | 13 |
| Ma, Y | 10 |
| Liu, Z | 7 |
| Dong, H | 6 |
| Li, Q | 16 |
| Ge, J | 1 |
| Yu, M | 8 |
| Fei, J | 6 |
| Sun, R | 2 |
| Huang, F | 8 |
| Hescham, SA | 1 |
| Chiang, PH | 1 |
| Gregurec, D | 1 |
| Moon, J | 1 |
| Christiansen, MG | 1 |
| Jahanshahi, A | 1 |
| Liu, H | 4 |
| Rosenfeld, D | 1 |
| Pralle, A | 1 |
| Anikeeva, P | 1 |
| Temel, Y | 1 |
| Isenbrandt, A | 1 |
| Morissette, M | 11 |
| Bourque, M | 5 |
| Lamontagne-Proulx, J | 1 |
| Coulombe, K | 2 |
| Soulet, D | 2 |
| Di Paolo, T | 15 |
| Shan, J | 1 |
| Qu, Y | 3 |
| Wang, S | 11 |
| Wei, Y | 3 |
| Chang, L | 3 |
| Ma, L | 3 |
| Hashimoto, K | 4 |
| Chetia Phukan, B | 1 |
| Dutta, A | 2 |
| Deb, S | 1 |
| Saikia, R | 1 |
| Mazumder, MK | 2 |
| Paul, R | 3 |
| Bhattacharya, P | 2 |
| Sandhir, R | 3 |
| Borah, A | 4 |
| Shamadykova, DV | 1 |
| Panteleev, DY | 1 |
| Kust, NN | 1 |
| Savchenko, EA | 1 |
| Rybalkina, EY | 1 |
| Revishchin, AV | 2 |
| Pavlova, GV | 2 |
| Pathania, A | 1 |
| Garg, P | 1 |
| Guo, K | 1 |
| Zhang, Y | 40 |
| Li, L | 4 |
| Zhang, J | 22 |
| Rong, H | 2 |
| Liu, D | 2 |
| Jin, M | 6 |
| Luo, N | 2 |
| Seo, MH | 3 |
| Lim, S | 5 |
| Yeo, S | 7 |
| Ahuja, M | 2 |
| Ammal Kaidery, N | 2 |
| Attucks, OC | 1 |
| McDade, E | 1 |
| Hushpulian, DM | 2 |
| Gaisin, A | 2 |
| Gaisina, I | 1 |
| Ahn, YH | 1 |
| Nikulin, S | 1 |
| Poloznikov, A | 1 |
| Gazaryan, I | 2 |
| Yamamoto, M | 2 |
| Matsumoto, M | 1 |
| Igarashi, K | 1 |
| Sharma, SM | 2 |
| Thomas, B | 4 |
| Gao, J | 3 |
| Zhang, W | 5 |
| Chai, X | 1 |
| Tan, X | 1 |
| Yang, Z | 1 |
| Ribeiro-Carvalho, A | 1 |
| Leal-Rocha, PH | 1 |
| Isnardo-Fernandes, J | 1 |
| Araújo, UC | 1 |
| Abreu-Villaça, Y | 1 |
| Filgueiras, CC | 1 |
| Manhães, AC | 1 |
| Mo, J | 1 |
| Xiong, B | 1 |
| Liao, Q | 1 |
| Chen, Y | 7 |
| Wang, Y | 27 |
| Xing, S | 1 |
| He, S | 1 |
| Lyu, W | 1 |
| Zhang, N | 2 |
| Sun, H | 4 |
| Wang, K | 3 |
| Lu, C | 3 |
| Wang, T | 4 |
| Qiao, C | 4 |
| Lu, L | 6 |
| Wu, D | 1 |
| Lu, M | 8 |
| Chen, R | 1 |
| Fan, L | 1 |
| Tang, J | 2 |
| Han, S | 2 |
| Liu, J | 6 |
| Ye, T | 1 |
| Yu, Q | 1 |
| Yu, J | 2 |
| Yuan, S | 2 |
| Gao, X | 4 |
| Wan, X | 1 |
| Zhang, R | 3 |
| Han, W | 1 |
| Sun, B | 2 |
| Yang, J | 5 |
| Chen, Z | 4 |
| Li, Z | 6 |
| Li, H | 13 |
| Shen, L | 1 |
| Li, X | 11 |
| Gao, D | 2 |
| Paudel, YN | 2 |
| Zheng, M | 1 |
| Liu, G | 1 |
| Chu, L | 1 |
| He, F | 1 |
| Cui, C | 6 |
| Hong, H | 3 |
| Shi, Y | 2 |
| Zhou, Y | 9 |
| Qiao, CM | 4 |
| Zhao, WJ | 4 |
| Zhao, LP | 2 |
| Wu, J | 7 |
| Quan, W | 2 |
| Niu, GY | 2 |
| Wu, YB | 1 |
| Li, CS | 1 |
| Cheng, L | 3 |
| Hong, Y | 2 |
| Shen, YQ | 5 |
| Liu, N | 2 |
| Bai, L | 1 |
| Lu, Z | 3 |
| Gu, R | 1 |
| Zhao, D | 1 |
| Yan, F | 2 |
| Bai, J | 2 |
| Wang, F | 7 |
| Zhou, Z | 3 |
| Jiang, X | 6 |
| Li, F | 2 |
| Feng, Y | 3 |
| Liu, C | 4 |
| Fan, S | 2 |
| Wu, X | 6 |
| Huang, C | 3 |
| Perez Visñuk, D | 1 |
| Teran, MDM | 1 |
| Savoy de Giori, G | 1 |
| LeBlanc, JG | 1 |
| de Moreno de LeBlanc, A | 1 |
| Cheng, YY | 1 |
| Chen, BY | 1 |
| Bian, GL | 1 |
| Ding, YX | 2 |
| Chen, LW | 2 |
| Dongjie, S | 1 |
| Rajendran, RS | 1 |
| Xia, Q | 1 |
| She, G | 1 |
| Tu, P | 1 |
| Liu, K | 4 |
| Yang, Y | 6 |
| Zhang, S | 8 |
| Guan, J | 1 |
| Jiang, Y | 4 |
| Luo, L | 1 |
| Sun, C | 1 |
| Sun, CP | 1 |
| Zhou, JJ | 2 |
| Yu, ZL | 1 |
| Huo, XK | 1 |
| Morisseau, C | 1 |
| Hammock, BD | 3 |
| Ma, XC | 1 |
| Huang, R | 2 |
| Gao, Y | 12 |
| Chen, J | 6 |
| Duan, Q | 1 |
| He, P | 2 |
| Huang, H | 4 |
| Zhang, Q | 8 |
| Ma, G | 1 |
| Nie, K | 4 |
| Wang, L | 16 |
| Pereira, MCL | 1 |
| Boese, AC | 1 |
| Murad, R | 1 |
| Yin, J | 2 |
| Hamblin, MH | 1 |
| Lee, JP | 1 |
| Zuo, T | 1 |
| Xie, M | 1 |
| Yan, M | 1 |
| Zhang, Z | 26 |
| Tian, T | 1 |
| Zhu, Y | 1 |
| Sun, Y | 2 |
| Rong, Q | 1 |
| Ren, Q | 2 |
| Zhang, P | 4 |
| Sheng, W | 1 |
| Shang, X | 1 |
| Alshammari, A | 1 |
| Alharbi, M | 1 |
| Albekairi, NA | 1 |
| Albekairi, TH | 1 |
| Alharbi, OO | 1 |
| Yeapuri, P | 1 |
| Singh, S | 4 |
| Han, X | 2 |
| Liu, Y | 14 |
| Dai, Y | 1 |
| Xu, T | 1 |
| Hu, Q | 1 |
| Yi, X | 1 |
| Rui, L | 1 |
| Hu, G | 8 |
| Hu, J | 1 |
| Pamies, D | 1 |
| Wiersma, D | 1 |
| Katt, ME | 1 |
| Zhao, L | 5 |
| Burtscher, J | 1 |
| Harris, G | 1 |
| Smirnova, L | 1 |
| Searson, PC | 1 |
| Hartung, T | 1 |
| Hogberg, HT | 1 |
| Peng, H | 1 |
| Yu, S | 3 |
| Yin, Y | 1 |
| Zhou, J | 4 |
| Kim, A | 2 |
| Pavlova, E | 2 |
| Kolacheva, A | 2 |
| Bogdanov, V | 2 |
| Dilmukhametova, L | 1 |
| Blokhin, V | 1 |
| Valuev, L | 1 |
| Valuev, I | 1 |
| Gorshkova, M | 1 |
| Ugrumov, M | 3 |
| Lin, CY | 3 |
| Tseng, HC | 1 |
| Chu, YR | 1 |
| Wu, CL | 1 |
| Zhang, PH | 2 |
| Tsai, HJ | 1 |
| Park, JE | 5 |
| Leem, YH | 5 |
| Park, JS | 5 |
| Kim, DY | 7 |
| Kang, JL | 2 |
| Kim, HS | 5 |
| Hang, W | 1 |
| Fan, HJ | 2 |
| Li, YR | 1 |
| Xiao, Q | 3 |
| Jia, L | 2 |
| Song, LJ | 2 |
| Jin, XM | 2 |
| Xiao, BG | 4 |
| Yu, JZ | 1 |
| Ma, CG | 3 |
| Chai, Z | 2 |
| Wang, M | 5 |
| Zhao, Y | 3 |
| Yang, G | 2 |
| Lim, HS | 3 |
| Park, G | 4 |
| Tran, KKN | 1 |
| Wong, VHY | 1 |
| Lim, JKH | 1 |
| Shahandeh, A | 1 |
| Hoang, A | 1 |
| Finkelstein, DI | 6 |
| Bui, BV | 1 |
| Nguyen, CTO | 1 |
| Wang, B | 3 |
| Lu, J | 1 |
| Xia, W | 1 |
| Lillethorup, TP | 1 |
| Noer, O | 1 |
| Alstrup, AKO | 1 |
| Real, CC | 1 |
| Stokholm, K | 1 |
| Thomsen, MB | 1 |
| Zaer, H | 1 |
| Orlowski, D | 1 |
| Mikkelsen, TW | 1 |
| Glud, AN | 2 |
| Nielsen, EHT | 1 |
| Schacht, AC | 1 |
| Winterdahl, M | 1 |
| Brooks, DJ | 1 |
| Sørensen, JCH | 1 |
| Landau, AM | 1 |
| Smeyne, RJ | 8 |
| Eells, JB | 1 |
| Chatterjee, D | 1 |
| Byrne, M | 1 |
| Akula, SM | 1 |
| Sriramula, S | 1 |
| O'Rourke, DP | 1 |
| Schmidt, P | 1 |
| Su, Y | 3 |
| Ma, J | 4 |
| Yuan, Y | 3 |
| Shi, M | 2 |
| Zhao, Z | 3 |
| Holscher, C | 7 |
| Phukan, BC | 1 |
| Roy, R | 1 |
| Choudhury, A | 2 |
| Kumar, D | 1 |
| Nath, J | 1 |
| Kumar, S | 3 |
| Wang, SM | 1 |
| Wang, Q | 5 |
| Ye, LY | 1 |
| Chen, SX | 1 |
| Tao, L | 1 |
| Yang, ZS | 1 |
| Xu, B | 1 |
| Wang, X | 16 |
| Xu, Z | 2 |
| Quan, J | 1 |
| Wang, XL | 3 |
| Feng, ST | 1 |
| Wang, YT | 1 |
| Zhang, NN | 1 |
| Guo, ZY | 2 |
| Yan, X | 1 |
| Yuan, YH | 4 |
| Wang, ZZ | 1 |
| Chen, NH | 4 |
| Palese, F | 1 |
| Pontis, S | 3 |
| Realini, N | 1 |
| Torrens, A | 1 |
| Ahmed, F | 1 |
| Assogna, F | 1 |
| Pellicano, C | 1 |
| Bossù, P | 1 |
| Spalletta, G | 1 |
| Green, K | 1 |
| Piomelli, D | 1 |
| Hu, N | 1 |
| Li, S | 8 |
| Narmashiri, A | 1 |
| Abbaszadeh, M | 1 |
| Ghazizadeh, A | 1 |
| Yu, Z | 3 |
| Qin, G | 1 |
| Ge, Z | 1 |
| Li, W | 2 |
| Jiao, L | 1 |
| Su, LY | 2 |
| Liu, Q | 2 |
| Luo, R | 2 |
| Qiao, X | 1 |
| Xie, T | 1 |
| Yang, LX | 2 |
| Chen, C | 3 |
| Yao, YG | 2 |
| Zhang, K | 2 |
| Liu, P | 2 |
| Yuan, L | 1 |
| Geng, Z | 1 |
| Li, B | 3 |
| Zhang, B | 7 |
| Wu, Y | 4 |
| Sheng, H | 1 |
| Xun, D | 1 |
| Wu, H | 6 |
| Xiao, S | 1 |
| Bi, Y | 1 |
| Rui, WJ | 1 |
| Yang, L | 15 |
| Fan, Y | 4 |
| Hu, YC | 1 |
| Ma, CM | 1 |
| Wang, BW | 1 |
| Shi, JP | 1 |
| D'Amico, R | 2 |
| Impellizzeri, D | 2 |
| Genovese, T | 1 |
| Fusco, R | 1 |
| Peritore, AF | 2 |
| Crupi, R | 2 |
| Interdonato, L | 1 |
| Franco, G | 1 |
| Marino, Y | 1 |
| Arangia, A | 1 |
| Gugliandolo, E | 2 |
| Cuzzocrea, S | 4 |
| Di Paola, R | 2 |
| Siracusa, R | 3 |
| Cordaro, M | 2 |
| Qi, Y | 2 |
| Zhao, G | 3 |
| Cao, Y | 1 |
| Li, Y | 16 |
| Xue, J | 2 |
| Tang, X | 2 |
| Vora, U | 1 |
| Vyas, VK | 1 |
| Wal, P | 1 |
| Saxena, B | 1 |
| Jia, M | 1 |
| Feng, J | 1 |
| Han, Y | 1 |
| Yu, H | 2 |
| Li, G | 3 |
| Guo, L | 1 |
| Qiu, J | 1 |
| Du, J | 2 |
| Zhang, T | 3 |
| Kim, YM | 2 |
| Choi, SY | 5 |
| Hwang, O | 4 |
| Lee, JY | 2 |
| Zhou, L | 5 |
| An, J | 1 |
| Zheng, X | 1 |
| Han, D | 1 |
| Hong, DG | 2 |
| Lee, S | 3 |
| Kim, J | 5 |
| Yang, S | 5 |
| Lee, M | 1 |
| Ahn, J | 1 |
| Lee, H | 7 |
| Chang, SC | 2 |
| Ha, NC | 1 |
| Lee, J | 7 |
| Guo, Y | 2 |
| Xu, J | 7 |
| Jiang, C | 1 |
| Ye, K | 1 |
| Chang, N | 1 |
| Ge, Q | 2 |
| Wang, G | 4 |
| Zhao, X | 2 |
| Sun, X | 6 |
| Kang, Z | 1 |
| Cai, L | 1 |
| Ding, J | 6 |
| Santoro, M | 3 |
| Fadda, P | 1 |
| Klephan, KJ | 1 |
| Hull, C | 1 |
| Teismann, P | 9 |
| Platt, B | 1 |
| Riedel, G | 4 |
| Razali, K | 1 |
| Mohd Nasir, MH | 1 |
| Othman, N | 1 |
| Doolaanea, AA | 1 |
| Kumar, J | 1 |
| Nabeel Ibrahim, W | 1 |
| Mohamed, WMY | 1 |
| Dang, T | 1 |
| Zhou, YZ | 1 |
| Zhao, R | 1 |
| Huang, L | 4 |
| Xia, Y | 4 |
| Cheng, S | 1 |
| Yang, C | 4 |
| Zou, Z | 1 |
| Tian, X | 2 |
| Ye, Q | 2 |
| Lin, S | 3 |
| Yang, X | 4 |
| Chen, S | 14 |
| Wu, N | 1 |
| Xu, RC | 1 |
| Miao, WT | 1 |
| Xu, JY | 1 |
| Xu, WX | 1 |
| Liu, MR | 1 |
| Ding, ST | 1 |
| Jian, YX | 1 |
| Lei, YH | 1 |
| Yan, N | 1 |
| Liu, HD | 1 |
| Zolotarev, YA | 1 |
| Shram, SI | 1 |
| Dadayan, AK | 1 |
| Dolotov, OV | 1 |
| Markov, DD | 1 |
| Nagaev, IY | 1 |
| Kudrin, VS | 4 |
| Narkevich, VB | 2 |
| Sokolov, OY | 1 |
| Kost, NV | 1 |
| Li, C | 3 |
| Zhu, D | 1 |
| Cheng, O | 1 |
| Cui, J | 2 |
| Ding, Y | 1 |
| Zhou, M | 1 |
| Zheng, R | 1 |
| Ma, R | 2 |
| Deng, J | 3 |
| Hao, WZ | 1 |
| Zhang, JC | 1 |
| Ho, CT | 1 |
| Huang, JQ | 1 |
| Song, J | 3 |
| Liu, L | 8 |
| Mao, T | 2 |
| Chen, X | 5 |
| Shang, Y | 1 |
| Sun, T | 4 |
| Luo, Y | 1 |
| Tan, D | 1 |
| Tong, X | 1 |
| Dai, F | 1 |
| Shen, J | 1 |
| Zha, Q | 1 |
| Yang, QH | 1 |
| Zhou, YQ | 1 |
| Liang, X | 1 |
| Chen, YJ | 1 |
| Qi, GX | 1 |
| Zhang, XJ | 2 |
| Yao, WB | 1 |
| Gao, XD | 1 |
| Heng, Y | 3 |
| Li, YY | 1 |
| Wen, L | 3 |
| Yan, JQ | 1 |
| Li, T | 4 |
| Chu, C | 2 |
| Yu, L | 2 |
| Zhai, Q | 2 |
| Zhao, J | 5 |
| Zhang, H | 3 |
| Tian, F | 2 |
| Ojha, U | 2 |
| Khanal, S | 1 |
| Park, PH | 2 |
| Hong, JT | 5 |
| Choi, DY | 5 |
| Lin, HC | 3 |
| Wu, YH | 3 |
| Huang, CW | 4 |
| Ker, MD | 3 |
| Wan, J | 3 |
| Tan, J | 3 |
| Yi, S | 3 |
| Huang, K | 3 |
| Chang, D | 3 |
| Xie, J | 4 |
| Ishola, IO | 4 |
| Oloyo, AK | 3 |
| Olubodun-Obadun, TG | 4 |
| Godswill, OD | 3 |
| Omilabu, SA | 3 |
| Adeyemi, OO | 4 |
| Zhang, M | 6 |
| Hu, ZF | 3 |
| Dong, XL | 3 |
| Chen, WF | 6 |
| Pu, Z | 4 |
| Du, Z | 3 |
| Guo, Z | 4 |
| Bai, Q | 5 |
| Zhu, X | 3 |
| Mao, Y | 2 |
| Cao, F | 2 |
| Presti-Silva, SM | 2 |
| Herlinger, AL | 2 |
| Martins-Silva, C | 2 |
| Pires, RGW | 2 |
| Ibarra-Gutiérrez, MT | 1 |
| Serrano-García, N | 1 |
| Orozco-Ibarra, M | 1 |
| Shi, L | 2 |
| Xiu, M | 1 |
| Chen, L | 7 |
| Liu, R | 3 |
| Liu, QS | 2 |
| Cheng, Y | 4 |
| Bannikova, A | 1 |
| Huang, SY | 1 |
| Su, ZY | 1 |
| Han, YY | 1 |
| Shang, YJ | 1 |
| Mai, ZF | 1 |
| Zeng, ZW | 1 |
| Li, CH | 1 |
| Mo, C | 1 |
| Ye, S | 2 |
| Liang, H | 1 |
| Ma, H | 1 |
| Shen, C | 3 |
| Fan, W | 1 |
| He, Q | 2 |
| Lv, J | 1 |
| Zhu, J | 3 |
| Wang, P | 1 |
| Liu, T | 2 |
| Yuan, J | 2 |
| Yin, H | 1 |
| Lan, Y | 1 |
| Sun, Q | 3 |
| Ding, G | 1 |
| Zhou, C | 2 |
| Wang, H | 6 |
| Wang, Z | 9 |
| Oduola-Akande, MD | 1 |
| Akande, AJ | 1 |
| Aktas, B | 1 |
| Kartik, S | 2 |
| Pal, R | 2 |
| Chaudhary, MJ | 2 |
| Nath, R | 2 |
| Kumar, M | 2 |
| Binwal, M | 1 |
| Bawankule, DU | 1 |
| De Araújo, FM | 1 |
| Frota, AF | 1 |
| de Jesus, LB | 1 |
| Cuenca-Bermejo, L | 2 |
| Ferreira, KMS | 1 |
| Santos, CC | 2 |
| Soares, EN | 1 |
| Souza, JT | 1 |
| Sanches, FS | 1 |
| Costa, ACS | 1 |
| Farias, AA | 1 |
| de Fatima Dias Costa, M | 1 |
| Munoz, P | 1 |
| Menezes-Filho, JA | 1 |
| Segura-Aguilar, J | 1 |
| Costa, SL | 1 |
| Herrero, MT | 10 |
| Silva, VDA | 1 |
| Chiu, YJ | 1 |
| Lin, CH | 1 |
| Yang, PN | 1 |
| Lo, YS | 1 |
| Chen, YC | 2 |
| Chen, CM | 2 |
| Wu, YR | 1 |
| Yao, CF | 1 |
| Chang, KH | 1 |
| Lee-Chen, GJ | 1 |
| Tiwari, PC | 1 |
| Chen, YH | 4 |
| Kuo, YY | 1 |
| You, YQ | 1 |
| Lin, YT | 1 |
| Chen, PC | 2 |
| Briñez-Gallego, P | 1 |
| da Costa Silva, DG | 1 |
| Cordeiro, MF | 1 |
| Horn, AP | 1 |
| Hort, MA | 1 |
| Huang, J | 5 |
| Ren, XL | 1 |
| Zhang, MD | 1 |
| Wu, KN | 1 |
| Chu, ZW | 1 |
| Liu, SS | 1 |
| Jiang, XX | 1 |
| Zhu, JH | 3 |
| Wu, HM | 1 |
| Cai, H | 2 |
| Li, M | 4 |
| Zhang, L | 4 |
| Lei, J | 1 |
| Ren, K | 1 |
| Ming, J | 1 |
| Tian, B | 1 |
| Zhang, C | 4 |
| Xue, Z | 1 |
| Zhu, L | 2 |
| Zhuo, L | 2 |
| Han, L | 1 |
| Liao, W | 1 |
| Conquet, F | 1 |
| Charvin, D | 1 |
| Fukunaga, K | 2 |
| Cheng, A | 2 |
| Arimura, N | 1 |
| Yoshino, H | 1 |
| Sasaki, T | 1 |
| Kawahata, I | 2 |
| Tong, J | 2 |
| Zhou, R | 1 |
| Yildirim, S | 1 |
| Oylumlu, E | 1 |
| Ozkan, A | 2 |
| Sinen, O | 2 |
| Bulbul, M | 2 |
| Goksu, ET | 1 |
| Ertosun, MG | 1 |
| Tanriover, G | 4 |
| Jiang, W | 2 |
| Rong, Z | 1 |
| Sun, L | 1 |
| Guo, S | 1 |
| Yao, Y | 2 |
| Liao, C | 1 |
| Qiu, H | 1 |
| Liang, L | 3 |
| Zheng, W | 1 |
| Wu, L | 3 |
| Meng, F | 1 |
| Tang, C | 1 |
| Liu, M | 4 |
| Xiang, J | 1 |
| Li, D | 4 |
| Ran, S | 1 |
| Chen, G | 1 |
| Guo, M | 1 |
| Lanza, M | 1 |
| Cucinotta, L | 1 |
| Casili, G | 1 |
| Filippone, A | 2 |
| Basilotta, R | 1 |
| Capra, AP | 1 |
| Campolo, M | 2 |
| Paterniti, I | 2 |
| Esposito, E | 2 |
| Meng, HW | 2 |
| Shen, ZB | 1 |
| Meng, XS | 1 |
| Yin, ZQ | 1 |
| Wang, XR | 1 |
| Zou, TF | 1 |
| Liu, ZG | 2 |
| Wang, TX | 1 |
| Chen, YL | 1 |
| Yang, XX | 2 |
| Li, QS | 1 |
| Duan, YJ | 1 |
| Liu, S | 5 |
| Yan, J | 3 |
| Tang, Y | 3 |
| Xiao, H | 2 |
| Wang, W | 3 |
| Deng, P | 1 |
| Gao, H | 2 |
| Xu, FH | 1 |
| Qiu, YZ | 1 |
| Yang, FH | 1 |
| Ji, MM | 1 |
| Liu, KC | 1 |
| Zhang, SS | 1 |
| Pan, B | 1 |
| Niu, B | 1 |
| He, Y | 3 |
| Xia, C | 1 |
| Atiq, A | 1 |
| Lee, HJ | 2 |
| Khan, A | 1 |
| Kang, MH | 1 |
| Rehman, IU | 1 |
| Ahmad, R | 1 |
| Tahir, M | 1 |
| Ali, J | 1 |
| Choe, K | 1 |
| Kim, MO | 1 |
| Duan, Y | 2 |
| Sekar, S | 3 |
| Miranzadeh Mahabadi, H | 1 |
| Buettner, B | 1 |
| Taghibiglou, C | 1 |
| Yang, R | 2 |
| Xie, S | 1 |
| He, L | 4 |
| Shi, J | 1 |
| Menshchikova, EB | 1 |
| Khrapova, MV | 1 |
| Kozhin, PM | 1 |
| Chechushkov, AV | 1 |
| Serykh, AE | 1 |
| Romakh, LP | 1 |
| Kandalintseva, NV | 1 |
| Pan, T | 1 |
| Xu, L | 3 |
| Qin, SC | 1 |
| Fujimori, H | 1 |
| Ohba, T | 1 |
| Nakamura, S | 1 |
| Shimazawa, M | 2 |
| Hara, H | 3 |
| Ren, Z | 2 |
| Xiu, S | 1 |
| Yang, N | 2 |
| Chan, P | 1 |
| Zheng, Y | 1 |
| Rostyslav, P | 1 |
| Finiuk, N | 1 |
| Sik, A | 1 |
| Stoika, R | 1 |
| Guo, X | 2 |
| Sheng, X | 1 |
| Zheng, L | 1 |
| Usenko, T | 1 |
| Bezrukova, A | 1 |
| Rudenok, MM | 2 |
| Basharova, K | 1 |
| Shadrina, MI | 2 |
| Slominsky, PA | 2 |
| Zakharova, E | 1 |
| Pchelina, S | 1 |
| Lian, C | 1 |
| Pan, L | 1 |
| Lai, W | 1 |
| Zhang, F | 1 |
| Peng, L | 1 |
| Zhou, S | 3 |
| Zhang, G | 2 |
| Tan, Z | 1 |
| Heo, EJ | 1 |
| Lee, Y | 11 |
| Hyung Seo, M | 1 |
| He, D | 1 |
| Cui, M | 2 |
| Ye, B | 1 |
| Huang, B | 1 |
| Fu, S | 1 |
| Meka, ST | 1 |
| Bojja, SL | 1 |
| Kumar, G | 1 |
| Birangal, SR | 1 |
| Rao, CM | 1 |
| Park, M | 1 |
| Ha, J | 1 |
| Choi, HS | 1 |
| Kim, BS | 3 |
| Jeong, YK | 1 |
| Li, HY | 1 |
| Liu, DS | 1 |
| Li, LB | 1 |
| Zhang, YB | 1 |
| Dong, HY | 1 |
| Zhang, JY | 1 |
| Wang, JP | 1 |
| Fidelis, EM | 1 |
| Savall, ASP | 1 |
| Mello, JD | 1 |
| Quines, CB | 1 |
| Comis-Neto, AA | 1 |
| Sampaio, TB | 2 |
| Denardin, CC | 1 |
| de Ávila, DS | 1 |
| Rosa, SG | 1 |
| Pinton, S | 1 |
| Tang, L | 1 |
| Xu, N | 1 |
| Huang, M | 1 |
| Yi, W | 2 |
| Sang, X | 2 |
| Shao, M | 1 |
| Hao, ZZ | 1 |
| Shen, Y | 4 |
| Yue, F | 2 |
| Xu, C | 1 |
| Fujita, A | 2 |
| Fujita, Y | 1 |
| Pu, Y | 2 |
| Jarras, H | 1 |
| Poirier, AA | 1 |
| Balke, D | 1 |
| Tatenhorst, L | 1 |
| Dambeck, V | 1 |
| Ribas, VT | 1 |
| Vahsen, BF | 1 |
| Michel, U | 1 |
| Bähr, M | 5 |
| Lingor, P | 3 |
| Datta, I | 1 |
| Mekha, SR | 1 |
| Kaushal, A | 1 |
| Ganapathy, K | 1 |
| Razdan, R | 1 |
| Mei, M | 1 |
| Zhao, F | 1 |
| Lin, QS | 1 |
| Chen, P | 1 |
| Wang, WX | 1 |
| Lin, CC | 1 |
| Yu, LH | 1 |
| Lin, YX | 1 |
| Xu, YF | 1 |
| Kang, DZ | 1 |
| Xu, M | 1 |
| Bohlen, JK | 1 |
| Moore, C | 6 |
| Nipper, MA | 1 |
| Finn, DA | 1 |
| Jones, CE | 1 |
| Lim, MM | 1 |
| Meshul, CK | 9 |
| Ando, K | 3 |
| Inoue, T | 3 |
| Hikishima, K | 2 |
| Komaki, Y | 2 |
| Kawai, K | 2 |
| Inoue, R | 1 |
| Nishime, C | 1 |
| Nishinaka, E | 1 |
| Urano, K | 1 |
| Okano, H | 2 |
| Xue, B | 1 |
| Xiao, W | 1 |
| Tian, H | 1 |
| Edwards Iii, G | 1 |
| Gamez, N | 1 |
| Armijo, E | 1 |
| Kramm, C | 1 |
| Morales, R | 1 |
| Taylor-Presse, K | 1 |
| Schulz, PE | 1 |
| Soto, C | 1 |
| Moreno-Gonzalez, I | 1 |
| Mishra, A | 1 |
| Tiwari, V | 1 |
| Shukla, S | 1 |
| Dong, K | 1 |
| Sun, YJ | 1 |
| Liu, CF | 5 |
| Xing, MJ | 1 |
| Cheng, X | 1 |
| Wei, S | 1 |
| Zheng, JW | 1 |
| Zhao, XF | 1 |
| Wang, XM | 1 |
| Fu, J | 1 |
| Song, HF | 1 |
| Mitsumoto, Y | 5 |
| Takamori, S | 1 |
| Kishida, K | 1 |
| Ji, R | 1 |
| Smith, M | 1 |
| Niimi, Y | 1 |
| Karakatsani, ME | 1 |
| Murillo, MF | 1 |
| Jackson-Lewis, V | 16 |
| Przedborski, S | 16 |
| Konofagou, EE | 1 |
| Wu, XF | 1 |
| Duan, LX | 1 |
| Gao, XL | 1 |
| Guo, ML | 1 |
| Wang, DM | 1 |
| Barth, AL | 1 |
| Schneider, JS | 12 |
| Johnston, TH | 5 |
| Hill, MP | 2 |
| Brotchie, JM | 14 |
| Moskal, JR | 1 |
| Cearley, CN | 1 |
| Selvakumar, GP | 3 |
| Ahmed, ME | 2 |
| Thangavel, R | 2 |
| Kempuraj, D | 2 |
| Dubova, I | 2 |
| Raikwar, SP | 1 |
| Zaheer, S | 2 |
| Iyer, SS | 1 |
| Zaheer, A | 2 |
| Huang, Y | 3 |
| He, X | 4 |
| Lin, L | 1 |
| Jin, L | 1 |
| Zhu, R | 2 |
| Liu, A | 1 |
| Fan, H | 2 |
| Qiao, L | 1 |
| Shen, M | 1 |
| Lai, X | 1 |
| Barilar, JO | 1 |
| Knezovic, A | 1 |
| Perhoc, AB | 1 |
| Homolak, J | 1 |
| Riederer, P | 3 |
| Salkovic-Petrisic, M | 1 |
| Seo, J | 2 |
| Park, J | 8 |
| Kim, K | 2 |
| Won, J | 2 |
| Yeo, HG | 1 |
| Jin, YB | 2 |
| Koo, BS | 2 |
| Lim, KS | 2 |
| Jeong, KJ | 2 |
| Kang, P | 2 |
| Lee, HY | 1 |
| Choi, WS | 2 |
| Baek, SH | 2 |
| Jeon, CY | 2 |
| Hong, JJ | 2 |
| Huh, JW | 2 |
| Kim, YH | 4 |
| Park, SJ | 2 |
| Kim, SU | 1 |
| Lee, DS | 2 |
| Lee, SR | 2 |
| Guo, CH | 1 |
| Cao, T | 1 |
| Zheng, LT | 1 |
| Waddington, JL | 1 |
| Zhen, XC | 1 |
| Haga, H | 1 |
| Yamada, R | 1 |
| Izumi, H | 1 |
| Shinoda, Y | 1 |
| Miyachi, H | 1 |
| Massaquoi, MS | 1 |
| Liguore, WA | 1 |
| Churchill, MJ | 2 |
| Melrose, HL | 1 |
| Moreau, C | 1 |
| Rolland, AS | 2 |
| Pioli, E | 1 |
| Odou, P | 1 |
| Barthelemy, C | 1 |
| Lannoy, D | 1 |
| Demailly, A | 1 |
| Carta, N | 1 |
| Deramecourt, V | 1 |
| Auger, F | 1 |
| Kuchcinski, G | 1 |
| Laloux, C | 2 |
| Defebvre, L | 1 |
| Bordet, R | 4 |
| Duce, J | 1 |
| Devedjian, JC | 1 |
| Bezard, E | 27 |
| Fisichella, M | 1 |
| Devos, D | 1 |
| Togashi, K | 3 |
| Hasegawa, M | 2 |
| Nagai, J | 3 |
| Kotaka, K | 1 |
| Yazawa, A | 1 |
| Takahashi, M | 1 |
| Masukawa, D | 2 |
| Goshima, Y | 4 |
| Hensley, K | 2 |
| Ohshima, T | 3 |
| Liu, WW | 1 |
| Wei, SZ | 1 |
| Huang, GD | 1 |
| Liu, LB | 1 |
| Gu, C | 1 |
| Wang, XH | 2 |
| Xia, ST | 1 |
| Xie, AM | 1 |
| Hu, LF | 2 |
| Mann, E | 1 |
| Jackson, M | 4 |
| Lincoln, L | 2 |
| Fisher, R | 2 |
| Rose, S | 4 |
| Duty, S | 2 |
| Javed, H | 2 |
| Schwartz, N | 1 |
| Iyer, S | 1 |
| Khan, MM | 2 |
| Kong, F | 1 |
| Ding, Q | 1 |
| Cai, Y | 2 |
| Hao, Y | 1 |
| Tang, B | 1 |
| Zhu, M | 2 |
| Gong, D | 1 |
| Yu, R | 1 |
| Li, J | 4 |
| Lin, Z | 2 |
| Ouyang, Z | 1 |
| Huang, X | 4 |
| Reglodi, D | 2 |
| Vaudry, D | 1 |
| Jia, E | 1 |
| Ouyang, T | 1 |
| Pan, M | 1 |
| Bai, Y | 3 |
| Tan, Y | 1 |
| Luo, Q | 1 |
| Zeng, W | 2 |
| Shi, R | 1 |
| Zhengli, C | 1 |
| Ji, YJ | 1 |
| Wang, HL | 1 |
| Yin, BL | 1 |
| Ren, XY | 1 |
| Imai, Y | 2 |
| Singh, SS | 1 |
| Rai, SN | 1 |
| Birla, H | 1 |
| Zahra, W | 1 |
| Rathore, AS | 1 |
| Dilnashin, H | 1 |
| Singh, R | 1 |
| Singh, SP | 3 |
| Hamadjida, A | 3 |
| Nuara, SG | 3 |
| Frouni, I | 3 |
| Kwan, C | 4 |
| Bédard, D | 2 |
| Gourdon, JC | 3 |
| Huot, P | 4 |
| Üstündağ, FD | 1 |
| Ünal, İ | 2 |
| Cansız, D | 2 |
| Üstündağ, ÜV | 2 |
| Subaşat, HK | 1 |
| Alturfan, AA | 2 |
| Tiber, PM | 1 |
| Emekli-Alturfan, E | 2 |
| Travagli, RA | 1 |
| Browning, KN | 1 |
| Camilleri, M | 1 |
| Liao, JF | 1 |
| Cheng, YF | 1 |
| You, ST | 1 |
| Kuo, WC | 1 |
| Chiou, JJ | 1 |
| Hsu, CC | 1 |
| Hsieh-Li, HM | 1 |
| Tsai, YC | 1 |
| Moon, BC | 2 |
| Choi, G | 1 |
| Qiu, Y | 1 |
| Qing, Y | 1 |
| Dai, W | 1 |
| Hu, X | 2 |
| Jin, W | 1 |
| Deng, Z | 1 |
| Wang, CC | 1 |
| Shi, HH | 1 |
| Yanagita, T | 1 |
| Xue, CH | 1 |
| Zhang, TT | 1 |
| Wang, YM | 1 |
| Yang, W | 2 |
| Hao, W | 1 |
| Meng, Z | 1 |
| Ding, S | 1 |
| Huang, W | 3 |
| Gu, X | 1 |
| Wi, R | 1 |
| Chung, YC | 5 |
| Jin, BK | 5 |
| Gong, J | 2 |
| Ding, L | 2 |
| Pan, X | 1 |
| Guo, W | 1 |
| Peng, G | 1 |
| Lin, Y | 1 |
| Gao, F | 1 |
| Xuan, A | 1 |
| Xu, P | 2 |
| Jeon, H | 3 |
| Kim, HY | 4 |
| Bae, CH | 2 |
| Kim, S | 6 |
| Park, H | 2 |
| Chang, KA | 1 |
| Song, SY | 1 |
| Kim, IS | 3 |
| Koppula, S | 3 |
| Park, JY | 5 |
| Kim, BW | 3 |
| Yoon, SH | 2 |
| Choi, DK | 6 |
| Yang, H | 3 |
| Lin, J | 2 |
| Gao, WQ | 1 |
| Xu, H | 4 |
| Ardah, MT | 2 |
| Bharathan, G | 1 |
| Kitada, T | 1 |
| Haque, ME | 2 |
| Witzig, VS | 1 |
| Komnig, D | 2 |
| Falkenburger, BH | 4 |
| Bonifácio, MJ | 1 |
| Sousa, F | 1 |
| Soares-da-Silva, P | 1 |
| Thadathil, N | 1 |
| Xiao, J | 1 |
| Hori, R | 1 |
| Alway, SE | 1 |
| Mailman, RB | 1 |
| Ding, ZX | 1 |
| Luo, X | 1 |
| Mustapha, M | 1 |
| Mat Taib, CN | 1 |
| Zhang, HQ | 1 |
| Wang, JY | 1 |
| Li, ZF | 1 |
| Cui, L | 1 |
| Huang, SS | 1 |
| Zhu, LB | 1 |
| Fan, HH | 1 |
| Hao, L | 1 |
| Shao, S | 1 |
| Dionísio, PA | 1 |
| Amaral, JD | 1 |
| Rodrigues, CMP | 2 |
| Suh, YJ | 1 |
| Ishigami, A | 2 |
| Kim, H | 4 |
| Hur, JS | 1 |
| Ren, C | 1 |
| Li, LX | 2 |
| Dong, AQ | 1 |
| Zhang, YT | 1 |
| Hu, H | 1 |
| Mao, CJ | 2 |
| Du, RW | 1 |
| Bu, WG | 1 |
| Zhang, DD | 1 |
| Zhang, CY | 1 |
| Zhang, YX | 2 |
| Cui, HP | 1 |
| Jia, H | 1 |
| Zhou, H | 2 |
| Meng, L | 1 |
| Xia, X | 1 |
| Zhou, W | 1 |
| Pang, N | 1 |
| Bian, T | 1 |
| Yuan, T | 1 |
| Niu, L | 1 |
| Zheng, H | 1 |
| Jia, XB | 2 |
| Huang, SB | 1 |
| Yao, L | 2 |
| Cao, H | 1 |
| Jia, Y | 2 |
| McQuade, RM | 1 |
| Singleton, LM | 1 |
| Constable, R | 1 |
| Di Natale, M | 1 |
| Ringuet, MT | 1 |
| Berger, JP | 1 |
| Kauhausen, J | 1 |
| Parish, CL | 1 |
| Furness, JB | 1 |
| Diwakarla, S | 1 |
| Hou, Y | 1 |
| Ge, S | 1 |
| Pizzichini, E | 1 |
| Gonçalves, VC | 1 |
| Guillén-Díaz, M | 1 |
| Aguilar-Moñino, E | 1 |
| Sánchez-Rodrigo, C | 1 |
| González-Cuello, AM | 1 |
| Fernández-Villalba, E | 7 |
| Maegawa, H | 1 |
| Niwa, H | 1 |
| Qin, X | 1 |
| Hu, Y | 3 |
| Amin, SN | 1 |
| Khashaba, AS | 1 |
| Latif, NSA | 1 |
| El Gazzar, WB | 1 |
| Hussein, UK | 1 |
| Kim, JS | 1 |
| Ang, MJ | 2 |
| Kim, SH | 3 |
| Moon, CJ | 1 |
| Seong, B | 1 |
| Jang, YJ | 1 |
| Kim, C | 1 |
| Lv, M | 1 |
| Xue, G | 2 |
| Cheng, H | 1 |
| Meng, P | 1 |
| Lian, X | 1 |
| Deng, R | 1 |
| Jia, JJ | 1 |
| Zhou, X | 3 |
| Chang, E | 1 |
| Choi, YJ | 2 |
| Kim, DW | 4 |
| Shin, MJ | 3 |
| Yeo, HJ | 1 |
| Yeo, EJ | 2 |
| Lee, LR | 1 |
| Song, Y | 1 |
| Kim, DS | 5 |
| Han, KH | 3 |
| Lee, KW | 1 |
| Park, JK | 1 |
| Eum, WS | 4 |
| Dong, Q | 1 |
| Wada, M | 1 |
| Weerasinghe-Mudiyanselage, PDE | 1 |
| Kim, JC | 1 |
| Shin, T | 1 |
| Moon, C | 1 |
| Derin, N | 2 |
| Akçay, G | 1 |
| Parlak, H | 1 |
| Aydın Aslan, M | 1 |
| Ağar, A | 4 |
| Ci, L | 1 |
| Shen, R | 1 |
| Zheng, S | 1 |
| Huang, Q | 1 |
| Wei, Z | 4 |
| Ma, S | 1 |
| Woodgett, JR | 1 |
| Heo, G | 1 |
| Lee, KM | 3 |
| Kim, AH | 2 |
| Chung, KW | 1 |
| Im, E | 1 |
| Chung, HY | 1 |
| Spathis, AD | 1 |
| Asvos, X | 1 |
| Ziavra, D | 1 |
| Karampelas, T | 1 |
| Topouzis, S | 1 |
| Cournia, Z | 1 |
| Qing, X | 1 |
| Alexakos, P | 1 |
| Smits, LM | 1 |
| Dalla, C | 1 |
| Rideout, HJ | 1 |
| Schwamborn, JC | 1 |
| Tamvakopoulos, C | 1 |
| Fokas, D | 1 |
| Vassilatis, DK | 1 |
| Bulteau, AL | 1 |
| Mena, NP | 1 |
| Auchère, F | 1 |
| Lee, I | 1 |
| Prigent, A | 3 |
| Lobsiger, CS | 1 |
| Camadro, JM | 1 |
| Hirsch, EC | 12 |
| Gnanasegaran, N | 1 |
| Govindasamy, V | 1 |
| Simon, C | 1 |
| Gan, QF | 1 |
| Vincent-Chong, VK | 1 |
| Mani, V | 1 |
| Krishnan Selvarajan, K | 1 |
| Subramaniam, V | 1 |
| Musa, S | 1 |
| Abu Kasim, NH | 1 |
| Carelli, S | 2 |
| Giallongo, T | 2 |
| Viaggi, C | 2 |
| Latorre, E | 1 |
| Gombalova, Z | 2 |
| Raspa, A | 1 |
| Mazza, M | 2 |
| Vaglini, F | 3 |
| Di Giulio, AM | 2 |
| Gorio, A | 1 |
| Liang, LP | 1 |
| Fulton, R | 1 |
| Pearson-Smith, JN | 1 |
| Day, BJ | 1 |
| Patel, M | 1 |
| Ahn, S | 1 |
| Song, TJ | 1 |
| Park, SU | 1 |
| Jeon, S | 1 |
| Oh, JY | 1 |
| Jang, J | 1 |
| Hong, S | 2 |
| Song, MA | 1 |
| Shin, HS | 1 |
| Jung, YR | 1 |
| Park, HJ | 10 |
| Kinoshita, KI | 1 |
| Muroi, Y | 1 |
| Unno, T | 1 |
| Ishii, T | 1 |
| Mingazov, ER | 1 |
| Khakimova, GR | 1 |
| Kozina, EA | 4 |
| Medvedev, AE | 2 |
| Buneeva, OA | 2 |
| Bazyan, AS | 1 |
| Ugrumov, MV | 2 |
| Gotsbacher, MP | 1 |
| Telfer, TJ | 1 |
| Witting, PK | 1 |
| Double, KL | 1 |
| Codd, R | 1 |
| Du, ZR | 2 |
| Xu, AL | 2 |
| Yan, Z | 2 |
| Xiao, HH | 1 |
| Wong, MS | 3 |
| Yao, XS | 1 |
| Bhatnagar, M | 1 |
| Goel, I | 1 |
| Roy, T | 1 |
| Shukla, SD | 1 |
| Khurana, S | 1 |
| Wang, QM | 1 |
| Xu, YY | 1 |
| Ma, ZG | 1 |
| Koo, JH | 1 |
| Jang, YC | 1 |
| Hwang, DJ | 1 |
| Um, HS | 1 |
| Lee, NH | 1 |
| Jung, JH | 2 |
| Cho, JY | 1 |
| Pérez-Rodríguez, M | 1 |
| García-Mendoza, E | 1 |
| Farfán-García, ED | 1 |
| Das, BC | 1 |
| Ciprés-Flores, FJ | 1 |
| Trujillo-Ferrara, JG | 1 |
| Tamay-Cach, F | 1 |
| Soriano-Ursúa, MA | 1 |
| Niu, J | 1 |
| Xiong, J | 1 |
| Hu, D | 1 |
| Zeng, F | 1 |
| Nie, S | 1 |
| Mao, S | 1 |
| Zhang, QS | 3 |
| Mou, Z | 1 |
| Huang, JY | 1 |
| Modo, M | 1 |
| Crum, WR | 1 |
| Gerwig, M | 1 |
| Vernon, AC | 1 |
| Patel, P | 1 |
| Jackson, MJ | 7 |
| Jenner, P | 22 |
| Iravani, MM | 4 |
| Lin, JG | 1 |
| Chen, CJ | 1 |
| Yang, HB | 1 |
| Hung, SY | 1 |
| Kikuchi, T | 1 |
| Morizane, A | 2 |
| Doi, D | 1 |
| Magotani, H | 1 |
| Onoe, H | 1 |
| Mizuma, H | 1 |
| Takara, S | 1 |
| Takahashi, R | 2 |
| Inoue, H | 1 |
| Morita, S | 1 |
| Okita, K | 1 |
| Nakagawa, M | 1 |
| Parmar, M | 1 |
| Takahashi, J | 4 |
| Kopylov, AT | 1 |
| Nerobkova, LN | 2 |
| Kapitsa, IG | 2 |
| Zgoda, VG | 1 |
| Zhao, TT | 2 |
| Kim, KS | 2 |
| Shin, KS | 2 |
| Kim, HJ | 2 |
| Lee, KE | 2 |
| Lee, MK | 2 |
| Tunje, R | 1 |
| Ye, YL | 1 |
| Sonauddin, A | 1 |
| Hansraj, B | 1 |
| Ngawang, S | 1 |
| Shivani, S | 1 |
| Liu, RP | 1 |
| Andersen, AH | 2 |
| Hardy, PA | 1 |
| Forman, E | 1 |
| Evans, A | 1 |
| Ai, Y | 3 |
| Yue, J | 1 |
| Yue, G | 1 |
| Gash, DM | 6 |
| Grondin, R | 7 |
| Klemann, CJHM | 1 |
| Xicoy, H | 1 |
| Poelmans, G | 1 |
| Bloem, BR | 2 |
| Martens, GJM | 1 |
| Visser, JE | 1 |
| Singh, B | 2 |
| Pandey, S | 3 |
| Yadav, SK | 2 |
| Verma, R | 2 |
| Mahdi, AA | 2 |
| Météreau, E | 1 |
| Beaudoin-Gobert, M | 1 |
| Duperrier, S | 1 |
| Thobois, S | 1 |
| Tremblay, L | 2 |
| Sgambato-Faure, V | 1 |
| Kusuda, Y | 1 |
| Takemura, A | 1 |
| Nakano, M | 1 |
| Ishihara, A | 1 |
| Yeon, SK | 1 |
| Choi, JW | 2 |
| Park, JH | 1 |
| Lee, YR | 1 |
| Shin, SJ | 1 |
| Jang, BK | 2 |
| Bahn, YS | 1 |
| Han, G | 1 |
| Lee, YS | 1 |
| Pae, AN | 1 |
| Park, KD | 2 |
| Feher, M | 1 |
| Gaszner, B | 1 |
| Tamas, A | 1 |
| Gil-Martinez, AL | 2 |
| Luo, S | 1 |
| Gu, Q | 1 |
| Zhou, T | 1 |
| Liang, Z | 1 |
| Abbate, V | 1 |
| Hider, R | 1 |
| Lees, A | 1 |
| Alieva, AK | 1 |
| Zyrin, VS | 1 |
| Kolacheva, AA | 1 |
| Shulskaya, MV | 1 |
| Ugryumov, MV | 1 |
| Ren, M | 1 |
| Wei, X | 1 |
| Yan, S | 1 |
| Qin, Y | 1 |
| Jiang, F | 1 |
| Lou, H | 1 |
| Kabel, AM | 1 |
| Omar, MS | 1 |
| Alhadhrami, A | 1 |
| Alharthi, SS | 1 |
| Alrobaian, MM | 1 |
| Mani, S | 2 |
| Barathidasan, R | 1 |
| Manivasagam, T | 4 |
| Thenmozhi, AJ | 2 |
| Sevanan, M | 1 |
| Chidambaram, SB | 2 |
| Essa, MM | 4 |
| Guillemin, GJ | 3 |
| Sakharkar, MK | 1 |
| Bagga, P | 1 |
| Pickup, S | 1 |
| Crescenzi, R | 1 |
| Martinez, D | 1 |
| Borthakur, A | 1 |
| D'Aquilla, K | 1 |
| Singh, A | 1 |
| Verma, G | 1 |
| Detre, JA | 1 |
| Greenberg, J | 1 |
| Hariharan, H | 1 |
| Reddy, R | 1 |
| Moreno-Galarza, N | 1 |
| Mendieta, L | 1 |
| Palafox-Sánchez, V | 1 |
| Herrando-Grabulosa, M | 1 |
| Gil, C | 1 |
| Limón, DI | 1 |
| Aguilera, J | 1 |
| Feng, P | 1 |
| Ji, C | 2 |
| Yuan, Z | 1 |
| Wang, R | 2 |
| Iannielli, A | 1 |
| Bido, S | 2 |
| Folladori, L | 1 |
| Segnali, A | 1 |
| Cancellieri, C | 1 |
| Maresca, A | 1 |
| Massimino, L | 1 |
| Rubio, A | 1 |
| Morabito, G | 1 |
| Caporali, L | 1 |
| Tagliavini, F | 1 |
| Musumeci, O | 1 |
| Gregato, G | 1 |
| Carelli, V | 1 |
| Tiranti, V | 1 |
| Broccoli, V | 1 |
| Wen, Y | 1 |
| Li, A | 1 |
| Geng, L | 1 |
| Duan, D | 1 |
| Ge, G | 1 |
| Guderyon, MJ | 1 |
| He, Z | 1 |
| Yu, Y | 3 |
| Clark, RA | 2 |
| Stahl, K | 1 |
| Rahmani, S | 1 |
| Prydz, A | 1 |
| Skauli, N | 1 |
| MacAulay, N | 1 |
| Mylonakou, MN | 1 |
| Torp, R | 1 |
| Skare, Ø | 1 |
| Berg, T | 1 |
| Leergaard, TB | 1 |
| Paulsen, RE | 1 |
| Ottersen, OP | 1 |
| Amiry-Moghaddam, M | 1 |
| L'Episcopo, F | 4 |
| Tirolo, C | 4 |
| Peruzzotti-Jametti, L | 1 |
| Serapide, MF | 2 |
| Testa, N | 4 |
| Caniglia, S | 4 |
| Balzarotti, B | 1 |
| Pluchino, S | 2 |
| Marchetti, B | 4 |
| Feng, S | 2 |
| Gan, R | 1 |
| Hu, XL | 1 |
| Lv, XY | 1 |
| Feng, JH | 1 |
| Zhang, XQ | 1 |
| Ye, WC | 1 |
| Rosa, AI | 1 |
| Duarte-Silva, S | 1 |
| Silva-Fernandes, A | 1 |
| Nunes, MJ | 1 |
| Carvalho, AN | 2 |
| Rodrigues, E | 2 |
| Gama, MJ | 2 |
| Maciel, P | 1 |
| Castro-Caldas, M | 2 |
| Ma, M | 1 |
| Nonaka, R | 1 |
| Yamaguchi, A | 1 |
| Ishikawa, KI | 1 |
| Kobayashi, K | 2 |
| Murayama, S | 1 |
| Hwang, SH | 1 |
| Saiki, S | 1 |
| Akamatsu, W | 1 |
| Hattori, N | 2 |
| Lee, E | 1 |
| Hwang, I | 1 |
| Park, S | 3 |
| Hwang, B | 1 |
| Cho, Y | 1 |
| Son, J | 1 |
| Yu, JW | 2 |
| Xue, L | 1 |
| Zheng, J | 2 |
| Tong, Q | 2 |
| Shao, W | 1 |
| Yuan, C | 2 |
| Yuan, X | 1 |
| Jiang, Q | 1 |
| Chen, M | 1 |
| Mori, A | 2 |
| Rajamani, B | 1 |
| Bhat, A | 1 |
| Ray, B | 1 |
| Yu, SJ | 1 |
| Lecca, D | 2 |
| Glotfelty, E | 1 |
| Kim, HK | 1 |
| Choi, HI | 1 |
| Hoffer, BJ | 2 |
| Greig, NH | 2 |
| Choi, JG | 3 |
| Huh, E | 1 |
| Ju, IG | 1 |
| Kim, N | 1 |
| Yun, J | 1 |
| Oh, MS | 8 |
| Yamaguchi, H | 3 |
| Yamasaki, R | 1 |
| Cui, Y | 1 |
| Matsuoka, Y | 1 |
| Yamada, KI | 1 |
| Kira, JI | 1 |
| Kang, YC | 1 |
| Son, M | 1 |
| Kang, S | 2 |
| Im, S | 1 |
| Piao, Y | 3 |
| Song, MY | 1 |
| Park, KS | 1 |
| Pak, YK | 3 |
| Nigmatullina, R | 1 |
| Zalyalova, Z | 1 |
| Soshnikova, N | 1 |
| Krasnov, A | 1 |
| Vorobyeva, N | 1 |
| Georgieva, S | 1 |
| Kudrin, V | 1 |
| Narkevich, V | 1 |
| Choudhury, GR | 1 |
| Daadi, MM | 2 |
| Jang, Y | 1 |
| Kwon, I | 1 |
| Song, W | 1 |
| Cosio-Lima, LM | 1 |
| Taylor, S | 2 |
| Haeri, P | 1 |
| Mohammadipour, A | 1 |
| Heidari, Z | 1 |
| Ebrahimzadeh-Bideskan, A | 1 |
| Lai, F | 1 |
| Jiang, R | 1 |
| Xie, W | 1 |
| Ansari, JA | 1 |
| Yu, X | 1 |
| Sui, D | 1 |
| Chen, H | 3 |
| Lv, Y | 1 |
| Jiao, J | 1 |
| Mao, X | 1 |
| Xue, X | 1 |
| Su, J | 1 |
| Huang, P | 2 |
| Qin, M | 1 |
| Lu, Q | 1 |
| Liu, F | 1 |
| Wu, R | 1 |
| Lee, SB | 1 |
| Kim, HT | 1 |
| Yang, HO | 2 |
| Jang, W | 1 |
| Tonouchi, A | 2 |
| Yoon, HJ | 1 |
| Yoo, J | 1 |
| Park, HS | 1 |
| Ahn, YJ | 1 |
| Lim, SM | 1 |
| Nicholatos, JW | 1 |
| Francisco, AB | 1 |
| Bender, CA | 1 |
| Yeh, T | 1 |
| Lugay, FJ | 1 |
| Salazar, JE | 1 |
| Glorioso, C | 1 |
| Libert, S | 1 |
| Song, DH | 1 |
| Kim, GJ | 1 |
| Lee, KJ | 1 |
| Shin, JS | 1 |
| Kim, DH | 2 |
| Park, BJ | 1 |
| An, JH | 1 |
| Zhu, YL | 1 |
| Sun, MF | 1 |
| Cheng, K | 1 |
| Xu, YD | 1 |
| Zhou, ZL | 1 |
| Yang, XS | 1 |
| Cuenca, L | 1 |
| Sánchez, C | 1 |
| Estrada, C | 1 |
| Rey, F | 1 |
| Gorio, MCF | 1 |
| Ali, SJ | 2 |
| Ellur, G | 1 |
| Khan, MT | 1 |
| Sharan, K | 1 |
| Vidyadhara, DJ | 1 |
| Sasidharan, A | 1 |
| Kutty, BM | 1 |
| Raju, TR | 1 |
| Alladi, PA | 1 |
| Dou, F | 1 |
| Chu, X | 1 |
| Lu, G | 3 |
| Pupyshev, AB | 1 |
| Tikhonova, MA | 2 |
| Akopyan, AA | 1 |
| Tenditnik, MV | 1 |
| Dubrovina, NI | 1 |
| Korolenko, TA | 1 |
| Xu, SF | 1 |
| Zhang, YH | 2 |
| Pang, ZQ | 1 |
| Fan, YG | 1 |
| Li, JY | 1 |
| Wang, ZY | 1 |
| Guo, C | 1 |
| Xu, LL | 1 |
| Wu, YF | 1 |
| Li, CC | 1 |
| Dai, Z | 1 |
| You, QD | 1 |
| Jiang, ZY | 1 |
| Di, B | 1 |
| Gratuze, M | 1 |
| Josset, N | 1 |
| Petry, FR | 1 |
| Pflieger, M | 1 |
| Eyoum Jong, L | 1 |
| Truchetti, G | 1 |
| Poitras, I | 1 |
| Julien, J | 1 |
| Bezeau, F | 1 |
| Morin, F | 1 |
| Samadi, P | 3 |
| Cicchetti, F | 4 |
| Bretzner, F | 1 |
| Planel, E | 1 |
| Jiang, PE | 1 |
| Lang, QH | 1 |
| Yu, QY | 1 |
| Tang, XY | 1 |
| Liu, QQ | 1 |
| Li, XY | 1 |
| Feng, XZ | 1 |
| Chang, HC | 1 |
| Liu, KF | 1 |
| Teng, CJ | 1 |
| Lai, SC | 1 |
| Yang, SE | 1 |
| Ching, H | 1 |
| Wu, CR | 1 |
| Kim, KI | 1 |
| Selvaraj, V | 1 |
| Venkatasubramanian, H | 1 |
| Ilango, K | 1 |
| Santhakumar, K | 1 |
| Dou, S | 1 |
| Cheng, B | 1 |
| Ma, K | 1 |
| Han, C | 1 |
| Wan, F | 1 |
| Yin, S | 1 |
| Kou, L | 1 |
| Xiong, N | 1 |
| Tang, H | 1 |
| Gao, L | 2 |
| Huang, Z | 1 |
| Lv, DJ | 1 |
| Wang, YL | 1 |
| Qi, D | 1 |
| Zhu, Z | 2 |
| Qian, C | 1 |
| Xie, L | 1 |
| Chattopadhyay, M | 1 |
| Chowdhury, AR | 1 |
| Feng, T | 1 |
| Assenmacher, CA | 1 |
| Radaelli, E | 1 |
| Guengerich, FP | 1 |
| Avadhani, NG | 1 |
| Whittemore, K | 1 |
| Derevyanko, A | 1 |
| Martinez, P | 1 |
| Serrano, R | 1 |
| Pumarola, M | 1 |
| Bosch, F | 1 |
| Blasco, MA | 1 |
| Sampath, C | 1 |
| Kalpana, R | 1 |
| Ansah, T | 1 |
| Charlton, C | 1 |
| Hale, A | 1 |
| Channon, KM | 1 |
| Srinivasan, S | 1 |
| Gangula, PR | 1 |
| Xing, Y | 1 |
| Hu, ZL | 1 |
| Ding, JH | 2 |
| Du, RH | 1 |
| Ding, W | 1 |
| Fan, K | 1 |
| Qi, M | 1 |
| Xu, Y | 1 |
| Hu, YB | 1 |
| Zhang, YF | 1 |
| Ren, RJ | 1 |
| Cui, HL | 1 |
| Huang, WY | 1 |
| Cheng, Q | 1 |
| Chen, HZ | 1 |
| Steidinger, TU | 2 |
| Slone, SR | 1 |
| Ding, H | 2 |
| Standaert, DG | 4 |
| Yacoubian, TA | 3 |
| Al-Jarrah, M | 3 |
| Obaidat, H | 1 |
| Bataineh, Z | 1 |
| Walton, L | 1 |
| Al-Khateeb, A | 1 |
| Ayton, S | 1 |
| Lei, P | 1 |
| Duce, JA | 1 |
| Wong, BX | 1 |
| Sedjahtera, A | 1 |
| Adlard, PA | 2 |
| Bush, AI | 1 |
| Villalba, RM | 1 |
| Wichmann, T | 5 |
| Smith, Y | 3 |
| Zhu, G | 3 |
| Wu, S | 1 |
| Moro, C | 5 |
| Torres, N | 5 |
| El Massri, N | 5 |
| Ratel, D | 1 |
| Johnstone, DM | 6 |
| Stone, J | 6 |
| Mitrofanis, J | 10 |
| Benabid, AL | 9 |
| Amini, M | 1 |
| Ma, CL | 1 |
| Farazifard, R | 1 |
| Vanderluit, J | 1 |
| Zoltewicz, JS | 1 |
| Hage, F | 1 |
| Savitt, JM | 1 |
| Lagace, DC | 1 |
| Slack, RS | 3 |
| Beique, JC | 1 |
| Baudry, M | 1 |
| Greer, PA | 1 |
| Bergeron, R | 1 |
| Park, DS | 5 |
| Castro, AA | 4 |
| Wiemes, BP | 1 |
| Matheus, FC | 4 |
| Lapa, FR | 1 |
| Viola, GG | 1 |
| Santos, AR | 2 |
| Tasca, CI | 4 |
| Prediger, RD | 8 |
| Dixit, A | 1 |
| Srivastava, G | 1 |
| Verma, D | 1 |
| Mishra, M | 2 |
| Singh, PK | 1 |
| Prakash, O | 1 |
| Singh, MP | 3 |
| González, H | 1 |
| Contreras, F | 1 |
| Prado, C | 1 |
| Elgueta, D | 1 |
| Franz, D | 1 |
| Bernales, S | 1 |
| Pacheco, R | 1 |
| Tristão, FS | 1 |
| Amar, M | 1 |
| Latrous, I | 1 |
| Del-Bel, EA | 1 |
| Raisman-Vozari, R | 3 |
| Quiroga-Varela, A | 1 |
| Walters, JR | 1 |
| Brazhnik, E | 1 |
| Marin, C | 1 |
| Obeso, JA | 2 |
| Imam, SZ | 1 |
| Trickler, W | 1 |
| Kimura, S | 1 |
| Binienda, ZK | 1 |
| Paule, MG | 1 |
| Slikker, W | 1 |
| Ali, SF | 2 |
| Fifel, K | 2 |
| Dkhissi-Benyahya, O | 1 |
| Cooper, HM | 2 |
| Mundiñano, IC | 1 |
| Hernandez, M | 1 |
| Dicaudo, C | 1 |
| Ordoñez, C | 1 |
| Marcilla, I | 2 |
| Tuñon, MT | 1 |
| Luquin, MR | 4 |
| Alvarez-Fischer, D | 4 |
| Noelker, C | 3 |
| Grünewald, A | 1 |
| Vulinović, F | 2 |
| Guerreiro, S | 2 |
| Fuchs, J | 1 |
| Lombès, A | 2 |
| Oertel, WH | 7 |
| Michel, PP | 3 |
| Hartmann, A | 5 |
| Lao, CL | 1 |
| Kuo, YH | 1 |
| Hsieh, YT | 1 |
| Chen, JC | 1 |
| Li, XZ | 2 |
| Zhang, SN | 1 |
| Lu, F | 3 |
| Wang, N | 1 |
| Liu, SM | 3 |
| Zhao, Q | 1 |
| Cai, D | 1 |
| Li, P | 1 |
| Zhang, ZJ | 1 |
| Ren, HB | 1 |
| Zhang, SZ | 1 |
| Ni, YY | 1 |
| Lu, JW | 1 |
| Wu, XL | 1 |
| Gu, MM | 1 |
| Lu, ZY | 1 |
| Wang, ZG | 2 |
| Ren, ZH | 1 |
| Hao, D | 1 |
| Purushothuman, S | 1 |
| Nandasena, C | 1 |
| Peoples, CL | 2 |
| Zachrisson, O | 1 |
| Zhao, M | 1 |
| Andersson, A | 1 |
| Dannaeus, K | 1 |
| Häggblad, J | 1 |
| Isacson, R | 1 |
| Nielsen, E | 1 |
| Patrone, C | 1 |
| Rönnholm, H | 1 |
| Wikstrom, L | 1 |
| Delfani, K | 2 |
| McCormack, AL | 2 |
| Palmer, T | 1 |
| Di Monte, DA | 5 |
| Janson Lang, AM | 1 |
| Haegerstrand, A | 1 |
| Zhelev, Z | 1 |
| Bakalova, R | 1 |
| Aoki, I | 1 |
| Lazarova, D | 1 |
| Saga, T | 1 |
| Rekha, KR | 1 |
| Santha, K | 1 |
| Inmozhi Sivakamasundari, R | 1 |
| Kurtenbach, S | 1 |
| Wewering, S | 1 |
| Hatt, H | 1 |
| Neuhaus, EM | 1 |
| Lübbert, H | 1 |
| Guo, B | 1 |
| Xu, D | 3 |
| Duan, H | 1 |
| Lee, SM | 1 |
| Prakash, J | 1 |
| Chouhan, S | 1 |
| Westfall, S | 1 |
| Verma, M | 1 |
| Singh, TD | 1 |
| Kim, HG | 5 |
| Kang, MS | 1 |
| Hong, SP | 1 |
| Porras, G | 2 |
| De Deurwaerdere, P | 1 |
| Marti, M | 1 |
| Morgenstern, R | 1 |
| Sohr, R | 1 |
| Morari, M | 1 |
| Meissner, WG | 2 |
| Willis, GL | 2 |
| Armstrong, SM | 2 |
| Youn, JK | 1 |
| Kim, ST | 4 |
| Park, SY | 2 |
| Lee, HR | 1 |
| Cho, SW | 2 |
| Hwang, HS | 2 |
| Pérez-H, J | 1 |
| Carrillo-S, C | 1 |
| García, E | 2 |
| Ruiz-Mar, G | 1 |
| Pérez-Tamayo, R | 1 |
| Chavarría, A | 1 |
| Shin, JY | 3 |
| Kim, HN | 2 |
| Oh, SH | 2 |
| Lee, PH | 3 |
| Shi, X | 2 |
| Miao, S | 1 |
| Bi, L | 1 |
| Yang, Q | 1 |
| Xie, Y | 1 |
| Miao, Q | 1 |
| Wakeman, DR | 1 |
| Redmond, DE | 8 |
| Dodiya, HB | 1 |
| Sladek, JR | 7 |
| Leranth, C | 1 |
| Teng, YD | 1 |
| Samulski, RJ | 1 |
| Snyder, EY | 1 |
| Sikorska, M | 1 |
| Lanthier, P | 1 |
| Miller, H | 1 |
| Beyers, M | 1 |
| Sodja, C | 1 |
| Zurakowski, B | 1 |
| Gangaraju, S | 1 |
| Sandhu, JK | 1 |
| Karuppagounder, SS | 2 |
| Brahmachari, S | 2 |
| Dawson, VL | 4 |
| Dawson, TM | 4 |
| Ko, HS | 1 |
| Kanagaraj, N | 1 |
| Beiping, H | 1 |
| Dheen, ST | 1 |
| Tay, SS | 1 |
| Tian, L | 3 |
| Karimi, M | 3 |
| Brown, CA | 2 |
| Loftin, SK | 2 |
| Perlmutter, JS | 3 |
| Feng, G | 1 |
| Bao, Q | 1 |
| Jiang, J | 2 |
| Smith, ML | 1 |
| King, J | 2 |
| Dent, L | 1 |
| Mackey, V | 2 |
| Muthian, G | 2 |
| Griffin, B | 1 |
| Charlton, CG | 2 |
| Morel, L | 1 |
| Osterloh, A | 1 |
| Lescot, T | 1 |
| Breloer, M | 1 |
| Gold, M | 1 |
| Henze, C | 1 |
| Dodel, RC | 1 |
| Hunot, S | 3 |
| Khan, HA | 1 |
| Dugan, LL | 1 |
| Quick, KL | 1 |
| Hardt, JI | 1 |
| Brown, C | 1 |
| Loftin, S | 1 |
| Flores, H | 1 |
| Moerlein, SM | 1 |
| Polich, J | 1 |
| Tabbal, SD | 1 |
| Mink, JW | 1 |
| Morin, N | 2 |
| Grégoire, L | 6 |
| Johnston, TM | 1 |
| Fox, SH | 9 |
| Sun, N | 1 |
| Yun, HM | 1 |
| Oh, KW | 3 |
| Rajini, PS | 1 |
| Wei, D | 1 |
| Yang, M | 1 |
| Kong, L | 1 |
| Lee, JA | 1 |
| Kim, JH | 1 |
| Woo, SY | 1 |
| Son, HJ | 3 |
| Han, SH | 1 |
| Kim, DJ | 1 |
| Eom, SA | 1 |
| Ahn, EH | 2 |
| Chung, SY | 1 |
| Sohn, EJ | 1 |
| Jo, HS | 1 |
| Jeon, SJ | 1 |
| Kwon, HY | 1 |
| Rappold, PM | 1 |
| Grima, JC | 1 |
| Fan, RZ | 1 |
| de Mesy-Bentley, KL | 1 |
| Zhuang, X | 1 |
| Bowers, WJ | 1 |
| Tieu, K | 4 |
| Jin, H | 1 |
| Kanthasamy, A | 4 |
| Harischandra, DS | 1 |
| Anantharam, V | 1 |
| Rana, A | 1 |
| Poulin, JF | 1 |
| Zou, J | 1 |
| Drouin-Ouellet, J | 1 |
| Kim, KY | 1 |
| Awatramani, RB | 1 |
| Kim, YS | 3 |
| Park, PJ | 2 |
| Lim, JH | 1 |
| Peritore, C | 1 |
| Ginsberg, J | 1 |
| Shih, J | 1 |
| Arun, S | 1 |
| Donmez, G | 1 |
| Tyagi, RK | 1 |
| Bisht, R | 2 |
| Pant, J | 1 |
| Kumar, P | 1 |
| Majeed, AB | 1 |
| Prakash, A | 2 |
| Hong, X | 1 |
| Depboylu, C | 2 |
| Rösler, TW | 1 |
| de Andrade, A | 1 |
| Höglinger, GU | 3 |
| Lim, HW | 1 |
| Park, JI | 1 |
| More, SV | 1 |
| Jeon, SB | 1 |
| Yun, YS | 1 |
| Park, EJ | 1 |
| Yano, R | 4 |
| Itoh, T | 2 |
| Yamada, M | 4 |
| Momoshima, S | 1 |
| Okano, HJ | 1 |
| Wales, P | 1 |
| Quinti, L | 1 |
| Zuo, F | 2 |
| Moniot, S | 2 |
| Herisson, F | 1 |
| Rauf, NA | 1 |
| Silverman, RB | 1 |
| Ayata, C | 1 |
| Maxwell, MM | 1 |
| Steegborn, C | 2 |
| Schwarzschild, MA | 5 |
| Outeiro, TF | 2 |
| Kazantsev, AG | 1 |
| Manolov, AI | 1 |
| Dolgikh, VV | 1 |
| Ukraintseva, IuV | 1 |
| Zavalko, IM | 1 |
| Pronina, TS | 1 |
| Ugriumov, MV | 4 |
| Dorokhov, VB | 1 |
| Koval'zon, VM | 1 |
| Jing, H | 2 |
| Guo, H | 2 |
| Chai, L | 1 |
| Hu, L | 1 |
| Bao, XQ | 2 |
| Wu, LY | 2 |
| Zhang, D | 2 |
| Zuo, P | 1 |
| Anitua, E | 1 |
| Pascual, C | 1 |
| Pérez-Gonzalez, R | 1 |
| Orive, G | 1 |
| Carro, E | 1 |
| Erekat, NS | 1 |
| Stojkovska, I | 1 |
| Wagner, BM | 1 |
| Morrison, BE | 1 |
| Takahashi-Niki, K | 1 |
| Inafune, A | 1 |
| Michitani, N | 1 |
| Hatakeyama, Y | 1 |
| Suzuki, K | 1 |
| Sasaki, M | 1 |
| Kitamura, Y | 3 |
| Niki, T | 1 |
| Iguchi-Ariga, SM | 1 |
| Ariga, H | 1 |
| Cappelletti, G | 1 |
| Casagrande, F | 1 |
| Calogero, A | 1 |
| De Gregorio, C | 1 |
| Pezzoli, G | 1 |
| Cartelli, D | 1 |
| Yang, RY | 1 |
| Lian, WW | 1 |
| Fang, JS | 1 |
| Pang, XC | 1 |
| Qin, XM | 1 |
| Liu, AL | 1 |
| Du, GH | 1 |
| Nevin, DK | 1 |
| Mulas, G | 1 |
| Casu, MA | 1 |
| Diana, A | 1 |
| Rossi, D | 1 |
| Sacchetti, G | 1 |
| Carta, AR | 2 |
| Urs, NM | 1 |
| Peterson, SM | 1 |
| Daigle, TL | 1 |
| Bass, CE | 1 |
| Gainetdinov, RR | 2 |
| Caron, MG | 2 |
| Hu, R | 1 |
| Li, K | 1 |
| Jourdain, VA | 1 |
| Sconce, MD | 2 |
| Greene, RE | 1 |
| Wang, YQ | 1 |
| Wang, MY | 1 |
| Fu, XR | 1 |
| Gao, GF | 1 |
| Fan, YM | 1 |
| Duan, XL | 1 |
| Zhao, BL | 1 |
| Chang, YZ | 1 |
| Shi, ZH | 1 |
| Lim, CS | 1 |
| Seo, H | 1 |
| Park, CA | 1 |
| Zhuo, M | 1 |
| Kaang, BK | 1 |
| Lee, K | 1 |
| Wang, XQ | 1 |
| Qiu, YH | 1 |
| Peng, YP | 1 |
| Xi, J | 1 |
| Xiao, B | 1 |
| Ma, C | 1 |
| Höllerhage, M | 1 |
| Sturn, A | 1 |
| Roscher, R | 1 |
| Andreas, H | 1 |
| Ferguson, SA | 1 |
| Law, CD | 1 |
| Sarkar, S | 1 |
| Lv, E | 1 |
| Gong, X | 1 |
| Jia, J | 1 |
| Jalewa, J | 1 |
| Sharma, M | 1 |
| Ray, A | 1 |
| Sehgal, N | 1 |
| Karunakaran, S | 2 |
| Rangarajan, G | 1 |
| Ravindranath, V | 2 |
| Hong, J | 3 |
| Sha, S | 1 |
| Zhai, SY | 1 |
| Zhang, HN | 1 |
| Wang, YH | 1 |
| Pu, XP | 2 |
| He, XJ | 2 |
| Nakayama, H | 2 |
| Mounsey, RB | 2 |
| Mustafa, S | 3 |
| Robinson, L | 1 |
| Ross, RA | 1 |
| Pertwee, RG | 1 |
| Choi, JS | 2 |
| Bae, WY | 1 |
| Park, C | 1 |
| Jeong, JW | 2 |
| Lv, L | 1 |
| Feng, YM | 1 |
| Li, GD | 1 |
| Zhou, HJ | 1 |
| Lei, XG | 1 |
| Li, JL | 1 |
| Hu, XT | 1 |
| Underwood, R | 1 |
| Lavalley, N | 1 |
| Pflibsen, L | 2 |
| Stang, KA | 1 |
| Wilson, VB | 1 |
| Hood, RL | 1 |
| Mitchell, SH | 1 |
| Binukumar, BK | 1 |
| Shukla, V | 1 |
| Amin, ND | 1 |
| Grant, P | 1 |
| Bhaskar, M | 1 |
| Skuntz, S | 1 |
| Steiner, J | 1 |
| Pant, HC | 1 |
| Franke, SK | 2 |
| van Kesteren, RE | 2 |
| Wubben, JA | 2 |
| Hofman, S | 2 |
| Paliukhovich, I | 1 |
| van der Schors, RC | 1 |
| van Nierop, P | 1 |
| Smit, AB | 3 |
| Philippens, IH | 4 |
| Chun, HJ | 2 |
| Jung, YS | 1 |
| Schlachetzki, JC | 2 |
| Grimm, T | 1 |
| Schlachetzki, Z | 1 |
| Ben Abdallah, NM | 1 |
| Ettle, B | 1 |
| Vöhringer, P | 1 |
| Ferger, B | 7 |
| Winner, B | 1 |
| Nuber, S | 1 |
| Winkler, J | 2 |
| Chung, ES | 2 |
| Lee, G | 2 |
| Lee, C | 1 |
| Ye, M | 1 |
| Chung, HS | 1 |
| Bae, SJ | 1 |
| Hwang, DS | 2 |
| Bae, H | 3 |
| Darlot, F | 3 |
| Chabrol, C | 4 |
| Reinhart, F | 2 |
| Agay, D | 3 |
| Bekha, D | 1 |
| Auboiroux, V | 2 |
| Costecalde, T | 1 |
| Anastascio, HD | 1 |
| Shaw, VE | 2 |
| Filali, M | 1 |
| Lalonde, R | 1 |
| Muñoz-Manchado, AB | 1 |
| Villadiego, J | 2 |
| Romo-Madero, S | 1 |
| Suárez-Luna, N | 1 |
| Bermejo-Navas, A | 1 |
| Rodríguez-Gómez, JA | 1 |
| Garrido-Gil, P | 3 |
| Labandeira-García, JL | 3 |
| Echevarría, M | 1 |
| López-Barneo, J | 2 |
| Toledo-Aral, JJ | 2 |
| Martin, HL | 3 |
| Forrester, JV | 2 |
| Bae, N | 1 |
| Qu, HD | 2 |
| Menon, SA | 1 |
| Al-Mansoori, KM | 1 |
| Al-Wandi, A | 1 |
| Majbour, NK | 1 |
| Varghese, S | 1 |
| Vaikath, NN | 1 |
| Azzouz, M | 1 |
| El-Agnaf, OM | 1 |
| Mandal, S | 1 |
| Mandal, SD | 1 |
| Chuttani, K | 1 |
| Sawant, KK | 1 |
| Subudhi, BB | 1 |
| Mu, Z | 1 |
| Hu, JF | 1 |
| Liang, R | 1 |
| Yang, B | 1 |
| Fang, F | 1 |
| Thiollier, T | 1 |
| Wu, C | 1 |
| Contamin, H | 1 |
| Zhao, XD | 2 |
| Wang, FX | 1 |
| Cao, WF | 1 |
| Mitra, S | 1 |
| Ghosh, N | 1 |
| Sinha, P | 1 |
| Chakrabarti, N | 1 |
| Bhattacharyya, A | 1 |
| Hwang, CJ | 2 |
| Jung, YY | 1 |
| Lee, YJ | 1 |
| Yun, JS | 1 |
| Han, SB | 2 |
| Oh, S | 1 |
| Park, MH | 1 |
| Viana, SD | 1 |
| Fernandes, RC | 1 |
| Canas, PM | 1 |
| Silva, AM | 1 |
| Carvalho, F | 1 |
| Fontes Ribeiro, CA | 1 |
| Pereira, FC | 1 |
| Lauretti, E | 1 |
| Di Meco, A | 1 |
| Merali, S | 1 |
| Praticò, D | 1 |
| Al-Sweidi, S | 2 |
| Maetzler, W | 2 |
| Stathakos, P | 1 |
| Hobert, MA | 1 |
| Rattay, TW | 1 |
| Gasser, T | 1 |
| Berg, D | 4 |
| Tracey, KJ | 1 |
| Quek, CY | 1 |
| Hung, LW | 1 |
| Sharples, RA | 1 |
| Sherratt, NA | 1 |
| Barnham, KJ | 1 |
| Hill, AF | 1 |
| Weng, JC | 1 |
| Chen, JH | 1 |
| Shen, MS | 1 |
| Meng, WY | 1 |
| Chang, YT | 1 |
| Chen, KH | 1 |
| Liang, KC | 1 |
| Hung, CS | 1 |
| Amstislavskaya, TG | 1 |
| Ho, YJ | 2 |
| Ren, YD | 1 |
| Jing, YE | 1 |
| Zhang, SX | 1 |
| Sarath Babu, N | 1 |
| Murthy, ChL | 1 |
| Kakara, S | 1 |
| Sharma, R | 1 |
| Brahmendra Swamy, CV | 1 |
| Idris, MM | 1 |
| Miville-Godbout, E | 1 |
| Smith, T | 1 |
| Mochizuki, A | 1 |
| Senanayake, V | 1 |
| Jayasinghe, D | 1 |
| Goodenowe, D | 1 |
| Cui, B | 1 |
| Dai, ZX | 1 |
| Shi, PK | 1 |
| Wang, ZH | 2 |
| Guo, YY | 1 |
| Kuo, HC | 1 |
| Lu, CC | 1 |
| Shen, CH | 1 |
| Tung, SY | 1 |
| Hsieh, MC | 1 |
| Lee, KC | 1 |
| Lee, LY | 1 |
| Chen, CC | 1 |
| Teng, CC | 1 |
| Huang, WS | 1 |
| Chen, TC | 1 |
| Lee, KF | 1 |
| Klein, C | 1 |
| Rasińska, J | 1 |
| Empl, L | 1 |
| Sparenberg, M | 1 |
| Poshtiban, A | 1 |
| Hain, EG | 1 |
| Iggena, D | 1 |
| Rivalan, M | 1 |
| Winter, Y | 1 |
| Steiner, B | 2 |
| Alam, G | 1 |
| Miller, DB | 1 |
| O'Callaghan, JP | 1 |
| Williams, RW | 1 |
| Jones, BC | 1 |
| Guan, Q | 1 |
| Hsieh, HY | 1 |
| Wu, SR | 1 |
| Tsai, CH | 1 |
| Huang, CY | 1 |
| Hua, MY | 1 |
| Wei, KC | 1 |
| Yeh, CK | 1 |
| Liu, HL | 1 |
| Kim, JY | 1 |
| Zhai, S | 1 |
| Xing, D | 1 |
| Calingasan, N | 1 |
| Smirnova, N | 1 |
| Gaisina, IN | 1 |
| Kaddour-Djebbar, I | 1 |
| Bollag, WB | 1 |
| Morgan, JC | 1 |
| Ratan, RR | 1 |
| Starkov, AA | 2 |
| Beal, MF | 14 |
| Guo, YJ | 1 |
| Dong, SY | 1 |
| Cui, XX | 1 |
| Yin, M | 1 |
| Kuo, SH | 1 |
| Tan, EK | 1 |
| Wu, YC | 1 |
| Zhang, LX | 1 |
| Sun, XY | 1 |
| Lee, HP | 1 |
| Jeong, HS | 1 |
| Kim, TH | 1 |
| Lee, TH | 1 |
| Moon, DB | 1 |
| Park, SS | 1 |
| Kim, SY | 4 |
| Hwang, DY | 1 |
| Zhang, JL | 1 |
| Duan, YL | 1 |
| Li, GF | 1 |
| Zheng, DL | 1 |
| Shin, WH | 1 |
| Baek, JY | 1 |
| Cho, EJ | 1 |
| Baik, HH | 1 |
| Kim, SR | 1 |
| Won, SY | 1 |
| Deffains, M | 1 |
| Iskhakova, L | 1 |
| Katabi, S | 1 |
| Haber, SN | 3 |
| Israel, Z | 2 |
| Bergman, H | 9 |
| Li, YH | 1 |
| Xi, JY | 2 |
| Yu, WB | 2 |
| Liu, JC | 1 |
| Feng, L | 2 |
| Yan, YP | 1 |
| Zhang, GX | 1 |
| Xiao-Feng, L | 1 |
| Wen-Ting, Z | 1 |
| Yuan-Yuan, X | 1 |
| Chong-Fa, L | 1 |
| Jin-Jun, R | 1 |
| Wen-Ya, W | 1 |
| Wang, YD | 2 |
| Xu, S | 1 |
| Yu, WW | 1 |
| Cao, SN | 1 |
| Hu, JP | 1 |
| Yu, SS | 1 |
| Joshi, BC | 1 |
| Kalia, AN | 1 |
| Marcondes Sari, MH | 1 |
| Pesarico, AP | 1 |
| Nogueira, CW | 1 |
| Yu, C | 1 |
| Kim, E | 1 |
| Li, DW | 1 |
| Zhou, SY | 1 |
| Sun, WP | 1 |
| Kammermeier, S | 1 |
| Pittard, D | 1 |
| Hamada, I | 1 |
| Nielsen, MS | 1 |
| Møller, A | 1 |
| Mogensen, P | 1 |
| Bender, D | 1 |
| Sørensen, JC | 1 |
| Doudet, D | 4 |
| Bjarkam, CR | 1 |
| Gu, PS | 1 |
| Moon, M | 2 |
| Da Costa, B | 1 |
| Dumon, E | 1 |
| Le Moigno, L | 1 |
| Bodard, S | 3 |
| Castelnau, P | 2 |
| Letellier, T | 1 |
| Rocher, C | 1 |
| Kim, D | 1 |
| Ryu, S | 1 |
| Koo, S | 1 |
| Ha, KT | 1 |
| Jiang, M | 1 |
| Yun, Q | 1 |
| Niu, G | 1 |
| Shi, F | 1 |
| Rajput, SK | 1 |
| Sharma, AK | 1 |
| Meena, CL | 1 |
| Pant, AB | 1 |
| Jain, R | 1 |
| Sharma, SS | 1 |
| Imgrund, S | 1 |
| Reich, A | 1 |
| Gründer, S | 1 |
| Wu, AG | 1 |
| Wong, VK | 1 |
| Zhu, YZ | 1 |
| Lo, AC | 1 |
| Law, BY | 1 |
| Zhao, YF | 1 |
| Massri, NE | 1 |
| Molet, J | 1 |
| Lee, JH | 2 |
| Bok, E | 1 |
| Huh, SH | 2 |
| Lee, JE | 1 |
| Ko, HW | 1 |
| Shadfar, S | 1 |
| Kim, YG | 1 |
| Katila, N | 1 |
| Neupane, S | 1 |
| Bhurtel, S | 1 |
| Srivastav, S | 1 |
| Jeong, GS | 1 |
| Cho, YJ | 1 |
| Cai, W | 1 |
| Maguire, M | 1 |
| Ya, B | 1 |
| Logan, R | 1 |
| Robinson, K | 1 |
| Vanderburg, CR | 1 |
| Fisher, DE | 1 |
| Masilamoni, GJ | 2 |
| Groover, O | 1 |
| Fu, W | 1 |
| Viveros-Paredes, JM | 1 |
| Gonzalez-Castañeda, RE | 1 |
| Escalante-Castañeda, A | 1 |
| Tejeda-Martínez, AR | 1 |
| Castañeda-Achutiguí, F | 1 |
| Flores-Soto, ME | 1 |
| Shen, XL | 1 |
| Song, N | 1 |
| Du, XX | 1 |
| Xie, JX | 4 |
| Jiang, H | 2 |
| Stayte, S | 1 |
| Rentsch, P | 1 |
| Tröscher, AR | 1 |
| Bamberger, M | 1 |
| Li, KM | 1 |
| Vissel, B | 1 |
| Meng, X | 1 |
| Tong, H | 1 |
| Qu, S | 2 |
| Giri, A | 1 |
| Lei, M | 1 |
| Janakiraman, U | 1 |
| Justin Thenmozhi, A | 1 |
| Dhanalakshmi, C | 1 |
| Song, BJ | 1 |
| Belloli, S | 1 |
| Pannese, M | 1 |
| Buonsanti, C | 1 |
| Maiorino, C | 1 |
| Di Grigoli, G | 1 |
| Carpinelli, A | 1 |
| Monterisi, C | 1 |
| Moresco, RM | 1 |
| Panina-Bordignon, P | 1 |
| Chen, XH | 1 |
| Teng, JJ | 1 |
| de Oliveira, RM | 1 |
| Vicente Miranda, H | 1 |
| Francelle, L | 1 |
| Pinho, R | 1 |
| Szegö, ÉM | 1 |
| Martinho, R | 1 |
| Munari, F | 1 |
| Lázaro, DF | 1 |
| Guerreiro, P | 1 |
| Fonseca-Ornelas, L | 1 |
| Marijanovic, Z | 1 |
| Antas, P | 1 |
| Gerhardt, E | 1 |
| Enguita, FJ | 1 |
| Fauvet, B | 1 |
| Penque, D | 1 |
| Pais, TF | 1 |
| Becker, S | 1 |
| Kügler, S | 1 |
| Lashuel, HA | 1 |
| Zweckstetter, M | 1 |
| Weng, CC | 1 |
| Chen, ZA | 1 |
| Chao, KT | 1 |
| Ee, TW | 1 |
| Lin, KJ | 2 |
| Chan, MH | 1 |
| Hsiao, IT | 1 |
| Yen, TC | 1 |
| Kung, MP | 1 |
| Hsu, CH | 1 |
| Wey, SP | 1 |
| Langston, JW | 9 |
| Castro-Hernández, J | 1 |
| Al Sweidi, S | 1 |
| Callier, S | 1 |
| Bian, M | 1 |
| Deng, C | 1 |
| Sun, F | 1 |
| Ding, F | 1 |
| Luan, L | 1 |
| Walton, A | 1 |
| Gerhardt, GA | 3 |
| Natale, G | 1 |
| Pasquali, L | 1 |
| Ruggieri, S | 2 |
| Paparelli, A | 2 |
| Fornai, F | 4 |
| Kawasaki, T | 2 |
| Ago, Y | 2 |
| Kitao, T | 1 |
| Nashida, T | 2 |
| Takagi, A | 1 |
| Takuma, K | 2 |
| Matsuda, T | 2 |
| Li, LJ | 1 |
| Meredith, GE | 4 |
| Totterdell, S | 3 |
| Potashkin, JA | 1 |
| Surmeier, DJ | 2 |
| Arias, RL | 1 |
| Sung, ML | 2 |
| Vasylyev, D | 1 |
| Zhang, MY | 1 |
| Albinson, K | 2 |
| Kubek, K | 2 |
| Kagan, N | 1 |
| Beyer, C | 1 |
| Lin, Q | 1 |
| Dwyer, JM | 1 |
| Zaleska, MM | 2 |
| Bowlby, MR | 1 |
| Dunlop, J | 1 |
| Monaghan, M | 1 |
| Mak, SK | 1 |
| Shenasa, M | 1 |
| Langston, WJ | 1 |
| Forno, LS | 2 |
| Panaro, MA | 1 |
| Lofrumento, DD | 1 |
| Saponaro, C | 1 |
| De Nuccio, F | 1 |
| Cianciulli, A | 1 |
| Mitolo, V | 1 |
| Nicolardi, G | 1 |
| Ho, G | 1 |
| Kng, YL | 1 |
| Vucković, MG | 2 |
| Wood, RI | 3 |
| Holschneider, DP | 1 |
| Abernathy, A | 1 |
| Togasaki, DM | 2 |
| Smith, A | 1 |
| Petzinger, GM | 6 |
| Jakowec, MW | 6 |
| Saurini, F | 1 |
| Marien, M | 1 |
| Sokoloff, P | 1 |
| Dorval, AD | 1 |
| Russo, GS | 3 |
| Hashimoto, T | 5 |
| Xu, W | 2 |
| Grill, WM | 1 |
| Vitek, JL | 5 |
| Minematsu, M | 1 |
| Nakajima, K | 1 |
| Boger, HA | 1 |
| Middaugh, LD | 1 |
| Zaman, V | 1 |
| Hoffer, B | 2 |
| Granholm, AC | 1 |
| Domino, EF | 5 |
| Ni, L | 1 |
| Muñoz, A | 1 |
| Gardoni, F | 1 |
| Marcello, E | 1 |
| Qin, C | 3 |
| Carlsson, T | 1 |
| Kirik, D | 2 |
| Di Luca, M | 1 |
| Björklund, A | 2 |
| Carta, M | 1 |
| Muroyama, A | 1 |
| Inaka, M | 1 |
| Matsushima, H | 1 |
| Sugino, H | 1 |
| Marunaka, Y | 1 |
| Wang, YY | 2 |
| Wang, QD | 1 |
| Yuan, ZY | 1 |
| Zhang, ZX | 1 |
| Gu, P | 1 |
| Wang, MW | 1 |
| Limon, D | 1 |
| Perez-De La Cruz, V | 1 |
| Giordano, M | 1 |
| Diaz-Muñoz, M | 1 |
| Maldonado, PD | 1 |
| Herrera-Mundo, MN | 1 |
| Pedraza-Chaverri, J | 1 |
| Santamaria, A | 1 |
| Saeed, U | 1 |
| Valli, RK | 1 |
| Joshi, SD | 1 |
| Meka, DP | 1 |
| Seth, P | 1 |
| Campos-Romo, A | 1 |
| Ojeda-Flores, R | 1 |
| Moreno-Briseño, P | 1 |
| Fernandez-Ruiz, J | 2 |
| Byler, SL | 1 |
| Boehm, GW | 1 |
| Karp, JD | 1 |
| Kohman, RA | 1 |
| Tarr, AJ | 1 |
| Schallert, T | 1 |
| Barth, TM | 1 |
| Chaumette, T | 1 |
| Lebouvier, T | 1 |
| Aubert, P | 1 |
| Lardeux, B | 1 |
| Accary, D | 1 |
| Bruley des Varannes, S | 1 |
| Derkinderen, P | 1 |
| Neunlist, M | 1 |
| Takagi, Y | 2 |
| Saiki, H | 3 |
| Vázquez-Claverie, M | 2 |
| San Sebastián, W | 1 |
| Belzunegui, S | 1 |
| Izal-Azcárate, A | 1 |
| López, B | 1 |
| Visanji, NP | 5 |
| Johnston, T | 1 |
| Reyes, G | 1 |
| Millan, MJ | 2 |
| Pothakos, K | 2 |
| Kurz, MJ | 2 |
| Lau, YS | 7 |
| Perry, T | 1 |
| Kindy, MS | 1 |
| Harvey, BK | 1 |
| Tweedie, D | 1 |
| Holloway, HW | 1 |
| Powers, K | 1 |
| Shen, H | 1 |
| Egan, JM | 1 |
| Sambamurti, K | 1 |
| Brossi, A | 1 |
| Lahiri, DK | 1 |
| Mattson, MP | 2 |
| Graham, J | 1 |
| Bédard, PJ | 8 |
| Bartoszyk, GD | 1 |
| Vargas, MR | 1 |
| Pani, AK | 1 |
| Johnson, DA | 1 |
| Kan, YW | 1 |
| Johnson, JA | 1 |
| Kim, NK | 1 |
| Choi, BH | 1 |
| Snyder, BJ | 1 |
| Bukhari, S | 1 |
| Kong, TH | 1 |
| Park, HC | 1 |
| Park, SR | 1 |
| Ha, Y | 1 |
| Huang, LZ | 1 |
| Parameswaran, N | 1 |
| Bordia, T | 1 |
| Michael McIntosh, J | 1 |
| Quik, M | 4 |
| Eberling, JL | 3 |
| Kells, AP | 2 |
| Pivirotto, P | 4 |
| Beyer, J | 2 |
| Bringas, J | 3 |
| Federoff, HJ | 6 |
| Forsayeth, J | 2 |
| Bankiewicz, KS | 7 |
| Kurkowska-Jastrzebska, I | 5 |
| Bałkowiec-Iskra, E | 2 |
| Ciesielska, A | 2 |
| Joniec, I | 3 |
| Cudna, A | 1 |
| Zaremba, MM | 1 |
| Członkowski, A | 4 |
| Członkowska, A | 6 |
| Santiago, M | 2 |
| Hernández-Romero, MC | 1 |
| Machado, A | 2 |
| Cano, J | 2 |
| Dodd, CA | 1 |
| Klein, BG | 1 |
| Lagrue, E | 1 |
| Abert, B | 1 |
| Nadal, L | 1 |
| Tabone, L | 1 |
| Medja, F | 1 |
| Chalon, S | 3 |
| Shan, S | 1 |
| Hong-Min, T | 1 |
| Yi, F | 1 |
| Jun-Peng, G | 1 |
| Yan-Hong, T | 1 |
| Yun-Ke, Y | 1 |
| Wen-Wei, L | 1 |
| Xiang-Yu, W | 1 |
| Jun, M | 1 |
| Guo-Hua, W | 1 |
| Ya-Ling, H | 1 |
| Hua-Wei, L | 1 |
| Ding-Fang, C | 1 |
| Verhave, PS | 1 |
| Vanwersch, RA | 2 |
| van Helden, HP | 1 |
| Hwang, L | 1 |
| Seo, JH | 1 |
| Hwang, S | 1 |
| Lee, D | 1 |
| Chung, H | 1 |
| Lee, KT | 1 |
| Kasture, S | 1 |
| Pinna, A | 2 |
| Schintu, N | 2 |
| Spina, L | 1 |
| Longoni, R | 1 |
| Simola, N | 2 |
| Ballero, M | 1 |
| Morelli, M | 2 |
| Dluzen, DE | 1 |
| Gibrat, C | 2 |
| Saint-Pierre, M | 2 |
| Bousquet, M | 2 |
| Lévesque, D | 1 |
| Rouillard, C | 2 |
| Simon, A | 1 |
| Kirkham, M | 1 |
| Calingasan, NY | 6 |
| Wille, EJ | 2 |
| Cormier, K | 2 |
| Smith, K | 2 |
| Ferrante, RJ | 4 |
| Price, DA | 1 |
| Martinez, AA | 1 |
| Seillier, A | 1 |
| Koek, W | 1 |
| Acosta, Y | 1 |
| Fernandez, E | 1 |
| Strong, R | 1 |
| Lutz, B | 1 |
| Marsicano, G | 1 |
| Roberts, JL | 1 |
| Giuffrida, A | 1 |
| Brunet, JF | 1 |
| Bloch, J | 2 |
| Tandé, D | 1 |
| Karachi, C | 1 |
| François, C | 1 |
| Hoang, T | 1 |
| Nagai, M | 2 |
| Wu, DC | 3 |
| Nagata, T | 1 |
| Prou, D | 1 |
| Wilson, GL | 1 |
| Vila, M | 7 |
| Chesselet, MF | 1 |
| Winnik, B | 1 |
| Barr, DB | 1 |
| Thiruchelvam, M | 1 |
| Montesano, MA | 1 |
| Richfield, EK | 2 |
| Buckley, B | 1 |
| Aguiar, AS | 3 |
| Rojas-Mayorquin, AE | 1 |
| Figueiredo, CP | 3 |
| Ginestet, L | 1 |
| Chevarin, C | 1 |
| Bel, ED | 1 |
| Mongeau, R | 1 |
| Hamon, M | 1 |
| Lanfumey, L | 1 |
| Bian, MJ | 1 |
| Li, LM | 1 |
| Julien, C | 1 |
| Calon, F | 3 |
| Barraud, Q | 1 |
| Lambrecq, V | 1 |
| Forni, C | 1 |
| McGuire, S | 1 |
| Hill, M | 1 |
| Bioulac, B | 13 |
| Balzamo, E | 1 |
| Tison, F | 7 |
| Ghorayeb, I | 3 |
| Barber-Singh, J | 2 |
| Seo, BB | 4 |
| Nakamaru-Ogiso, E | 4 |
| Matsuno-Yagi, A | 4 |
| Yagi, T | 4 |
| Su, X | 1 |
| Huang, EJ | 1 |
| Lee, HS | 1 |
| Hadaczek, P | 1 |
| Penticuff, J | 1 |
| Eberling, J | 1 |
| Rial, D | 1 |
| Medeiros, R | 2 |
| Doty, RL | 1 |
| Takahashi, RN | 2 |
| Vautier, S | 1 |
| Milane, A | 1 |
| Fernandez, C | 1 |
| Chacun, H | 1 |
| Lacomblez, L | 1 |
| Farinotti, R | 1 |
| VanLeeuwen, JE | 1 |
| Walsh, JP | 1 |
| Akopian, GK | 1 |
| Vuckovic, M | 1 |
| Fujita, K | 1 |
| Seike, T | 1 |
| Yutsudo, N | 1 |
| Ohno, M | 2 |
| Yamada, H | 1 |
| Sakumi, K | 2 |
| Yamakawa, Y | 1 |
| Kido, MA | 1 |
| Takaki, A | 1 |
| Katafuchi, T | 1 |
| Tanaka, Y | 1 |
| Nakabeppu, Y | 2 |
| Noda, M | 1 |
| Ono, S | 1 |
| Hirai, K | 1 |
| Tokuda, E | 1 |
| Choi, JH | 1 |
| Ji, IJ | 1 |
| Kalivendi, SV | 2 |
| Yedlapudi, D | 1 |
| Hillard, CJ | 2 |
| Kalyanaraman, B | 2 |
| Ghosh, A | 3 |
| Roy, A | 2 |
| Matras, J | 1 |
| Gendelman, HE | 4 |
| Pahan, K | 2 |
| Tronci, E | 1 |
| Volpini, R | 1 |
| Cristalli, G | 1 |
| Yokoyama, H | 6 |
| Kuroiwa, H | 4 |
| Tsukada, T | 3 |
| Uchida, H | 4 |
| Kato, H | 8 |
| Araki, T | 8 |
| Pan, J | 1 |
| Qian, J | 1 |
| Hong, MS | 1 |
| Park, HK | 4 |
| Yang, JS | 1 |
| Kim, SN | 4 |
| Song, JY | 1 |
| Jo, DJ | 1 |
| Park, SW | 1 |
| HwanYun, D | 1 |
| Ban, JY | 2 |
| Chung, JH | 1 |
| Doo, AR | 3 |
| Moon, W | 2 |
| Yin, CS | 1 |
| Chae, Y | 2 |
| Sager, TN | 1 |
| Kirchhoff, J | 1 |
| Mørk, A | 1 |
| Van Beek, J | 1 |
| Thirstrup, K | 1 |
| Didriksen, M | 1 |
| Lauridsen, JB | 1 |
| Shu, D | 1 |
| He, J | 1 |
| Zigmond, MJ | 1 |
| Cameron, JL | 1 |
| Leak, RK | 1 |
| Mirnics, K | 1 |
| Russell, VA | 1 |
| Smith, AD | 1 |
| Malagelada, C | 1 |
| Jin, ZH | 1 |
| Greene, LA | 2 |
| Huo, QL | 1 |
| Liu, MN | 1 |
| Lin, XX | 1 |
| Liu, SJ | 1 |
| Gerecke, KM | 1 |
| Jiao, Y | 2 |
| Pani, A | 1 |
| Pagala, V | 1 |
| Garcia, BG | 1 |
| Neely, MD | 1 |
| Deutch, AY | 2 |
| Xu, G | 2 |
| Xiong, Z | 2 |
| Yong, Y | 1 |
| Ke, Z | 2 |
| Xia, Z | 3 |
| Sawada, H | 1 |
| Suzuki, H | 1 |
| Nagatsu, T | 2 |
| Sawada, M | 1 |
| Monaghan, MM | 1 |
| Leddy, L | 1 |
| Pangalos, MN | 1 |
| Reinhart, PH | 1 |
| Comery, TA | 1 |
| Subramanian, T | 1 |
| Lieu, CA | 1 |
| Guttalu, K | 1 |
| Keay, KA | 1 |
| Ashkan, K | 4 |
| Singh, K | 2 |
| Singhal, NK | 1 |
| Sharma, A | 1 |
| Parmar, D | 1 |
| Lee, MS | 2 |
| Antzoulatos, E | 1 |
| McCollum, M | 1 |
| Ma, Z | 1 |
| Cohen, E | 1 |
| Leon, R | 1 |
| Tao, R | 1 |
| Wu, JY | 1 |
| Maharaj, D | 1 |
| Wei, J | 1 |
| Reksidler, AB | 2 |
| Lima, MM | 4 |
| Dombrowski, PA | 3 |
| Barnabé, GF | 1 |
| Andersen, ML | 2 |
| Tufik, S | 2 |
| Vital, MA | 4 |
| Kasahara, J | 2 |
| Kimoto, H | 2 |
| Kreisler, A | 2 |
| Duhamel, A | 1 |
| Vanbesien-Mailliot, C | 1 |
| Destée, A | 3 |
| Shah, A | 1 |
| Garzon-Muvdi, T | 1 |
| Mahajan, R | 1 |
| Duenas, VJ | 1 |
| Quiñones-Hinojosa, A | 1 |
| Phani, S | 1 |
| Gonye, G | 1 |
| Iacovitti, L | 1 |
| Mohanakumar, KP | 5 |
| Gorton, LM | 1 |
| Vertelkina, N | 1 |
| Bazzu, G | 1 |
| Calia, G | 1 |
| Puggioni, G | 1 |
| Spissu, Y | 1 |
| Rocchitta, G | 2 |
| Debetto, P | 1 |
| Grigoletto, J | 1 |
| Zusso, M | 1 |
| Migheli, R | 1 |
| Serra, PA | 3 |
| Desole, MS | 2 |
| Miele, E | 2 |
| Khaindrava, VG | 4 |
| Kucherianu, VG | 2 |
| Klodt, PD | 3 |
| Bocharov, EV | 3 |
| Raevskiĭ, KS | 3 |
| Kryzhanovskiĭ, GN | 6 |
| Santiago, RM | 1 |
| Barbieiro, J | 1 |
| Andreatini, R | 3 |
| Jamous, M | 1 |
| Al Zailaey, K | 1 |
| Bweir, SO | 1 |
| Ariza, D | 1 |
| Moreira, CG | 1 |
| Avila, TV | 1 |
| Allemand, A | 1 |
| Mendes, DA | 1 |
| Da Cunha, C | 5 |
| Sallinen, V | 1 |
| Kolehmainen, J | 1 |
| Priyadarshini, M | 1 |
| Toleikyte, G | 1 |
| Panula, P | 1 |
| Ju, MS | 1 |
| Cho, SH | 1 |
| Cho, KH | 2 |
| Park, W | 1 |
| Lee, EH | 2 |
| Eun-Kyung, K | 1 |
| Moon, SK | 1 |
| Jung, WS | 1 |
| Hodgson, RA | 1 |
| Varty, GB | 1 |
| Kazdoba, TM | 1 |
| Grzelak, ME | 1 |
| Pond, AJ | 1 |
| Hadjtahar, A | 1 |
| Belanger, N | 2 |
| Dare, A | 1 |
| Neustadt, BR | 1 |
| Stamford, AW | 1 |
| Hunter, JC | 1 |
| Rivlin-Etzion, M | 2 |
| Elias, S | 1 |
| Heimer, G | 2 |
| Akazawa, YO | 1 |
| Saito, Y | 1 |
| Hamakubo, T | 1 |
| Masuo, Y | 1 |
| Yoshida, Y | 1 |
| Nishio, K | 1 |
| Shichiri, M | 1 |
| Miyasaka, T | 1 |
| Iwanari, H | 1 |
| Mochizuki, Y | 1 |
| Kodama, T | 1 |
| Noguchi, N | 1 |
| Niki, E | 1 |
| Ovsepian, LM | 1 |
| Kazarian, GS | 1 |
| Zakarian, AV | 1 |
| L'vov, MV | 1 |
| Melkonian, MM | 1 |
| Zakharian, GV | 1 |
| Akopdzhanian, AA | 1 |
| Ershov, PV | 1 |
| Antsiperov, VE | 1 |
| Obukhov, IuV | 1 |
| Nanaev, AK | 2 |
| Chandran, K | 1 |
| Joseph, J | 1 |
| Antholine, WE | 1 |
| Tayarani-Binazir, K | 1 |
| McCreary, AC | 1 |
| Rylander, D | 1 |
| Parent, M | 1 |
| O'Sullivan, SS | 1 |
| Dovero, S | 7 |
| Lees, AJ | 1 |
| Descarries, L | 1 |
| Cenci, MA | 1 |
| Kida, K | 2 |
| Amutuhaire, W | 1 |
| Ichinose, F | 2 |
| Kaneki, M | 2 |
| Choi, CB | 1 |
| Lee, SH | 1 |
| Jahng, GH | 1 |
| Choe, BY | 1 |
| Ryu, KN | 1 |
| Yang, DM | 1 |
| Yim, SV | 1 |
| Pasquereau, B | 1 |
| Turner, RS | 1 |
| Tokuda, K | 1 |
| Marutani, E | 1 |
| Kakinohana, M | 1 |
| Seval-Celik, Y | 2 |
| Ozsoy, O | 3 |
| Akkoyunlu, G | 1 |
| Savcioglu, F | 1 |
| Hacioglu, G | 2 |
| Demir, N | 2 |
| Impagnatiello, F | 1 |
| Morale, MC | 3 |
| Santaniello, S | 2 |
| Gale, JT | 2 |
| Montgomery, EB | 2 |
| Sarma, SV | 2 |
| Kim, MC | 1 |
| Yang, WM | 1 |
| Huh, Y | 2 |
| Uysal, N | 1 |
| Gemici, B | 1 |
| Kencebay, C | 1 |
| Yargicoglu, P | 1 |
| Aslan, M | 1 |
| Zimin, IA | 1 |
| Voronina, TA | 2 |
| Kovalev, GI | 2 |
| Chi, Y | 1 |
| Wen, X | 1 |
| Kong, H | 1 |
| Sonoda, L | 1 |
| Tripathi, P | 1 |
| Li, CJ | 1 |
| Yu, MS | 1 |
| Su, C | 1 |
| Miller, JA | 1 |
| Trout, BR | 1 |
| Sullivan, KA | 1 |
| Bialecki, RA | 1 |
| Roberts, RA | 1 |
| Tjalkens, RB | 1 |
| Kim, JI | 1 |
| Yang, EJ | 1 |
| Cho, IH | 1 |
| Koh, HK | 1 |
| Moreira, EL | 1 |
| Walz, R | 2 |
| De Bem, AF | 1 |
| Latini, A | 2 |
| Farina, M | 1 |
| Goldberg, NR | 2 |
| Acuña-Castroviejo, D | 1 |
| Tapias, V | 1 |
| López, LC | 1 |
| Doerrier, C | 1 |
| Camacho, E | 1 |
| Carrión, MD | 1 |
| Mora, F | 1 |
| Espinosa, A | 1 |
| Escames, G | 1 |
| Banerjee, R | 1 |
| Starkova, NN | 1 |
| Zhang, SF | 1 |
| Wille, E | 1 |
| Lorenzo, BJ | 1 |
| Ho, DJ | 1 |
| Starkov, A | 1 |
| Ardashov, OV | 1 |
| Pavlova, AV | 1 |
| Il'ina, IV | 1 |
| Morozova, EA | 1 |
| Korchagina, DV | 1 |
| Karpova, EV | 1 |
| Volcho, KP | 1 |
| Tolstikova, TG | 1 |
| Salakhutdinov, NF | 1 |
| Jiao, XY | 1 |
| Duan, L | 1 |
| Lee, MJ | 1 |
| Lee, BH | 1 |
| Han, HS | 1 |
| Domanskyi, A | 1 |
| Geissler, C | 1 |
| Vinnikov, IA | 1 |
| Alter, H | 1 |
| Schober, A | 2 |
| Vogt, MA | 1 |
| Gass, P | 1 |
| Parlato, R | 1 |
| Schütz, G | 1 |
| Jin, MY | 1 |
| Yoon, NS | 1 |
| Hong, JY | 1 |
| Hong, JK | 1 |
| Lira, A | 1 |
| Kulczycki, J | 1 |
| Slack, R | 2 |
| Anisman, H | 4 |
| Bogenpohl, JW | 1 |
| Alagille, D | 1 |
| Delevich, K | 1 |
| Tamagnan, G | 1 |
| Votaw, JR | 1 |
| Charron, G | 1 |
| Doudnikoff, E | 1 |
| Laux, A | 1 |
| Berthet, A | 1 |
| Canron, MH | 1 |
| Barroso-Chinea, P | 1 |
| Nosten-Bertrand, M | 1 |
| Giros, B | 1 |
| Delalande, F | 1 |
| Van Dorsselaer, A | 1 |
| Vital, A | 1 |
| Goumon, Y | 1 |
| Yasuda, T | 2 |
| Hayakawa, H | 3 |
| Nihira, T | 1 |
| Ren, YR | 2 |
| Nakata, Y | 1 |
| Miyake, K | 1 |
| Takada, M | 4 |
| Shimada, T | 1 |
| Mizuno, Y | 4 |
| Mochizuki, H | 3 |
| Salimov, RM | 1 |
| Vezoli, J | 1 |
| Leviel, V | 1 |
| Dehay, C | 1 |
| Kennedy, H | 1 |
| Gronfier, C | 1 |
| Procyk, E | 1 |
| Ota, Y | 1 |
| Cong, Y | 1 |
| Kitamoto, M | 1 |
| Takahashi, T | 1 |
| Shchepinov, MS | 1 |
| Chou, VP | 1 |
| Pollock, E | 1 |
| Cantor, CR | 1 |
| Molinari, RJ | 1 |
| Manning-Boğ, AB | 1 |
| Mudò, G | 1 |
| Mäkelä, J | 1 |
| Di Liberto, V | 1 |
| Tselykh, TV | 1 |
| Olivieri, M | 1 |
| Piepponen, P | 1 |
| Eriksson, O | 1 |
| Mälkiä, A | 1 |
| Bonomo, A | 1 |
| Kairisalo, M | 1 |
| Aguirre, JA | 1 |
| Korhonen, L | 1 |
| Belluardo, N | 1 |
| Lindholm, D | 1 |
| Xu, CL | 1 |
| Wang, QZ | 1 |
| Sun, LM | 1 |
| Li, XM | 1 |
| Deng, JM | 1 |
| Li, LF | 1 |
| Xu, R | 1 |
| Ma, SP | 1 |
| Tachibana, Y | 2 |
| Iwamuro, H | 1 |
| Kita, H | 2 |
| Nambu, A | 3 |
| Bové, J | 1 |
| Perier, C | 2 |
| Peng, S | 1 |
| Spetsieris, PG | 1 |
| Sossi, V | 1 |
| Eidelberg, D | 1 |
| Doudet, DJ | 2 |
| Shim, I | 1 |
| Domenger, D | 1 |
| Dea, D | 1 |
| Theroux, L | 1 |
| Moquin, L | 1 |
| Gratton, A | 1 |
| Poirier, J | 2 |
| Lee, JM | 1 |
| Lee, CH | 1 |
| Meng, Y | 1 |
| Fields, V | 1 |
| Salvatore, MF | 1 |
| Soreq, L | 1 |
| Ben-Shaul, Y | 1 |
| Soreq, H | 1 |
| Hsieh, MH | 1 |
| Gu, SL | 1 |
| Ho, SC | 1 |
| Pawlak, CR | 1 |
| Lin, CL | 1 |
| Lai, TJ | 1 |
| Wu, FY | 1 |
| Kucheryanu, VG | 1 |
| Kryzhanovsky, GN | 1 |
| Blandini, F | 1 |
| Armentero, MT | 1 |
| Tass, PA | 1 |
| Qin, L | 1 |
| Hauptmann, C | 1 |
| Boraud, T | 6 |
| Ghisoni, K | 1 |
| Quevedo, J | 1 |
| Deleidi, M | 1 |
| Joglar, B | 1 |
| Rodriguez-Perez, AI | 1 |
| Guerra, MJ | 2 |
| Xia, H | 1 |
| Mach, RH | 1 |
| Lee, JD | 1 |
| Huang, CH | 1 |
| Yang, ST | 1 |
| Chu, YH | 1 |
| Shieh, YY | 1 |
| Chen, JW | 1 |
| Huo, Y | 1 |
| Frank, T | 1 |
| Klinker, F | 1 |
| Laage, R | 2 |
| Lühder, F | 1 |
| Göricke, B | 2 |
| Schneider, A | 2 |
| Neurath, H | 1 |
| Desel, H | 1 |
| Liebetanz, D | 1 |
| Weishaupt, JH | 4 |
| Annese, V | 1 |
| Barcia, C | 3 |
| Ros-Bernal, F | 1 |
| Gómez, A | 1 |
| Ros, CM | 1 |
| De Pablos, V | 1 |
| De Stefano, ME | 1 |
| Cho, AR | 1 |
| Lee, SC | 1 |
| Lee, BR | 1 |
| Kim, HO | 1 |
| Tasaki, Y | 1 |
| Yamamoto, J | 1 |
| Omura, T | 1 |
| Sakaguchi, T | 1 |
| Kimura, N | 1 |
| Ohtaki, K | 1 |
| Ono, T | 2 |
| Suno, M | 1 |
| Asari, M | 1 |
| Ohkubo, T | 1 |
| Noda, T | 1 |
| Awaya, T | 1 |
| Shimizu, K | 1 |
| Matsubara, K | 2 |
| Sheline, CT | 1 |
| Shi, C | 1 |
| Cai, AL | 1 |
| Anandhan, A | 1 |
| Schumm, S | 1 |
| Sebban, C | 1 |
| Cohen-Salmon, C | 2 |
| Callebert, J | 2 |
| Launay, JM | 3 |
| Golmard, JL | 1 |
| Boussicault, L | 1 |
| Petropoulos, I | 1 |
| Hild, A | 1 |
| Rousselet, E | 2 |
| Friguet, B | 1 |
| Mariani, J | 1 |
| Saka-Topcuoglu, E | 1 |
| Balkan, S | 1 |
| Marxreiter, F | 1 |
| Regensburger, M | 1 |
| Henderson, CJ | 1 |
| Wolf, CR | 1 |
| Rodrigues, CM | 1 |
| Grueter, BA | 1 |
| Malenka, RC | 1 |
| Steinberg, GK | 1 |
| Villarinho, JG | 1 |
| Ferreira, J | 1 |
| Yuan, HH | 1 |
| Chen, RJ | 1 |
| Zhu, YH | 1 |
| Peng, CL | 1 |
| Zhu, XR | 1 |
| Wu, DD | 1 |
| Li, YC | 1 |
| Stricker, S | 1 |
| Ghobril, JP | 1 |
| Priller, J | 1 |
| Obayashi, S | 1 |
| Nagai, Y | 1 |
| Oh-Nishi, A | 1 |
| Minamimoto, T | 1 |
| Higuchi, M | 1 |
| Suhara, T | 1 |
| Morganti, JM | 1 |
| Nash, KR | 1 |
| Grimmig, BA | 1 |
| Ranjit, S | 1 |
| Small, B | 1 |
| Bickford, PC | 1 |
| Gemma, C | 1 |
| Pain, S | 1 |
| Gochard, A | 1 |
| Gulhan, Z | 1 |
| Prunier-Aesch, C | 1 |
| Kim, JJ | 1 |
| Kim, MK | 1 |
| Oh, NH | 1 |
| Shin, YK | 1 |
| Kim, IH | 1 |
| Kang, TB | 1 |
| Lee, KH | 1 |
| Klaissle, P | 1 |
| Lesemann, A | 1 |
| Huehnchen, P | 1 |
| Hermann, A | 1 |
| Storch, A | 1 |
| Tsang, KS | 1 |
| Kwong, WH | 1 |
| Wu, FX | 1 |
| Jiang, S | 1 |
| Liu, SW | 1 |
| Ng, HK | 1 |
| Poon, WS | 1 |
| Sathe, K | 1 |
| Lang, JD | 1 |
| Fleckenstein, C | 1 |
| Schulte, C | 1 |
| Synofzik, M | 1 |
| Vukovic, Z | 1 |
| Itohara, S | 1 |
| Kim, YN | 1 |
| Kim, HR | 1 |
| Woo, SJ | 1 |
| Kim, SM | 1 |
| Parsons, D | 1 |
| Janaurajs, K | 1 |
| Ye, W | 1 |
| Pioli, EY | 1 |
| Jianzhong, Y | 1 |
| Carboni, E | 1 |
| Spiga, S | 1 |
| Aron Badin, R | 1 |
| Spinnewyn, B | 1 |
| Gaillard, MC | 2 |
| Jan, C | 1 |
| Malgorn, C | 1 |
| Van Camp, N | 1 |
| Dollé, F | 1 |
| Guillermier, M | 1 |
| Boulet, S | 1 |
| Bertrand, A | 1 |
| Savasta, M | 1 |
| Auguet, M | 1 |
| Brouillet, E | 5 |
| Chabrier, PE | 1 |
| Hantraye, P | 7 |
| Farah, R | 1 |
| Khamisy-Farah, R | 1 |
| Amit, T | 1 |
| Youdim, MB | 7 |
| Arraf, Z | 1 |
| Sun, HM | 1 |
| Gao, YS | 1 |
| Wu, HX | 1 |
| Gong, XG | 1 |
| Breidert, T | 2 |
| Heneka, MT | 1 |
| Landreth, G | 1 |
| Schroeder, JA | 1 |
| Bar-Gad, I | 1 |
| Goldberg, JA | 2 |
| Suganuma, H | 1 |
| Hirano, T | 1 |
| Arimoto, Y | 1 |
| Inakuma, T | 1 |
| Bolin, LM | 1 |
| Strycharska-Orczyk, I | 1 |
| Murray, R | 1 |
| Di Monte, D | 1 |
| Mandir, AS | 2 |
| Simbulan-Rosenthal, CM | 1 |
| Poitras, MF | 1 |
| Lumpkin, JR | 1 |
| Smulson, ME | 1 |
| Kupina, NC | 1 |
| Detloff, MR | 1 |
| Dutta, S | 1 |
| Hall, ED | 1 |
| Matsumura, M | 2 |
| Kurosaki, R | 1 |
| Muramatsu, Y | 1 |
| Michimata, M | 1 |
| Matsubara, M | 1 |
| Itoyama, Y | 1 |
| Oh, JD | 2 |
| Bibbiani, F | 3 |
| Chase, TN | 5 |
| Fernagut, PO | 4 |
| Stefanova, N | 3 |
| Wenning, GK | 4 |
| Kuoppamäki, M | 2 |
| Al-Barghouthy, G | 1 |
| Smith, L | 3 |
| Zeng, BY | 1 |
| Quinn, N | 1 |
| Willesen, MG | 1 |
| Gammeltoft, S | 1 |
| Vaudano, E | 1 |
| Maratos, EC | 1 |
| Pearce, RK | 4 |
| Cannizzaro, C | 1 |
| Sugama, S | 1 |
| Cho, BP | 1 |
| DeGiorgio, LA | 1 |
| Lorenzl, S | 1 |
| Albers, DS | 1 |
| Volpe, BT | 1 |
| Joh, TH | 1 |
| Tillerson, JL | 3 |
| Miller, GW | 7 |
| Gross, CE | 13 |
| Ravenscroft, P | 4 |
| Jaber, M | 1 |
| Podell, M | 1 |
| Hadjiconstantinou, M | 1 |
| Smith, MA | 1 |
| Neff, NH | 1 |
| Delgado, M | 1 |
| Ganea, D | 1 |
| Elder, CM | 2 |
| Okun, MS | 1 |
| Patrick, SK | 1 |
| Robinson, S | 1 |
| Freeman, P | 1 |
| Touchon, JC | 1 |
| Krentz, L | 1 |
| Ischiropoulos, H | 3 |
| Murray, TK | 2 |
| Whalley, K | 2 |
| Robinson, CS | 1 |
| Ward, MA | 2 |
| Hicks, CA | 2 |
| Lodge, D | 1 |
| Vandergriff, JL | 1 |
| Baumbarger, P | 1 |
| Siuda, E | 1 |
| Gates, M | 1 |
| Ogden, AM | 1 |
| Skolnick, P | 2 |
| Zimmerman, DM | 1 |
| Nisenbaum, ES | 1 |
| Bleakman, D | 1 |
| O'Neill, MJ | 2 |
| Meissner, W | 2 |
| Crocker, SJ | 3 |
| Smith, PD | 3 |
| Lamba, WR | 1 |
| Hayley, SP | 1 |
| Grimm, E | 1 |
| Callaghan, SM | 1 |
| Melloni, E | 1 |
| Robertson, GS | 2 |
| Merali, Z | 1 |
| Puschban, Z | 1 |
| Reindl, M | 1 |
| Jellinger, KA | 1 |
| Poewe, W | 2 |
| Ramirez, AD | 1 |
| Menniti, FS | 2 |
| Krupina, NA | 3 |
| Goldstein, DS | 1 |
| Li, ST | 1 |
| Holmes, C | 1 |
| Bankiewicz, K | 3 |
| Caudle, WM | 5 |
| Reverón, ME | 2 |
| Orth, M | 1 |
| Tabrizi, SJ | 1 |
| Chassain, C | 2 |
| Eschalier, A | 2 |
| Durif, F | 2 |
| Takahata, K | 2 |
| Shimazu, S | 2 |
| Yoneda, F | 2 |
| Ogawa, M | 1 |
| Iida, Y | 2 |
| Saji, H | 2 |
| Tamashiro, A | 1 |
| Bautista, V | 2 |
| Sánchez-Bahillo, A | 1 |
| Navarro-Ruis, JM | 1 |
| Barreiro, AF | 1 |
| Poza Y Poza, M | 2 |
| Höglinger, G | 1 |
| Parain, K | 2 |
| Feger, J | 1 |
| Ruberg, M | 2 |
| Thiffault, C | 1 |
| Oiwa, Y | 1 |
| Nagy, D | 1 |
| Emborg, ME | 3 |
| Smith, LA | 4 |
| Collier, TJ | 6 |
| Steece-Collier, K | 2 |
| Kordower, JH | 5 |
| Henry, B | 3 |
| Crossman, AR | 9 |
| Jordan-Sciutto, KL | 1 |
| Hayley, S | 2 |
| Mount, MP | 1 |
| O'Hare, MJ | 1 |
| Callaghan, S | 1 |
| Ghribi, O | 1 |
| Herman, MM | 1 |
| Pramoonjago, P | 1 |
| Savory, J | 1 |
| Xu, K | 2 |
| Oztas, E | 1 |
| Petzer, JP | 3 |
| Castagnoli, K | 3 |
| Castagnoli, N | 4 |
| Chen, JF | 4 |
| Steyn, S | 1 |
| Van der Schyf, CJ | 1 |
| Hadj Tahar, A | 3 |
| Ren, J | 1 |
| Porter, JE | 1 |
| Wold, LE | 1 |
| Aberle, NS | 1 |
| Muralikrishnan, D | 2 |
| Haselton, JR | 1 |
| Diguet, E | 3 |
| Battaglia, G | 3 |
| Busceti, CL | 2 |
| Molinaro, G | 2 |
| Biagioni, F | 2 |
| Storto, M | 1 |
| Nicoletti, F | 2 |
| Bruno, V | 1 |
| Kulak, JM | 2 |
| Woodhouse, S | 1 |
| Osborne, DJ | 1 |
| Furuya, T | 2 |
| Yoshimi, K | 1 |
| Hisahara, S | 1 |
| Miura, M | 1 |
| Shree, T | 1 |
| Mount, M | 1 |
| Harnack, D | 1 |
| Benazzouz, A | 1 |
| Klivenyi, P | 5 |
| Gardian, G | 3 |
| Browne, SE | 2 |
| Bubber, P | 1 |
| Gibson, GE | 1 |
| Patel, MS | 1 |
| Betarbet, R | 2 |
| Poisik, O | 1 |
| Sherer, TB | 2 |
| Greenamyre, JT | 6 |
| Sánchez Bahillo, A | 1 |
| Fernández-Barreiro, A | 2 |
| Pankova, NB | 1 |
| Vetrilé, LA | 1 |
| Basharova, LA | 1 |
| Khlebnikova, NN | 1 |
| Rodina, VI | 1 |
| Silverdale, MA | 2 |
| Nicholson, SL | 1 |
| Benner, EJ | 1 |
| Mosley, RL | 3 |
| Destache, CJ | 1 |
| Lewis, TB | 1 |
| Gorantla, S | 1 |
| Nemachek, C | 1 |
| Green, SR | 1 |
| Puskovic, V | 1 |
| Wolfe, D | 1 |
| Goss, J | 1 |
| Huang, S | 1 |
| Mata, M | 1 |
| Glorioso, JC | 1 |
| Fink, DJ | 1 |
| Linazasoro, G | 1 |
| Lai, A | 1 |
| Sum, J | 1 |
| McIntosh, JM | 2 |
| Miwa, T | 1 |
| Watanabe, A | 1 |
| Furukawa, M | 1 |
| Fukushima, N | 1 |
| Moriizumi, T | 2 |
| Liu, B | 1 |
| Rowlands, DK | 1 |
| Gou, YL | 1 |
| Leung, CC | 1 |
| Chung, YW | 1 |
| Chan, HC | 1 |
| Leng, A | 2 |
| Mura, A | 2 |
| Hengerer, B | 1 |
| Feldon, J | 2 |
| Litwin, T | 2 |
| Przybyłkowski, A | 1 |
| Miller, RM | 3 |
| Callahan, LM | 1 |
| Casaceli, C | 1 |
| Kiser, GL | 2 |
| Chui, B | 1 |
| Kaysser-Kranich, TM | 2 |
| Sendera, TJ | 1 |
| Palaniappan, C | 2 |
| Levitskaya, NG | 1 |
| Sebentsova, EA | 1 |
| Andreeva, LA | 1 |
| Alfeeva, LY | 1 |
| Kamenskii, AA | 1 |
| Myasoedov, NF | 1 |
| Pardini, C | 1 |
| Bartoli, C | 1 |
| Dinucci, D | 1 |
| Corsini, GU | 2 |
| Takamatsu, H | 1 |
| Kakiuchi, T | 1 |
| Noda, A | 1 |
| Nishiyama, S | 1 |
| Ichise, R | 1 |
| Iwashita, A | 1 |
| Mihara, K | 1 |
| Yamazaki, S | 1 |
| Matsuoka, N | 1 |
| Tsukada, H | 1 |
| Nishimura, S | 1 |
| Papa, SM | 2 |
| Auberson, YP | 1 |
| Dervan, AG | 1 |
| Beales, M | 1 |
| McBean, GJ | 1 |
| Snyder, AK | 1 |
| Aubert, I | 2 |
| Guigoni, C | 1 |
| Håkansson, K | 1 |
| Barthe, N | 1 |
| Bioulac, BH | 1 |
| Fisone, G | 1 |
| Bloch, B | 1 |
| Monaca, C | 1 |
| Jacquesson, JM | 1 |
| Gelé, P | 2 |
| Maréchal, X | 1 |
| Derambure, P | 1 |
| Wade, TV | 2 |
| Dong, Z | 1 |
| Wolfer, DP | 1 |
| Lipp, HP | 1 |
| Büeler, H | 1 |
| Maswood, N | 1 |
| Young, J | 1 |
| Tilmont, E | 1 |
| Roth, GS | 1 |
| Mattison, J | 1 |
| Lane, MA | 1 |
| Carson, RE | 1 |
| Cohen, RM | 1 |
| Mouton, PR | 1 |
| Quigley, C | 1 |
| Ingram, DK | 1 |
| Finch, CE | 1 |
| Cleren, C | 2 |
| Dung Ling, Z | 1 |
| Carvey, PM | 2 |
| Fletcher-Turner, A | 1 |
| Yurek, DM | 1 |
| Kishi, Y | 1 |
| Fukuda, H | 1 |
| Okamoto, Y | 1 |
| Koyanagi, M | 1 |
| Ideguchi, M | 1 |
| Hayashi, H | 1 |
| Imazato, T | 1 |
| Kawasaki, H | 1 |
| Suemori, H | 1 |
| Omachi, S | 1 |
| Iida, H | 1 |
| Itoh, N | 1 |
| Nakatsuji, N | 1 |
| Sasai, Y | 1 |
| Hashimoto, N | 1 |
| Andrews, ZB | 1 |
| Horvath, B | 1 |
| Barnstable, CJ | 1 |
| Elsworth, J | 1 |
| Elseworth, J | 1 |
| Roth, RH | 6 |
| Matthews, RT | 3 |
| Horvath, TL | 1 |
| Mandel, S | 4 |
| Maor, G | 2 |
| Costantini, LC | 1 |
| Patel, R | 1 |
| Braga, R | 1 |
| Kouzmine, I | 1 |
| Canteras, NS | 4 |
| Chen, LL | 1 |
| Giesler, TL | 1 |
| Syed, E | 1 |
| Johnston, LC | 1 |
| Shimoji, M | 1 |
| Méndez-Ferrer, S | 1 |
| Valdés-Sánchez, T | 1 |
| Silos-Santiago, I | 1 |
| Fariñas, I | 1 |
| Holmer, HK | 1 |
| Keyghobadi, M | 1 |
| Menashe, RA | 1 |
| Hebert, G | 2 |
| Moze, E | 1 |
| Neveu, PJ | 1 |
| Li, KS | 1 |
| Mingam, R | 1 |
| Arsaut, J | 1 |
| Dantzer, R | 1 |
| Demotes-Mainard, J | 1 |
| Novikova, L | 3 |
| Roels, C | 1 |
| Ferro, MM | 3 |
| Bellissimo, MI | 1 |
| Anselmo-Franci, JA | 2 |
| Angellucci, ME | 1 |
| Haobam, R | 1 |
| Sindhu, KM | 1 |
| Chandra, G | 1 |
| von Borstel, R | 1 |
| Saydoff, J | 1 |
| Cuadrado-Tejedor, M | 1 |
| Sesma, MT | 1 |
| Giménez-Amaya, JM | 1 |
| Ortiz, L | 1 |
| Ostergren, A | 1 |
| Fredriksson, A | 2 |
| Brittebo, EB | 1 |
| Silva, RM | 1 |
| Ries, V | 1 |
| Oo, TF | 1 |
| Yarygina, O | 1 |
| Ryu, EJ | 1 |
| Lu, PD | 1 |
| Marciniak, SJ | 1 |
| Ron, D | 1 |
| Kholodilov, N | 1 |
| Burke, RE | 1 |
| Bassilana, F | 1 |
| Mace, N | 1 |
| Stutzmann, JM | 2 |
| Pradier, L | 1 |
| Benavides, J | 1 |
| Ménager, J | 1 |
| Fitzpatrick, E | 1 |
| Wallace, BA | 3 |
| Shen, HY | 1 |
| He, JC | 1 |
| Huang, QY | 1 |
| Heise, CE | 1 |
| Teo, ZC | 1 |
| Kajitani, K | 1 |
| Dan, Y | 1 |
| Furuichi, M | 1 |
| Kang, D | 1 |
| Miklossy, J | 1 |
| Doudet, DD | 1 |
| Schwab, C | 1 |
| McGeer, EG | 1 |
| McGeer, PL | 1 |
| Gennuso, F | 1 |
| Giaquinta, G | 1 |
| Kaneda, K | 1 |
| Imanishi, M | 1 |
| Shigemoto, R | 1 |
| Shan, X | 1 |
| Chi, L | 1 |
| Bishop, M | 1 |
| Luo, C | 1 |
| Lien, L | 1 |
| Glaser, PE | 1 |
| Surgener, SP | 1 |
| Gash, CR | 1 |
| Palmer, M | 1 |
| Castellanos, FX | 1 |
| Haddon, CO | 1 |
| Cooper, JM | 1 |
| Schapira, AH | 2 |
| Mewes, K | 1 |
| Rye, DB | 1 |
| Gomez-Ramirez, J | 3 |
| Garris, BL | 1 |
| Garris, DR | 1 |
| Flotte, TR | 1 |
| Tripanichkul, W | 1 |
| Sripanichkulchai, K | 1 |
| Meuer, K | 3 |
| Pitzer, C | 1 |
| Krüger, C | 1 |
| Peters, K | 1 |
| Dietz, GP | 3 |
| Weber, D | 1 |
| Schäbitz, WR | 1 |
| Bach, A | 1 |
| Schulz, JB | 3 |
| Ohashi, S | 1 |
| Kurihara, N | 1 |
| Nakai, M | 1 |
| Teng, X | 1 |
| Sakai, T | 1 |
| Sakai, R | 1 |
| Kaji, R | 1 |
| Fukui, K | 1 |
| Valbuena, PC | 1 |
| Dietz, B | 2 |
| Müeller, P | 1 |
| Marella, M | 1 |
| Yamashita, T | 1 |
| Kao, MC | 1 |
| Knaryan, VH | 1 |
| Samantaray, S | 1 |
| Varghese, M | 1 |
| Srinivasan, A | 2 |
| Galoyan, AA | 1 |
| Chalimoniuk, M | 1 |
| Lukacova, N | 1 |
| Marsala, J | 1 |
| Langfort, J | 1 |
| Punati, A | 1 |
| Newman, MB | 1 |
| Soderstrom, K | 1 |
| O'Malley, J | 1 |
| Hasbani, DM | 1 |
| O'Malley, KL | 1 |
| Richardson, JR | 3 |
| Dean, ED | 1 |
| Pennell, KD | 2 |
| Batista, LC | 1 |
| Pandolfo, P | 1 |
| Florio, JC | 1 |
| von Bohlen und Halbach, O | 2 |
| Hertel, R | 1 |
| Unsicker, K | 1 |
| Dhanasekaran, M | 1 |
| Uthayathas, S | 1 |
| Parameshwaran, K | 1 |
| Suppiramaniam, V | 1 |
| Ebadi, M | 1 |
| Brown-Borg, HM | 1 |
| Dong, M | 1 |
| Yamauchi, H | 1 |
| Ueno, M | 1 |
| Uetsuka, K | 1 |
| Doi, K | 1 |
| Burton, NC | 1 |
| Kensler, TW | 1 |
| Guilarte, TR | 1 |
| Pires, D | 1 |
| Voon, V | 2 |
| Gomez-Gallego, M | 1 |
| Giorgi, FS | 1 |
| Bandettini di Poggio, A | 1 |
| Pellegrini, A | 1 |
| Murri, L | 1 |
| Guillot, TS | 1 |
| Watson, JL | 1 |
| Farrace, MG | 1 |
| Mastroberardino, PG | 1 |
| Viti, I | 1 |
| Fimia, GM | 1 |
| Van Beeumen, J | 1 |
| Devreese, B | 1 |
| Melino, G | 1 |
| Piacentini, M | 1 |
| Rojo, AI | 2 |
| Montero, C | 1 |
| Salazar, M | 1 |
| Close, RM | 1 |
| Sánchez-González, MA | 1 |
| de Sagarra, MR | 2 |
| Cavada, C | 2 |
| Cuadrado, A | 2 |
| Decamp, E | 2 |
| Hallett, PJ | 2 |
| Smith, CP | 1 |
| Collins, MA | 1 |
| Avila, I | 1 |
| Kalkonde, YV | 1 |
| Morgan, WW | 2 |
| Sigala, J | 1 |
| Maffi, SK | 1 |
| Condello, C | 1 |
| Kuziel, W | 1 |
| Ahuja, SS | 1 |
| Ahuja, SK | 1 |
| Nicholas, AP | 2 |
| Anderson, DW | 1 |
| Bradbury, KA | 1 |
| Laurie, C | 1 |
| Reynolds, A | 1 |
| Coskun, O | 1 |
| Bowman, E | 1 |
| Pollo, C | 1 |
| Brard, PY | 1 |
| Fagret, D | 1 |
| Wiart, JF | 1 |
| Lhermitte, M | 1 |
| Wietzikoski, S | 1 |
| Wietzikoski, EC | 1 |
| Silva, MH | 1 |
| Chandler, J | 1 |
| Angelucci, ME | 1 |
| Pattarini, R | 1 |
| Morgan, JI | 1 |
| Chefer, SI | 1 |
| Kimes, AS | 1 |
| Matochik, JA | 1 |
| Horti, AG | 1 |
| Kurian, V | 1 |
| Shumway, D | 1 |
| London, ED | 1 |
| Mukhin, AG | 1 |
| Baek, SY | 1 |
| Oh, SO | 1 |
| Lee, CR | 1 |
| Yoo, CI | 1 |
| Sim, CS | 1 |
| Kim, JW | 1 |
| Yoon, CS | 1 |
| Kim, Y | 1 |
| Milioli, EM | 1 |
| Cologni, P | 1 |
| Marcos, TD | 1 |
| Yunes, VM | 1 |
| Fernandes, MS | 1 |
| Schoenfelder, T | 1 |
| Costa-Campos, L | 1 |
| Chan, CS | 1 |
| Guzman, JN | 1 |
| Ilijic, E | 1 |
| Mercer, JN | 1 |
| Rick, C | 1 |
| Tkatch, T | 1 |
| Hamill, CE | 1 |
| Yuan, H | 1 |
| Greene, JG | 1 |
| Traynelis, SF | 1 |
| Cao, X | 1 |
| Hadcock, JR | 1 |
| Iredale, PA | 1 |
| Griffith, DA | 1 |
| Factor, S | 1 |
| Navneet, AK | 1 |
| Appukuttan, TA | 1 |
| Pandey, M | 1 |
| Wang, YS | 1 |
| Zhou, JP | 1 |
| Wei, ZF | 1 |
| Tian, QY | 1 |
| Zhou, HX | 1 |
| Smirnova, IV | 1 |
| Stehno-Bittel, L | 1 |
| Boyd, JD | 1 |
| Jang, H | 1 |
| Shepherd, KR | 1 |
| Faherty, C | 1 |
| Slack, S | 1 |
| Kanamatsu, T | 1 |
| Otsuki, T | 1 |
| Tokuno, H | 1 |
| Okamoto, K | 1 |
| Watanabe, H | 1 |
| Umeda, M | 2 |
| Tsukada, Y | 1 |
| Dombrowski, P | 1 |
| Zanata, SM | 1 |
| Oizumi, H | 1 |
| Hayashita-Kinoh, H | 1 |
| Arai, H | 1 |
| Seki, T | 1 |
| Mocchetti, I | 1 |
| Bachis, A | 1 |
| Nosheny, RL | 1 |
| Tanda, G | 1 |
| Lorenzo, B | 1 |
| Schomer, A | 1 |
| Sireci, A | 1 |
| Stockhausen, KV | 1 |
| Valbuena, P | 1 |
| Opazo, F | 1 |
| Mufson, EJ | 1 |
| Hartley, DM | 1 |
| Ghosh, S | 1 |
| Weinreb, O | 1 |
| Liu, LX | 1 |
| van Vliet, SA | 1 |
| van Vlieta, SA | 1 |
| Blezer, EL | 1 |
| Jongsma, MJ | 1 |
| Olivier, B | 1 |
| Wei, W | 1 |
| Gu, W | 1 |
| Ren, X | 1 |
| Marmor, O | 1 |
| Saban, G | 1 |
| Rosin, B | 1 |
| Vaadia, E | 4 |
| Prut, Y | 1 |
| Stack, EC | 1 |
| Ferro, JL | 1 |
| Del Signore, SJ | 1 |
| Goodrich, S | 1 |
| Matson, S | 1 |
| Hunt, BB | 1 |
| Matson, WR | 1 |
| Ryu, H | 1 |
| Takagi, S | 1 |
| Watanabe, Y | 3 |
| Brochier, C | 1 |
| Caudy, N | 1 |
| Dossat, C | 1 |
| Ségurens, B | 1 |
| Wincker, P | 1 |
| Roze, E | 1 |
| Caboche, J | 1 |
| Elalouf, JM | 1 |
| de Chaldée, M | 1 |
| Goetze, O | 1 |
| Woitalla, D | 1 |
| Kadoguchi, N | 2 |
| Hahn, PJ | 1 |
| Miocinovic, S | 1 |
| McIntyre, CC | 1 |
| Orsi, A | 1 |
| Howson, PA | 1 |
| Dixon, K | 1 |
| Callizot, N | 1 |
| Rees, DD | 1 |
| Patel, S | 1 |
| Patel, DK | 1 |
| Singh, C | 1 |
| Nath, C | 1 |
| Xin, T | 1 |
| Gerhardt, G | 2 |
| Gash, D | 1 |
| Rajeswari, A | 1 |
| Sabesan, M | 1 |
| Lubin, FD | 1 |
| Vattem, P | 1 |
| Sweatt, JD | 1 |
| Oyagi, A | 1 |
| Oida, Y | 1 |
| Izuta, H | 1 |
| Matsunaga, N | 1 |
| Adachi, T | 1 |
| Zhou, XP | 1 |
| Liu, HH | 1 |
| Li, BM | 1 |
| Hu, XW | 1 |
| Li, FQ | 1 |
| You, BM | 1 |
| Burns, RS | 3 |
| Chiueh, CC | 4 |
| Markey, SP | 2 |
| Ebert, MH | 1 |
| Jacobowitz, DM | 4 |
| Kopin, IJ | 6 |
| Sahgal, A | 1 |
| Andrews, JS | 2 |
| Biggins, JA | 1 |
| Candy, JM | 1 |
| Edwardson, JA | 1 |
| Keith, AB | 1 |
| Turner, JD | 1 |
| Wright, C | 1 |
| Kolata, G | 1 |
| Lewin, R | 1 |
| Blume, E | 1 |
| Rebert, CS | 1 |
| Irwin, I | 4 |
| Huang, CC | 1 |
| Gnanalingham, KK | 1 |
| Milkowski, NA | 1 |
| Hunter, AJ | 1 |
| Marsden, CD | 8 |
| Akai, T | 1 |
| Ozawa, M | 1 |
| Yamaguchi, M | 1 |
| Mizuta, E | 1 |
| Kuno, S | 1 |
| Stoddard, SL | 1 |
| Merkel, GJ | 1 |
| Cook, JA | 1 |
| Zinsmeister, AR | 1 |
| Carmichael, SW | 1 |
| Deng, XY | 1 |
| Zheng, ZT | 1 |
| Irifune, M | 2 |
| Nomoto, M | 2 |
| Fukuda, T | 2 |
| Belluzzi, JD | 1 |
| May, JM | 1 |
| McAfee, DA | 1 |
| Tang, Q | 1 |
| Xu, X | 1 |
| Sheng, J | 1 |
| Albanese, A | 1 |
| Granata, R | 1 |
| Gregori, B | 1 |
| Piccardi, MP | 1 |
| Colosimo, C | 1 |
| Tonali, P | 1 |
| Atadzhanov, MA | 2 |
| Mandel, RJ | 2 |
| Sofroniew, MV | 1 |
| Baskin, DS | 1 |
| Browning, JL | 1 |
| Widmayer, MA | 1 |
| Zhu, ZQ | 1 |
| Grossman, RG | 1 |
| Bieganowska, K | 1 |
| Bidziński, A | 1 |
| Mierzewska, H | 1 |
| Korlak, J | 1 |
| Smith, RD | 1 |
| Kurlan, R | 2 |
| McDermott, M | 1 |
| Orlova, IN | 1 |
| Kean, A | 1 |
| DiStefano, L | 1 |
| Shiosaki, K | 3 |
| Asin, KE | 1 |
| Britton, DR | 3 |
| Lin, CW | 1 |
| Michaelides, M | 1 |
| Bianchi, B | 1 |
| Didomenico, S | 1 |
| Hodges, L | 1 |
| Mahan, L | 1 |
| Mikusa, J | 1 |
| Miller, T | 1 |
| Nikkel, A | 1 |
| Stashko, M | 1 |
| Witte, D | 1 |
| Williams, M | 1 |
| Takeda, M | 1 |
| Naoi, M | 2 |
| Maruyama, W | 1 |
| Dostert, P | 1 |
| Pastoris, O | 1 |
| Dossena, M | 1 |
| Foppa, P | 1 |
| Catapano, M | 1 |
| Ferrari, R | 1 |
| Dagani, F | 1 |
| Snyder, SH | 2 |
| Ferrante, R | 1 |
| Palfi, S | 2 |
| Dolan, R | 1 |
| Plate, R | 1 |
| Plaum, MJ | 1 |
| de Boer, T | 1 |
| Rae, DR | 1 |
| Gibson, S | 1 |
| Rothblat, DS | 1 |
| Blanchet, PJ | 5 |
| Gross, C | 3 |
| Steiner, JP | 1 |
| Hamilton, GS | 1 |
| Ross, DT | 1 |
| Valentine, HL | 1 |
| Connolly, MA | 1 |
| Liang, S | 1 |
| Ramsey, C | 1 |
| Li, JH | 1 |
| Howorth, P | 1 |
| Soni, R | 1 |
| Fuller, M | 1 |
| Sauer, H | 1 |
| Nowotnik, AC | 1 |
| Suzdak, PD | 1 |
| Tatton, NA | 1 |
| Kish, SJ | 2 |
| Chan, GL | 1 |
| Holden, JE | 2 |
| Morrison, KS | 1 |
| Wyatt, RJ | 1 |
| Ruth, TJ | 1 |
| Klockgether, T | 1 |
| Dichgans, J | 1 |
| Smith, TS | 3 |
| Bennett, JP | 3 |
| Trimmer, PA | 1 |
| Khan, SM | 1 |
| Tinklepaugh, DL | 1 |
| Imbert, C | 3 |
| Deloire, X | 1 |
| Boireau, A | 3 |
| Bordier, F | 2 |
| Dubédat, P | 2 |
| Pény, C | 1 |
| Impérato, A | 3 |
| Cassarino, DS | 1 |
| Fall, CP | 1 |
| Swerdlow, RH | 1 |
| Halvorsen, EM | 1 |
| Miller, SW | 1 |
| Parks, JP | 1 |
| Parker, WD | 1 |
| Marcotte, ER | 1 |
| Chugh, A | 1 |
| Mishra, RK | 1 |
| Johnson, RL | 1 |
| Elsworth, JD | 5 |
| Brittan, MS | 1 |
| Taylor, JR | 4 |
| Innis, RB | 1 |
| Zea-Ponce, Y | 1 |
| Ho, A | 1 |
| Blum, M | 1 |
| Jagust, WJ | 1 |
| VanBrocklin, HF | 1 |
| Kohutnicka, M | 1 |
| Lewandowska, E | 1 |
| Rozas, G | 1 |
| López-Martín, E | 1 |
| Konitsiotis, S | 2 |
| Hyland, K | 1 |
| Arnold, LA | 1 |
| Pettigrew, KD | 1 |
| Iwata, S | 1 |
| Kaseda, S | 1 |
| Osame, M | 1 |
| Kakimura, J | 1 |
| Taniguchi, T | 2 |
| Brownell, AL | 3 |
| Jenkins, BG | 2 |
| Elmaleh, DR | 1 |
| Deacon, TW | 1 |
| Spealman, RD | 2 |
| Isacson, O | 3 |
| Jenkins, TA | 1 |
| Wong, JY | 1 |
| Howells, DW | 1 |
| Mendelsohn, FA | 1 |
| Chai, SY | 1 |
| Lonser, RR | 1 |
| Corthésy, ME | 1 |
| Morrison, PF | 1 |
| Gogate, N | 1 |
| Oldfield, EH | 2 |
| Grünblatt, E | 3 |
| Berkuzki, T | 1 |
| Chen, Q | 2 |
| Ovadia, A | 1 |
| Cass, WA | 1 |
| Avison, MJ | 1 |
| Tolwani, RJ | 1 |
| Green, S | 1 |
| Waggie, K | 1 |
| Peggs, D | 1 |
| Izawa, Y | 1 |
| Kato, T | 1 |
| Earl, CD | 1 |
| Kuschinsky, K | 1 |
| Wade, T | 1 |
| Brefel, C | 1 |
| Peyro-Saint-Paul, H | 1 |
| Ladure, P | 1 |
| Rascol, O | 1 |
| Friedrich, MJ | 1 |
| Andreassen, OA | 2 |
| Dedeoglu, A | 2 |
| Mueller, G | 1 |
| Lancelot, E | 1 |
| Bogdanov, M | 1 |
| Andersen, JK | 2 |
| Jiang, D | 1 |
| Guitraud, S | 1 |
| Moussaoui, S | 2 |
| Kanda, T | 1 |
| Nakamura, J | 1 |
| Kase, H | 1 |
| Kuwana, Y | 2 |
| Verhagen, L | 1 |
| Lamers, E | 1 |
| Agani, FH | 1 |
| Pichiule, P | 1 |
| Chavez, JC | 1 |
| LaManna, JC | 1 |
| MacKenzie, G | 1 |
| Peng, TI | 1 |
| Stephans, SE | 1 |
| Goulet, M | 2 |
| Doucet, JP | 1 |
| Nestler, E | 1 |
| Ma, SY | 1 |
| Chu, Y | 1 |
| Leventhal, L | 1 |
| McBride, J | 1 |
| Chen, EY | 1 |
| Roitberg, BZ | 1 |
| Brown, WD | 1 |
| Pyzalski, R | 1 |
| Taylor, MD | 1 |
| Carvey, P | 1 |
| Ling, Z | 1 |
| Trono, D | 1 |
| Déglon, N | 1 |
| Aebischer, P | 1 |
| Raz, A | 2 |
| Rosenblad, C | 1 |
| Georgievska, B | 1 |
| Lundberg, C | 1 |
| Shimohama, S | 1 |
| Akaike, A | 1 |
| Frechter-Mazar, V | 1 |
| Feingold, A | 1 |
| Abeles, M | 1 |
| Albers, DW | 1 |
| Carlson, EJ | 1 |
| Epstein, CJ | 1 |
| Schmidt, N | 2 |
| Hofele, K | 1 |
| Sedelis, M | 1 |
| Auburger, GW | 1 |
| Morgan, S | 1 |
| Huston, JP | 1 |
| Schwarting, RK | 1 |
| Youdim, M | 1 |
| Matarredona, ER | 1 |
| Venero, JL | 1 |
| Giasson, BI | 1 |
| Djaldatti, R | 1 |
| Vukosavic, S | 2 |
| Souza, JM | 1 |
| Lee, VM | 1 |
| Pérez, V | 1 |
| Morón, J | 1 |
| Pastó, M | 1 |
| Unzeta, M | 1 |
| Djaldetti, R | 1 |
| Liberatore, G | 1 |
| Offen, D | 1 |
| Korsmeyer, SJ | 1 |
| Troadec, JD | 1 |
| Kikly, K | 1 |
| Faucheux, BA | 1 |
| Mouatt-Prigent, A | 1 |
| Agid, Y | 2 |
| Turmel, H | 1 |
| Douhou, A | 1 |
| Lavertu, N | 1 |
| Lemieux, AM | 1 |
| Staal, R | 1 |
| Xu, YH | 1 |
| Beilstein, M | 1 |
| Sonsalla, PK | 3 |
| Polonskaya, Y | 1 |
| Strömberg, I | 2 |
| Törnqvist, N | 1 |
| Johansson, S | 1 |
| Bygdeman, M | 1 |
| Almqvist, PM | 1 |
| Prunier, C | 1 |
| Guilloteau, D | 1 |
| Petroske, E | 1 |
| Callen, S | 1 |
| Kupsch, A | 1 |
| Sautter, J | 1 |
| Götz, ME | 1 |
| Breithaupt, W | 1 |
| Schwarz, J | 2 |
| Gerlach, M | 2 |
| Ishiwata, K | 1 |
| Koyanagi, Y | 1 |
| Abe, K | 1 |
| Kawamura, K | 1 |
| Taguchi, K | 1 |
| Saitoh, T | 1 |
| Toda, J | 1 |
| Senda, M | 1 |
| Sano, T | 1 |
| Viswanath, V | 1 |
| Boonplueang, R | 1 |
| Stevenson, FF | 1 |
| Yantiri, F | 1 |
| Yee, RE | 1 |
| Milonas, C | 1 |
| Stout, DB | 1 |
| Huang, SC | 1 |
| Shoghi-Jadid, K | 1 |
| Satyamurthy, N | 1 |
| Delanney, LE | 1 |
| Farahani, KF | 1 |
| Janson, AM | 1 |
| Phelps, ME | 1 |
| Barrio, JR | 1 |
| Baron, MS | 1 |
| Ma, D | 1 |
| DeLong, MR | 3 |
| Obinu, MC | 1 |
| Reibaud, M | 1 |
| Blanchard, V | 1 |
| Muramatsu, S | 1 |
| Fujimoto, K | 1 |
| Ikeguchi, K | 1 |
| Shizuma, N | 1 |
| Kawasaki, K | 1 |
| Ono, F | 1 |
| Mizukami, H | 1 |
| Kume, A | 1 |
| Nagatsu, I | 1 |
| Urano, F | 1 |
| Ichinose, H | 1 |
| Terao, K | 1 |
| Nakano, I | 1 |
| Ozawa, K | 1 |
| Vadseth, C | 1 |
| Ikeda, K | 1 |
| Kurokawa, M | 1 |
| Aoyama, S | 1 |
| Kunikowska, G | 1 |
| Thiruchelvam, MJ | 1 |
| Cory-Slechta, DA | 1 |
| Wuertzer, C | 1 |
| Smeyne, M | 1 |
| Maraton, S | 1 |
| Chowdhury, R | 1 |
| Burov, IuV | 1 |
| Metkalova, SE | 1 |
| Kustov, AE | 1 |
| Petrov, GV | 1 |
| Shul'govskiĭ, VV | 1 |
| Lange, KW | 3 |
| Löschmann, PA | 2 |
| Wachtel, H | 2 |
| Horowski, R | 1 |
| Jähnig, P | 2 |
| Heikkila, RE | 3 |
| Hineno, T | 1 |
| Mizobuchi, M | 1 |
| Hiratani, K | 1 |
| Inami, Y | 1 |
| Kakimoto, Y | 1 |
| Elmaleh, D | 1 |
| Wüllner, U | 1 |
| Brownell, GL | 1 |
| Madras, BK | 1 |
| Pollard, HB | 1 |
| Dhariwal, K | 1 |
| Adeyemo, OM | 1 |
| Markey, CJ | 1 |
| Caohuy, H | 1 |
| Levine, M | 1 |
| Markey, S | 1 |
| Zuddas, A | 1 |
| Oberto, G | 1 |
| Fascetti, F | 1 |
| Nicklas, WJ | 1 |
| Saporito, M | 1 |
| Basma, A | 1 |
| Geller, HM | 1 |
| Misu, Y | 1 |
| Arai, N | 1 |
| Misugi, K | 1 |
| Date, I | 3 |
| Notter, MF | 1 |
| Felten, SY | 2 |
| Felten, DL | 3 |
| Russ, H | 2 |
| Mihatsch, W | 1 |
| Przuntek, H | 2 |
| Popilskis, S | 1 |
| Kostic, V | 1 |
| Levivier, M | 1 |
| Fahn, S | 1 |
| Cadet, JL | 2 |
| Laguna, J | 1 |
| Martínez-Lage, JM | 1 |
| Kunow, M | 1 |
| Rettig, KJ | 1 |
| Honoré, T | 1 |
| Turski, L | 1 |
| Gomez-Mancilla, B | 1 |
| Boucher, R | 1 |
| Chen, SD | 2 |
| Zhou, XD | 1 |
| Xu, DL | 3 |
| Li, GW | 1 |
| Tang, QM | 2 |
| Xu, XR | 2 |
| Gupta, M | 1 |
| Chen, XL | 1 |
| Roisen, FJ | 1 |
| Roeltgen, DP | 1 |
| Kim, MH | 1 |
| Asari, S | 1 |
| Nishimoto, A | 1 |
| Landau, WM | 1 |
| Tipton, KF | 1 |
| Buruma, OJ | 1 |
| Haan, J | 1 |
| Roos, RA | 1 |
| Tetrud, JW | 1 |
| Singer, TP | 1 |
| Ramsay, RR | 1 |
| Sturman, SG | 1 |
| Steventon, GB | 1 |
| Waring, RH | 1 |
| Williams, AC | 1 |
| Sundström, E | 1 |
| Archer, T | 1 |
| Watts, RL | 1 |
| Bakay, RA | 1 |
| Herring, CJ | 1 |
| Sweeney, KM | 1 |
| Colbassani, HJ | 1 |
| Mandir, A | 1 |
| Byrd, LD | 1 |
| Iuvone, PM | 1 |
| Boyce, S | 2 |
| Rupniak, NM | 1 |
| Steventon, M | 1 |
| Iversen, SD | 1 |
| Lai, M | 1 |
| Griffiths, HR | 1 |
| Allen, JM | 1 |
| Cross, AJ | 2 |
| Yeats, JC | 1 |
| Ghatei, MA | 1 |
| McGregor, GP | 1 |
| Close, SP | 1 |
| Pay, S | 1 |
| Marriott, AS | 1 |
| Tyers, MB | 1 |
| Crow, TJ | 1 |
| Henning, K | 1 |
| Eckhardt, H | 1 |
| Beale, AM | 1 |
| Work, T | 1 |
| Gee, SJ | 1 |
| Gunther, R | 1 |
| Higgins, RJ | 1 |
| Shinka, T | 1 |
| Perry, TL | 1 |
| Yong, VW | 1 |
| Ito, M | 1 |
| Jones, K | 1 |
| Wall, RA | 1 |
| Foulks, JG | 1 |
| Wright, JM | 1 |
| Haber, S | 1 |
| Clarke, CE | 2 |
| Sambrook, MA | 3 |
| Ogawa, N | 4 |
| Mizukawa, K | 3 |
| Hirose, Y | 2 |
| Kajita, S | 1 |
| Ohara, S | 2 |
| Waters, CM | 1 |
| Hunt, SP | 1 |
| Joyce, JN | 1 |
| Marshall, JF | 1 |
| Brooks, BA | 2 |
| Fuchs, AF | 1 |
| Finocchio, D | 1 |
| Olson, L | 1 |
| Backlund, EO | 1 |
| Lindvall, O | 1 |
| Rose, G | 1 |
| Seiger, A | 1 |
| Imai, H | 1 |
| D'Amato, RJ | 1 |
| Sandler, M | 1 |
| Schoenberg, DG | 1 |
| Schultz, W | 1 |
| Sheng, JG | 1 |
| Yu, HZ | 2 |
| Liang, PF | 1 |
| Lebrun-Grandié, P | 2 |
| Crampton, JM | 1 |
| Runice, CE | 1 |
| Doyle, TJ | 1 |
| Wilson, JA | 1 |
| Sora, YH | 2 |
| Brücke, T | 1 |
| Harvey-White, J | 1 |
| Kopin, I | 1 |
| Wolters, EC | 1 |
| Kebabian, JC | 1 |
| Guttman, M | 1 |
| Mak, E | 1 |
| Pate, BD | 1 |
| Calne, DB | 1 |
| Donaldson, J | 1 |
| Mitchell, IJ | 2 |
| Barsoum, NJ | 1 |
| Gough, AW | 1 |
| Sturgess, JM | 1 |
| de la Iglesia, FA | 1 |
| Doppman, JL | 1 |
| Renkawek, K | 1 |
| Friedman, J | 1 |
| Loc'h, C | 1 |
| Tacke, U | 1 |
| Riche, D | 1 |
| Stulzaft, O | 1 |
| Guibert, B | 1 |
| Naquet, R | 1 |
| Mazière, B | 1 |
| Mazière, M | 1 |
| Eidelberg, E | 1 |
| Walden, JG | 1 |
| Kokemoor, RH | 1 |
| Porrino, LJ | 1 |
| Crane, AM | 1 |
| Palombo, E | 1 |
| Sokoloff, L | 1 |
| Narabayashi, H | 1 |
| Sershen, H | 1 |
| Hashim, A | 1 |
| Lajtha, A | 1 |
| Sora, I | 1 |
| Barbeau, A | 1 |
| Dallaire, L | 1 |
| Buu, NT | 1 |
| Veilleux, F | 1 |
| Boyer, H | 1 |
| de Lanney, LE | 1 |
| Langston, EB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Center, Open, Single Dosing, Dose-escalation, Phase 1/2a Study to Evaluate the Safety and Exploratory Efficacy of Embryonic Stem Cell-derived A9 Dopamine Progenitor Cell (A9-DPC) Therapy in Patients With Parkinson's Disease[NCT05887466] | Phase 1/Phase 2 | 12 participants (Anticipated) | Interventional | 2023-05-09 | Recruiting | ||
| Role of Saffron and Chamomile and Their Active Compounds in the Management of Parkinson Disease in the Context of Psychometric and Biochemical Measures[NCT05696665] | 120 participants (Anticipated) | Interventional | 2022-07-05 | Recruiting | |||
| Clinical Trial for Near Infrared Endoventricular Illumination for Neuroprotection in Very Early Cases of Parkinson's Disease (Ev-NIRT)[NCT04261569] | 14 participants (Anticipated) | Interventional | 2020-12-14 | Recruiting | |||
| Role of Sleep Homeostasis in the Development of the L-Dopa Induced Dyskinesias in Patients With Parkinson's Disease[NCT02200887] | 48 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| Leukine (Sargramostim) for Parkinson's Disease[NCT01882010] | Phase 1 | 37 participants (Actual) | Interventional | 2013-09-01 | Completed | ||
| A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial To Assess The Safety And Tolerability Of 30mg/kg Daily Ursodeoxycholic Acid (UDCA) In Patients With Parkinson's Disease (PD)[NCT03840005] | Phase 2 | 31 participants (Actual) | Interventional | 2018-12-18 | Completed | ||
| Subthalamic Nucleus (STN) and Globus Pallidus Internus (GPi) Deep Brain Stimulation (DBS) in Patients With Primary Dystonia（RELAX Study）[NCT03017586] | 72 participants (Actual) | Interventional | 2017-12-27 | Completed | |||
| A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease[NCT00909545] | Phase 2 | 99 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects With Advanced Parkinson's Disease[NCT01621581] | Phase 1 | 25 participants (Actual) | Interventional | 2013-03-13 | Completed | ||
| TMS Measures in Parkinson's Disease[NCT00023062] | 80 participants | Observational | 2001-08-31 | Completed | |||
| Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy Associated With Dopaminergic Metabolism Deficit. A Randomized, Double Blind, Controlled Trial.[NCT00228371] | Phase 2/Phase 3 | 4 participants (Actual) | Interventional | 2005-09-30 | Terminated (stopped due to insufficent enrolement) | ||
| Can Subthreshold Transcranial Magnetic Stimulation (rTMS) to Motor Cortex and/or to Supplementary Motor Area (SMA) Improve Performance of Complex Motor Sequences in Parkinson's Disease?[NCT00001665] | 12 participants | Observational | 1997-01-31 | Completed | |||
| Deep Brain Stimulation Surgery for Movement Disorders[NCT01581580] | 200 participants (Anticipated) | Interventional | 2011-08-17 | Recruiting | |||
| Dual Frequency, Dual Region Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease[NCT04650932] | 10 participants (Anticipated) | Interventional | 2022-10-22 | Recruiting | |||
| NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease[NCT00001929] | Phase 2 | 20 participants | Interventional | 1999-03-31 | Completed | ||
| Convection Enhanced Delivery of Muscimol to Study the Pathophysiology Underlying the Clinical Features of Parkinson's Disease[NCT00921128] | Phase 1 | 0 participants (Actual) | Interventional | 2009-06-02 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Musculoskeletal and Connective Tissue Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Isradipine CR 5mg/Day | 0 |
| Isradipine CR 10mg/Day | 2 |
| Isradipine CR 20mg/Day | 3 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 3 |
| Isradipine CR 5mg/Day | 2 |
| Isradipine CR 10mg/Day | 3 |
| Isradipine CR 20mg/Day | 4 |
Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 3 |
| Isradipine CR 10mg/Day | 1 |
| Isradipine CR 20mg/Day | 1 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 1 |
| Isradipine CR 10mg/Day | 2 |
| Isradipine CR 20mg/Day | 1 |
Nervous system disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 7 |
| Isradipine CR 5mg/Day | 5 |
| Isradipine CR 10mg/Day | 6 |
| Isradipine CR 20mg/Day | 6 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 3 |
| Isradipine CR 5mg/Day | 1 |
| Isradipine CR 10mg/Day | 1 |
| Isradipine CR 20mg/Day | 1 |
General Disorders and Administration Site Conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 1 |
| Isradipine CR 10mg/Day | 3 |
| Isradipine CR 20mg/Day | 3 |
Nervous System disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 3 |
| Isradipine CR 5mg/Day | 3 |
| Isradipine CR 10mg/Day | 6 |
| Isradipine CR 20mg/Day | 4 |
Vascular Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Isradipine CR 5mg/Day | 1 |
| Isradipine CR 10mg/Day | 2 |
| Isradipine CR 20mg/Day | 2 |
Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 3 |
| Isradipine CR 10mg/Day | 1 |
| Isradipine CR 20mg/Day | 1 |
Infections and infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 4 |
| Isradipine CR 10mg/Day | 7 |
| Isradipine CR 20mg/Day | 4 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 3 |
| Isradipine CR 5mg/Day | 2 |
| Isradipine CR 10mg/Day | 1 |
| Isradipine CR 20mg/Day | 2 |
General disorders and administration site conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Isradipine CR 5mg/Day | 4 |
| Isradipine CR 10mg/Day | 10 |
| Isradipine CR 20mg/Day | 16 |
Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 3 |
| Isradipine CR 5mg/Day | 2 |
| Isradipine CR 10mg/Day | 1 |
| Isradipine CR 20mg/Day | 0 |
Nervous System Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 3 |
| Isradipine CR 10mg/Day | 2 |
| Isradipine CR 20mg/Day | 0 |
Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Isradipine CR 5mg/Day | 2 |
| Isradipine CR 10mg/Day | 5 |
| Isradipine CR 20mg/Day | 0 |
The outcome is defined as change in ADL subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part II) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part II: Activities of Daily Living in the week prior to the designated visit, consisting of 13 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part II score represents the sum of these 13 questions. A greater increase in score indicates a greater increase in disability. A total of 52 points are possible. 52 represents the worst (total) disability), 0--no disability (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 2.60 |
| Isradipine CR 5mg/Day | 3.20 |
| Isradipine CR 10mg/Day | 2.09 |
| Isradipine CR 20mg/Day | 1.86 |
The Beck Depression Inventory (BDI) is a validated self-reported 21-item depression scale that was tested and validated as a reliable instrument for screening for depression in PD. The outcome is defined as change in BDI-II between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total BDI score represents the sum of these 21-items. A higher change in score indicates a greater increase in disability. Total score of 0-13 is considered minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.52 |
| Isradipine CR 5mg/Day | 1.99 |
| Isradipine CR 10mg/Day | 0.11 |
| Isradipine CR 20mg/Day | 1.50 |
The outcome is defined as change in Mental subscale of Unified Parkinson's Disease Rating Scale(UPDRS Part I) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part I: Mentation, behavior and mood, consisting of 4 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score represents the sum of these 4 questions. A greater increase in score indicates a greater increase in disability. A total of 16 points are possible. 16 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.30 |
| Isradipine CR 5mg/Day | 0.76 |
| Isradipine CR 10mg/Day | 0.30 |
| Isradipine CR 20mg/Day | 0.03 |
The Modified Hoehn & Yahr Scale is an 8-level Parkinson's disease staging instrument. The outcome is defined as change in Modified Hoehn & Yahr Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. A greater increase in stage indicates a greater increase in disability. Stage ranges from 0-5 (also including 1.5 and 2.5) with 0 indicating no disability and 5 indicating maximum disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.27 |
| Isradipine CR 5mg/Day | 0.22 |
| Isradipine CR 10mg/Day | 0.12 |
| Isradipine CR 20mg/Day | 0.11 |
The Schwab & England scale is an investigator and subject assessment of the subject's level of independence at all scheduled study visits. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson's disease appeared. The outcome is defined as change in Schwab & England Independence Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Higher decrease in score indicates higher disability. Score ranges from 100% (complete independence) to 0% (total disability). (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -5.04 |
| Isradipine CR 5mg/Day | -5.56 |
| Isradipine CR 10mg/Day | -3.69 |
| Isradipine CR 20mg/Day | -3.76 |
The Montreal Cognitive Assessment(MoCA) is a brief 30-point screening instrument that was developed and validated to identify subjects with mild cognitive impairment. The outcome is defined as change in MoCA between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total MoCA score represents the sum of these 30-points, with a lower score indicating greater cognitive impairment. 30 is the maximum score, with a score of 26 or higher considered normal and below 26 indicative of Mild Cognitive Impairment. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.58 |
| Isradipine CR 5mg/Day | 0.06 |
| Isradipine CR 10mg/Day | 0.11 |
| Isradipine CR 20mg/Day | 0.36 |
The outcome is defined as change in Motor subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part III) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part III: motor abilities at the time of the visit, consisting of 27 items (including 13 general questions and 14 sub-questions) each answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part III score represents the sum of these 27 items. A total of 108 points are possible. 108 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Isradipine CR 5mg/Day | 3.49 |
| Isradipine CR 10mg/Day | 3.91 |
| Isradipine CR 20mg/Day | 3.69 |
The PD Quality of Life Scale(PDQ-39) asks the subject to evaluate how Parkinson disease has affected their health and overall quality of life at that point in time. The total quality of life scale includes subscales relating to social role, self-image/sexuality, sleep, outlook, physical function and urinary function. The outcome is defined as change in PDQ-39 between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. It is scored on a scale of zero to 100, with lower scores indicating better health and higher scores more severe disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.28 |
| Isradipine CR 5mg/Day | 3.47 |
| Isradipine CR 10mg/Day | 3.00 |
| Isradipine CR 20mg/Day | 3.35 |
Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 12 or the time to require dopaminergic therapy (last visit before subject goes on dopaminergic therapy), whichever occurs first. The UPDRS score has 4 components. Part I assesses mentation; Part II assesses activities of daily living; Part III assesses motor abilities; Part IV assesses complications of therapy. A total of 44 items are included in Parts I-III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Part IV contains 11 items, 4 of these items are scored 0-4 in the same manner, and 7 are scored 0-1, with 0 indicating the absence of impairment and 1 indicating the presence of impairment. Total UPDRS score represents the sum of these items in Parts I-IV. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | 7.40 |
| Isradipine CR 5mg/Day | 7.44 |
| Isradipine CR 10mg/Day | 6.30 |
| Isradipine CR 15-20mg/Day | 5.40 |
Tolerability will be judged by the proportion of subjects enrolled in a dosage group able to complete the 12 month study or to the time of initiation of dopaminergic therapy on their original assigned dosage. Tolerability of each active arm will be compared to placebo group. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 25 |
| Isradipine CR 5mg/Day | 19 |
| Isradipine CR 10mg/Day | 19 |
| Isradipine CR 20mg/Day | 9 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Placebo | -0.38 |
| Isradipine CR 5mg/Day | -4.20 |
| Isradipine CR 10mg/Day | -5.14 |
| Isradipine CR 20mg/Day | -4.34 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Placebo | 0.09 |
| Isradipine CR 5mg/Day | -2.79 |
| Isradipine CR 10mg/Day | -4.54 |
| Isradipine CR 20mg/Day | -3.63 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | beats per minute (Least Squares Mean) |
|---|---|
| Placebo | -0.08 |
| Isradipine CR 5mg/Day | -2.98 |
| Isradipine CR 10mg/Day | -2.29 |
| Isradipine CR 20mg/Day | -1.21 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | beats per minute (Least Squares Mean) |
|---|---|
| Placebo | -0.42 |
| Isradipine CR 5mg/Day | -0.71 |
| Isradipine CR 10mg/Day | -0.52 |
| Isradipine CR 20mg/Day | 0.18 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Placebo | -4.77 |
| Isradipine CR 5mg/Day | -9.85 |
| Isradipine CR 10mg/Day | -7.75 |
| Isradipine CR 20mg/Day | -6.30 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Placebo | -2.45 |
| Isradipine CR 5mg/Day | -8.59 |
| Isradipine CR 10mg/Day | -6.45 |
| Isradipine CR 20mg/Day | -7.01 |
79 reviews available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Disease Models, Animal
| Article | Year |
|---|---|
The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on the cognitive and motor functions in rodents: A systematic review and meta-analysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cognition; Disease Models, Animal; Mice; Park | 2022 |
Rotenone-Induced Model of Parkinson's Disease: Beyond Mitochondrial Complex I Inhibition.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Electron Tr | 2023 |
Experimental models of chemically induced Parkinson's disease in zebrafish at the embryonic larval stage: a systematic review.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Larva; Models | 2023 |
Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Animals; Disease Models, Animal; Do | 2020 |
Parkinson disease and the gut: new insights into pathogenesis and clinical relevance.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Enteric Nervou | 2020 |
MPTP-induced mouse model of Parkinson's disease: A promising direction of therapeutic strategies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apoptosis; Disease Mode | 2021 |
Oxidative stress and regulated cell death in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2021 |
Classic animal models of Parkinson's disease: a historical perspective.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Oxidopamine; | 2019 |
What basal ganglia changes underlie the parkinsonian state? The significance of neuronal oscillatory activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Biological Clocks; Disease Mod | 2013 |
Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Dysk | 2015 |
Parkinson's disease and enhanced inflammatory response.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyto | 2015 |
Linking microtubules to Parkinson's disease: the case of parkin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Huma | 2015 |
The MPTP Story.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Hist | 2017 |
Estrogen and SERM neuroprotection in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Neuroprote | 2008 |
Parkinson's disease and the gut: a well known clinical association in need of an effective cure and explanation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Central Nervous System; Disease Models, Anima | 2008 |
Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Disease Models, Animal; Dopamine; | 2008 |
Functional models of Parkinson's disease: a valuable tool in the development of novel therapies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Huma | 2008 |
Neuroprotective actions of sex steroids in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopamine Ag | 2009 |
Not lost in translation Sensing the loss and filling the gap during regeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Mesencephalon | 2009 |
Animal models of neurological disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Amyloid beta-Protein Precursor; Ani | 2010 |
alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain; Disease Models, Anima | 2010 |
The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Behavior, Animal; | 2011 |
[Pathophysiology of Parkinson's disease: an update].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomedical Research; Disease Models, Animal; | 2010 |
Neurotoxin-based models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Death; Disease Models, | 2012 |
Meta-analysis of genetic and environmental Parkinson's disease models reveals a common role of mitochondrial protection pathways.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain; Databases, Bibliograp | 2012 |
Animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Animals, Genetically Modifie | 2012 |
Adult neurogenesis in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Hipp | 2013 |
Experimental parkinsonism in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Apomorphine; Basal Ganglia | 2001 |
The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Parkinson Dis | 2003 |
[Insufficiency of nigrostriatal dopaminergic system as a disregulation mechanism of dopamine-dependent depression syndrome].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Depressive Disorder; Disease | 2003 |
Models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cells, Cultured; Disease Models, A | 2003 |
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Disease Models, Animal; Dopamine A | 2003 |
Animal models of Parkinson's disease in rodents induced by toxins: an update.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Basal Ganglia; Brain Stem; | 2003 |
The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agonists; Dr | 2003 |
Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A1 Receptor Antagonists; Adenosine A2 Recept | 2003 |
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechols; Disease Mode | 2004 |
Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Dise | 2004 |
MPTP as a mitochondrial neurotoxic model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Apoptosis; Disease Mo | 2004 |
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Huma | 2004 |
The MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Mod | 2005 |
Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gene Expression; Huma | 2005 |
Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Humans; In | 2006 |
Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Disease Models, Animal; Disease Progre | 2006 |
Neural repair strategies for Parkinson's disease: insights from primate models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Transplantation; Deep Brain Stimulation; | 2006 |
Modeling neurodegenerative diseases in vivo review.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Hapl | 2005 |
A short overview on the role of alpha-synuclein and proteasome in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Amphetamines; Animals; Disease Models | 2006 |
Nonhuman primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavioral Symptoms; Disease Models, Animal; | 2007 |
The role of MPTP in Parkinson's disease: connecting brain and gut?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Enteric Nervou | 2008 |
Trophism, transplantation, and animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Tissue Transplantation; Disease Models, | 1993 |
The use of toxins to elucidate neural function and disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Brain; Brain Diseases; Disease Models, Animal; Humans; | 1993 |
Dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines; oxidation and neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Isoq | 1995 |
Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antihypertensive Agents; Disease Models, Anim | 1995 |
The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Hydr | 1997 |
[Neurotoxin candidates as pathogenic agents of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Disease Models, Anima | 1997 |
[Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Carbolines; Disease Models, Animal; Do | 1998 |
Experimental models of Parkinson's disease: insights from many models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Met | 1999 |
Mitochondrial dysfunction in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Calcium; Disease Models, Animal; D | 1999 |
Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Animals; Cell Survival; Corpus Striatum; | 2000 |
The parkinsonian models: invertebrates to mammals.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Genetically Modified; Apoptosis; Cel | 2000 |
Neurochemical findings in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2001 |
Nitric oxide: an antioxidant and neuroprotector.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Citric Acid; Disease Models, An | 2002 |
The MPTP-treated mouse as a model of parkinsonism: how good is it?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Eval | 1992 |
Mitochondrial mechanisms of neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Biotransformatio | 1992 |
[Parkinsonism and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (review of the literature)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Guinea Pigs; H | 1991 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain Chemistry; Carotid Art | 1991 |
[Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 1991 |
[Parkinson's disease; etiology and animal model].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electron Transport; H | 1991 |
Clinical neuromythology VII. Artificial intelligence: the brain transplant cure for parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Artificial Intelligence; Cau | 1990 |
Biochemical aspects of drug-induced Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Monoamine Oxi | 1990 |
The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Parkinson Dis | 1990 |
Mechanism of the neurotoxicity of MPTP. An update.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biotransformation; Disease Models, Animal; Hu | 1990 |
[Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; | 1989 |
[MPTP and Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Designer Drugs; Disease Models, Animal | 1988 |
MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aging; Animals; Binding Sites; Disease Models, | 1986 |
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1986 |
MPTP in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Haplorhini; Mice; Par | 1988 |
MPTP-induced parkinsonism in monkeys: mechanism of action, selectivity and pathophysiology.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Haplorhini; Parkinson | 1988 |
The physiopathologic significance of manganese in brain: its relation to schizophrenia and neurodegenerative disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Glucose; Brain; Brain Chemistry; Chile; | 1987 |
1085 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Disease Models, Animal
| Article | Year |
|---|---|
Silibinin ameliorates depression/anxiety-like behaviors of Parkinson's disease mouse model and is associated with attenuated STING-IRF3-IFN-β pathway activation and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Depression; Disease Models, Animal; | 2021 |
Deficiency of
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Astrocytes; Dermis; Disease Models, An | 2021 |
Magnetothermal nanoparticle technology alleviates parkinsonian-like symptoms in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Deep Brain Stimulation; Dis | 2021 |
Effect of sex and gonadectomy on brain MPTP toxicity and response to dutasteride treatment in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Castration; Corpus Striatum; Disease Models, | 2021 |
Regulation of neurotoxicity in the striatum and colon of MPTP-induced Parkinson's disease mice by gut microbiome.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Colon; Corpus Striatum; Disease Models, Anima | 2021 |
Garcinol blocks motor behavioural deficits by providing dopaminergic neuroprotection in MPTP mouse model of Parkinson's disease: involvement of anti-inflammatory response.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2022 |
Neuroinductive properties of mGDNF depend on the producer, E. Coli or human cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Escherichia coli; Gan | 2021 |
Impaired mitochondrial functions and energy metabolism in MPTP-induced Parkinson's disease: comparison of mice strains and dose regimens.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Ener | 2021 |
Neuroprotective effect of paeoniflorin in the mouse model of Parkinson's disease through α-synuclein/protein kinase C δ subtype signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Annexin A5; Anti-Inflammator | 2021 |
Association of decreased triadin expression level with apoptosis of dopaminergic cells in Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Carrier Proteins; Cell Survival; D | 2021 |
Bach1 derepression is neuroprotective in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Antioxidant Response | 2021 |
Asparagine endopeptidase deletion ameliorates cognitive impairments by inhibiting proinflammatory microglial activation in MPTP mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cognitive Dysfunction; Cyst | 2022 |
Exposure to varenicline protects against locomotor alteration in a MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Male; Mice; Mice, Inb | 2021 |
Discovery of Resorcinol-Based Polycyclic Structures as Tyrosinase Inhibitors for Treatment of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Mice; Mice, Inbred C5 | 2022 |
Hyperoside suppresses NLRP3 inflammasome in Parkinson's disease via Pituitary Adenylate Cyclase-Activating Polypeptide.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Decrease in
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antigens, CD; Cell Line; Dis | 2021 |
Effect of Coffee against MPTP-Induced Motor Deficits and Neurodegeneration in Mice Via Regulating Gut Microbiota.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Coffee; Disease Models, Animal; Dopaminergic | 2022 |
Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Avoidance Learning; Blotting, Western; Chroni | 2022 |
Anti-Parkinson's Disease Activity of
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basidiomycota; Disease Models, Animal; Dopami | 2022 |
Vancomycin Pretreatment on MPTP-Induced Parkinson's Disease Mice Exerts Neuroprotection by Suppressing Inflammation Both in Brain and Gut.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Infl | 2023 |
TRPV4 contributes to ER stress and inflammation: implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Atractylon, a novel dopamine 2 receptor agonist, ameliorates Parkinsonian like motor dysfunctions in MPTP-induced mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2022 |
Neuroprotective Effect of Riboflavin Producing Lactic Acid Bacteria in Parkinsonian Models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Programmed Death-1 Deficiency Aggravates Motor Dysfunction in MPTP Model of Parkinson's Disease by Inducing Microglial Activation and Neuroinflammation in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Neuroprotective effects of Tongtian oral liquid, a Traditional Chinese Medicine in the Parkinson's disease-induced zebrafish model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
SIRT1 attenuates neuroinflammation by deacetylating HSPA4 in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; Animals; Cytokines; Disease Models, Anima | 2022 |
Kurarinone alleviated Parkinson's disease via stabilization of epoxyeicosatrienoic acids in animal model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Epoxide Hydrolases; F | 2022 |
TGR5 Agonist INT-777 Alleviates Inflammatory Neurodegeneration in Parkinson's Disease Mouse Model by Modulating Mitochondrial Dynamics in Microglia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cholic Acids; Di | 2022 |
Reduced dopaminergic neuron degeneration and global transcriptional changes in Parkinson's disease mouse brains engrafted with human neural stems during the early disease stage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Dopa | 2022 |
In situ analysis of acupuncture protecting dopaminergic neurons from lipid peroxidative damage in mice of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Animals; Disease Models, Animal; | 2022 |
Effect of Different MPTP Administration Intervals on Mouse Models of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Co-treatment with natural HMGB1 inhibitor Glycyrrhizin exerts neuroprotection and reverses Parkinson's disease like pathology in Zebrafish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Glycyrrhizic Acid; HM | 2022 |
Protective Effect of CP690550 in MPTP-Induced Parkinson's Like Behavioural, Biochemical and Histological Alterations in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytokines; Disease Models, Animal; Dopaminerg | 2022 |
Neuronal SH2B1 attenuates apoptosis in an MPTP mouse model of Parkinson's disease via promoting PLIN4 degradation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptor Proteins, Signal Transducing; Aged; Animals; A | 2022 |
Human IPSC 3D brain model as a tool to study chemical-induced dopaminergic neuronal toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopaminergic N | 2022 |
Intestinal Dopamine Receptor D2 is Required for Neuroprotection Against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Dopaminergic Neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2022 |
Development of early diagnosis of Parkinson's disease on animal models based on the intranasal administration of α-methyl-p-tyrosine methyl ester in a gel system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Corpus Striatum; | 2022 |
Cerebroventricular Injection of Pgk1 Attenuates MPTP-Induced Neuronal Toxicity in Dopaminergic Cells in Zebrafish Brain in a Glycolysis-Independent Manner.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Dopa | 2022 |
Anti-Inflammatory and Neuroprotective Mechanisms of GTS-21, an α7 Nicotinic Acetylcholine Receptor Agonist, in Neuroinflammation and Parkinson's Disease Mouse Models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti | 2022 |
Wuzi Yanzong pill attenuates MPTP-induced Parkinson's Disease via PI3K/Akt signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2022 |
Alpha-lipoic acid improved motor function in MPTP-induced Parkinsonian mice by reducing neuroinflammation in the nigral and spinal cord.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Resilin, an insect-derived elastomeric protein, protects dopaminergic neurons in Parkinson disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Disease Models, | 2022 |
Characterization of retinal function and structure in the MPTP murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2022 |
Chitosan oligosaccharides exert neuroprotective effects
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Chitosan; Disease Models, An | 2022 |
Spontaneous partial recovery of striatal dopaminergic uptake despite nigral cell loss in asymptomatic MPTP-lesioned female minipigs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2022 |
COVID-19 Infection Enhances Susceptibility to Oxidative Stress-Induced Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; COVID-19; Disease Models, Animal; Dopamine; H | 2022 |
Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cholecystokinin; Colon; Dise | 2022 |
Garcinia morella extract confers dopaminergic neuroprotection by mitigating mitochondrial dysfunctions and inflammation in mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2022 |
Association between Decreased ITGA7 Levels and Increased Muscle α-Synuclein in an MPTP-Induced Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antigens, CD; Disease Models | 2022 |
Effects of hCG on DA neuronal death of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chorionic Gonadotropin; Disease Models, Anima | 2022 |
Neurogenic effects of rotarod walking exercise in subventricular zone, subgranular zone, and substantia nigra in MPTP-induced Parkinson's disease mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Brain-Derived | 2022 |
N-cystaminylbiguanide MC001 prevents neuron cell death and alleviates motor deficits in the MPTP-model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cysteamine; Disease Models, Anima | 2022 |
Mangiferin, a natural glucoxilxanthone, inhibits mitochondrial dynamin-related protein 1 and relieves aberrant mitophagic proteins in mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Disease Models, Anima | 2022 |
Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amidohydrolases; Animals; Disease Models, Animal; Dopa | 2022 |
Cannabidiol Alleviates the Damage to Dopaminergic Neurons in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson's Disease Mice Via Regulating Neuronal Apoptosis and Neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cannabidiol; Disease Models, Anima | 2022 |
Beneficial effect of transient desflurane inhalation on relieving inflammation and reducing signaling induced by MPTP in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Desflurane; Disease Models, Animal; Glial Fib | 2022 |
GSNOR deficiency attenuates MPTP-induced neurotoxicity and autophagy by facilitating CDK5 S-nitrosation in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alcohol Dehydrogenase; Animals; Autophagy; Cyclin-Depe | 2022 |
Neuroprotective effects of TRPV1 by targeting GDF11 in the Mpp+/MPTP-induced Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bone Morphogenetic Proteins; Disease Models, | 2022 |
DiHuangYin decoction protects dopaminergic neurons in a Parkinson's disease model by alleviating peripheral inflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Microglial AIM2 alleviates antiviral-related neuro-inflammation in mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiviral Agents; Disease Models, Animal; DNA | 2022 |
Açai Berry Mitigates Parkinson's Disease Progression Showing Dopaminergic Neuroprotection via Nrf2-HO1 Pathways.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Disease Progression; | 2022 |
Expression profiles of microRNAs in midbrain of MPTP-treated mice determined by microRNA sequencing.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Effects of eugenol on the behavioral and pathological progression in the MPTP-induced Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Disea | 2022 |
Acute MPTP treatment decreases dendritic spine density of striatal medium spiny neurons via SNK-SPAR pathway in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dendritic Spines; Disease Mo | 2022 |
Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Creatine; Curcumin; Disease Models, Animal; G | 2022 |
Shikonin ameliorates oxidative stress and neuroinflammation via the Akt/ERK/JNK/NF-κB signalling pathways in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cyclooxygenase 2; Disease Models, Animal; Dop | 2022 |
Pyruvate Prevents Dopaminergic Neurodegeneration and Motor Deficits in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2022 |
Neuroprotective effects of human umbilical cord mesenchymal stromal cells in PD mice via centrally and peripherally suppressing NLRP3 inflammasome-mediated inflammatory responses.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytokines; Disease Models, Animal; Dopamine; | 2022 |
Anti-Inflammatory and Neuroprotective Effects of Morin in an MPTP-Induced Parkinson's Disease Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2022 |
Defining Specific Cell States of MPTP-Induced Parkinson's Disease by Single-Nucleus RNA Sequencing.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Endothelial Cells; Mi | 2022 |
GPBAR1 preserves neurite and synapse of dopaminergic neurons via RAD21-OPCML signaling: Role in preventing Parkinson's disease in mouse model and human patients.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analgesics, Opioid; Animals; Bile Acids and Salts; Cel | 2022 |
Neurochemical, histological, and behavioral profiling of the acute, sub-acute, and chronic MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Hyp | 2023 |
Characterization of neurobehavioral pattern in a zebrafish 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model: A 96-hour behavioral study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Targeting microglial NLRP3 in the SNc region as a promising disease-modifying therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Disease Models, | 2022 |
Analysis of m6A modification regulators in the substantia nigra and striatum of MPTP-induced Parkinson's disease mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2022 |
Fucosylated Chondroitin Sulfate against Parkinson's Disease through Inhibiting Inflammation Induced by Gut Dysbiosis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Chondroitin Sulfates; Diseas | 2022 |
Neuroprotective Effects of Sodium Butyrate and Monomethyl Fumarate Treatment through GPR109A Modulation and Intestinal Barrier Restoration on PD Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Butyric Acid; Claudin-1; Cytokines; Disease M | 2022 |
HLDF-6 peptides exhibit neuroprotective effects in the experimental model of preclinical Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estradiol; Humans; Mi | 2022 |
Dexmedetomidine alleviates pain in MPTP-treated mice by activating the AMPK/mTOR/NF-κB pathways in astrocytes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Astrocytes; De | 2022 |
Feruloylated oligosaccharides ameliorate MPTP-induced neurotoxicity in mice by activating ERK/CREB/BDNF/TrkB signalling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Disease Mo | 2023 |
Lycium barbarum polysaccharide improves dopamine metabolism and symptoms in an MPTP-induced model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Disease Models, Animal; Dopamin | 2022 |
Inhibiting von Hippel‒Lindau protein-mediated Dishevelled ubiquitination protects against experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; beta Catenin; Caenorhabditis elegans; Disease | 2023 |
Gastric Enteric Glial Cells: A New Contributor to the Synucleinopathies in the MPTP-Induced Parkinsonism Mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Mice | 2022 |
Neuroprotective Effects of
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bifidobacterium; Bifidobacterium breve; Disea | 2022 |
Association Between Decreased Srpk3 Expression and Increased Substantia Nigra Alpha-Synuclein Level in an MPTP-Induced Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; | 2023 |
Intermittent fasting protects the nigral dopaminergic neurons from MPTP-mediated dopaminergic neuronal injury in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Verification of the beta oscillations in the subthalamic nucleus of the MPTP-induced parkinsonian minipig model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Parkinsonian Disorder | 2023 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Exercise training has a protective effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model with improved neural and intestinal pathology and modified intestinal flora.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Exercise training has a protective effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model with improved neural and intestinal pathology and modified intestinal flora.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Exercise training has a protective effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model with improved neural and intestinal pathology and modified intestinal flora.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Exercise training has a protective effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model with improved neural and intestinal pathology and modified intestinal flora.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Transcriptomic and metabolomic analyses provide insights into the attenuation of neuroinflammation by nervonic acid in MPTP-stimulated PD model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arachidonic Acids; Disease Models, Animal; Hu | 2023 |
Transcriptomic and metabolomic analyses provide insights into the attenuation of neuroinflammation by nervonic acid in MPTP-stimulated PD model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arachidonic Acids; Disease Models, Animal; Hu | 2023 |
Transcriptomic and metabolomic analyses provide insights into the attenuation of neuroinflammation by nervonic acid in MPTP-stimulated PD model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arachidonic Acids; Disease Models, Animal; Hu | 2023 |
Transcriptomic and metabolomic analyses provide insights into the attenuation of neuroinflammation by nervonic acid in MPTP-stimulated PD model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arachidonic Acids; Disease Models, Animal; Hu | 2023 |
Biochemical and behavioral effects of rosmarinic acid treatment in an animal model of Parkinson's disease induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Mice; Mice, | 2023 |
Biochemical and behavioral effects of rosmarinic acid treatment in an animal model of Parkinson's disease induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Mice; Mice, | 2023 |
Biochemical and behavioral effects of rosmarinic acid treatment in an animal model of Parkinson's disease induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Mice; Mice, | 2023 |
Biochemical and behavioral effects of rosmarinic acid treatment in an animal model of Parkinson's disease induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Mice; Mice, | 2023 |
4-Aminopyridine Protects Nigral Dopaminergic Neurons in the MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 4-Aminopyridine; Animals; Disease Models, Animal; Dopa | 2023 |
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Disease Models, Animal; Dopaminergic Ne | 2023 |
Modeling of the Progressive Degradation of the Nigrostriatal Dopaminergic System in Mice to Study the Mechanisms of Neurodegeneration and Neuroplasticity in Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2022 |
Cordycepin improved the cognitive function through regulating adenosine A
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine; Animals; Cognition; Disease Models, Animal; | 2023 |
Qilong Capsule Alleviated MPTP-Induced Neuronal Defects by Inhibiting Apoptosis, Regulating Autophagy in Zebrafish Embryo Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Autophagy; Disease Models, Animal; | 2023 |
Artemisinin exerts a protective effect in the MPTP mouse model of Parkinson's disease by inhibiting microglial activation via the TLR4/Myd88/NF-KB pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptor Proteins, Signal Transducing; Animals; Artemis | 2023 |
Glimepiride Prevents 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Induced Dopamine Neurons Degeneration Through Attenuation of Glia Activation and Oxidative Stress in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diabetes Mellitus, Type 2; Disease Models, An | 2023 |
Gut Microbial Alteration in MPTP Mouse Model of Parkinson Disease is Administration Regimen Dependent.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Neuroprotective role of chloroquine via modulation of autophagy and neuroinflammation in MPTP-induced Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy; Chloroquine; Disease Models, Anima | 2023 |
Protective Effects of Flavonoid Rutin Against Aminochrome Neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2023 |
Investigating Therapeutic Effects of Indole Derivatives Targeting Inflammation and Oxidative Stress in Neurotoxin-Induced Cell and Mouse Models of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Disease Models, | 2023 |
Anti-oxidative and anti-neuroinflammatory role of Necrostatin-1s and docosahexaenoic acid in RIP-1-mediated neurotoxicity in MPTP-induced Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Disease Models, Animal; Docosah | 2023 |
Endonuclease VIII-like 1 deficiency potentiates nigrostriatal dopaminergic neuron degeneration in a male mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Deoxyribonuclease (Pyrimidin | 2023 |
Whether the Subacute MPTP-Treated Mouse is as Suitable as a Classic Model of Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2023 |
Zinc Deficiency Exacerbates Behavioral Impediments and Dopaminergic Neuron Degeneration in a Mouse Model of Parkinson Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diet; Disease Models, Animal; Dopamine; Dopam | 2023 |
Amygdalo-nigral circuit mediates stress-induced vulnerability to the parkinsonian toxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disabled Persons; Disease Models, Animal; Dop | 2023 |
Rhynchophylline alleviates neuroinflammation and regulates metabolic disorders in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Metabolic Diseases; M | 2023 |
Suppression of neuroinflammation and α-synuclein oligomerization by rotarod walking exercise in subacute MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Dopa | 2023 |
Foliglurax, a positive allosteric modulator of the metabotrophic glutamate receptor 4, protects dopaminergic neurons in MPTP-lesioned male mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Allosteric Regulation; Animals; Antiparkinson Agents; | 2023 |
Novel FABP3 ligand, HY-11-9, ameliorates neuropathological deficits in MPTP-induced Parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Dopa | 2023 |
NOD-like receptor NLRC5 promotes neuroinflammation and inhibits neuronal survival in Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2023 |
Zinc (Zn) and adipose-derived mesenchymal stem cells (AD-MSCs) on MPTP-induced Parkinson's disease model: A comparative evaluation of behavioral and immunohistochemical results.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Disease Mo | 2023 |
Involvement of Abnormal p-α-syn Accumulation and TLR2-Mediated Inflammation of Schwann Cells in Enteric Autonomic Nerve Dysfunction of Parkinson's Disease: an Animal Model Study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Autonomic Pathways; Disease | 2023 |
Neuroprotective microRNA-381 Binds to Repressed Early Growth Response 1 (EGR1) and Alleviates Oxidative Stress Injury in Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Disease Models, | 2023 |
Effect of Eleutheroside E on an MPTP-Induced Parkinson's Disease Cell Model and Its Mechanism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Mice; Mice, Inbred C5 | 2023 |
Treadmill Exercise Alleviates Cognition Disorder by Activating the FNDC5: Dual Role of Integrin αV/β5 in Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Cognition | 2023 |
Morin exhibits a neuroprotective effect in MPTP-induced Parkinson's disease model via TFEB/AMPK-mediated mitophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Disease Models | 2023 |
Necrosulfonamide exerts neuroprotective effect by inhibiting necroptosis, neuroinflammation, and α-synuclein oligomerization in a subacute MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Dopa | 2023 |
Orally Induced High Serum Level of Trimethylamine N-oxide Worsened Glial Reaction and Neuroinflammation on MPTP-Induced Acute Parkinson's Disease Model Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2023 |
A Low-Protein, High-Carbohydrate Diet Exerts a Neuroprotective Effect on Mice with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson's Disease by Regulating the Microbiota-Metabolite-Brain Axis and Fibroblast Growth Factor 21.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Diet; Disease Models, Animal; Dopamine | 2023 |
The Transcription Factor Nrf2 Mediates the Effects of
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Novel flavonoid 1,3,4-oxadiazole derivatives ameliorate MPTP-induced Parkinson's disease via Nrf2/NF-κB signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Disea | 2023 |
Casein Reactivates Dopaminergic Nerve Injury and Intestinal Inflammation with Disturbing Intestinal Microflora and Fecal Metabolites in a Convalescent Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caseins; Disease Models, Animal; Dopamine; Ga | 2023 |
Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gastrointestinal Micr | 2023 |
The molecular mechanism of three novel peptides from C-phycocyanin alleviates MPTP-induced Parkinson's disease-like pathology in zebrafish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholinesterase; Animals; Antioxidants; Disease M | 2023 |
Integrative multilevel exploration of the mechanism by which Er-Zhi-Wan alleviates the Parkinson's disease (PD)-like phenotype in the MPTP-induced PD mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, Liquid; Disease Models, Anima | 2023 |
Vitamin E Analog Trolox Attenuates MPTP-Induced Parkinson's Disease in Mice, Mitigating Oxidative Stress, Neuroinflammation, and Motor Impairment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
HDAC6 Deficiency Has Moderate Effects on Behaviors and Parkinson's Disease Pathology in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2023 |
Low-Field Magnetic Stimulation Alleviates MPTP-Induced Alterations in Motor Function and Dopaminergic Neurons in Male Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2023 |
Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Corpus Striatum; Disease Models, Ani | 2023 |
Protective Effect of a New Monophenolic Antioxidant TS-13 in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Disease Models, Animal; Mice; M | 2023 |
Wuzi Yanzong Pill relieves MPTP-induced motor dysfunction and neuron loss by inhibiting NLRP3 inflammasome-mediated neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2023 |
The Involvement of Progranulin for α-Synuclein Reduction through Autolysosome Formation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Dopa | 2023 |
Investigation of rhodamine derivative on behavioral impairment in a double neurotoxin lesion of substantia nigra and locus coeruleus dysfunctional mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Neuroprotective effect of chlorogenic acid on Parkinson's disease like symptoms through boosting the autophagy in zebrafish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy; Chlorogenic Acid; Disease Models, | 2023 |
Huperzine A injection ameliorates motor and cognitive abnormalities via regulating multiple pathways in a murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholinesterase; Animals; Cognition; Disease Mode | 2023 |
Whole Transcriptome Analysis of Substantia Nigra in Mice with MPTP-Induced Parkinsonism Bearing Defective Glucocerebrosidase Activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gene Expression Profi | 2023 |
N-acetyl-L-leucine protects MPTP-treated Parkinson's disease mouse models by suppressing Desulfobacterota via the gut-brain axis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Gut Axis; Disease Models, Animal; Dopam | 2023 |
Association between SGK1 and α-synuclein in skeletal muscle in an MPTP-induced Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Dopa | 2023 |
Oral administration of sophoricoside (SOP) inhibits neuronal damage and neuroinflammation to curb neurodegeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Administration, Oral; Ani | 2023 |
Novel HDAC inhibitors provide neuroprotection in MPTP-induced Parkinson's disease model of rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Histone Dea | 2023 |
TLR2 deficiency is beneficial at the late phase in MPTP-induced Parkinson' disease mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2023 |
Low-moderate dose whole-brain γ-ray irradiation modulates the expressions of glial fibrillary acidic protein and intercellular adhesion molecule-1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopaminergic N | 2023 |
Total Glucosides of White Paeony Capsule ameliorates Parkinson's disease-like behavior in MPTP-induced mice model by regulating LRRK2/alpha-synuclein signaling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Dopa | 2024 |
Purple pitanga extract (Eugenia uniflora) attenuates oxidative stress induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Disease Models, Animal; Eugenia | 2023 |
A primate nigrostriatal atlas of neuronal vulnerability and resilience in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Anesthetics, Dissociative; | 2020 |
Neuroprotection and immunomodulation of progesterone in the gut of a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain-Derived Neurotrophic Factor; Dis | 2020 |
AAV-Mediated Expression of Dominant-Negative ULK1 Increases Neuronal Survival and Enhances Motor Performance in the MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy-Related Protein-1 Homolog; Behavior | 2020 |
Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Alanine Transaminase; Anim | 2020 |
Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Blood | 2019 |
RIP1/RIP3/MLKL mediates dopaminergic neuron necroptosis in a mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytokines; Disease Models, Animal; Dopaminerg | 2020 |
Effects of sleep disruption on stress, nigrostriatal markers, and behavior in a chronic/progressive MPTP male mouse model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Corticosterone; Disease Mode | 2019 |
Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious precl
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Callithrix; Corpus S | 2020 |
Nei-like 1 inhibition results in motor dysfunction and promotes inflammation in Parkinson's disease mice model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Disease Models, Animal; DNA Glyc | 2020 |
Peripheral Delivery of Neural Precursor Cells Ameliorates Parkinson's Disease-Associated Pathology.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Embryonic Stem Cells; | 2019 |
Enhanced neuroinflammation and oxidative stress are associated with altered hippocampal neurogenesis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Dopa | 2019 |
Comparative strategies for stem cell biodistribution in a preclinical study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Disease Models, A | 2020 |
Psychosocial stress enhances susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in C57BL/6N mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Mice; Neurotoxicity S | 2019 |
Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Basal Ganglia; Bl | 2019 |
[Study on preventive and therapeutic effects of Erzhi Pills on mice with Parkinson's disease induced by MPTP].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Drugs, Chinese Herbal | 2019 |
Acupuncture Inhibits the Increase in Alpha-Synuclein in Substantia Nigra in an MPTP- Induced Parkinsonism Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; alpha-Synuclein; Animals; Disease | 2020 |
NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cognition; Disease Mode | 2020 |
A role for glia maturation factor dependent activation of mast cells and microglia in MPTP induced dopamine loss and behavioural deficits in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2020 |
Pro-survival and anti-inflammatory roles of NF-κB c-Rel in the Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Case-Control Studies; Cell Line; Disease Mode | 2020 |
Activation of CB2R with AM1241 ameliorates neurodegeneration via the Xist/miR-133b-3p/Pitx3 axis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cannabinoids; Disease Models, Animal; Dopamin | 2020 |
Simvastatin Improves Behavioral Disorders and Hippocampal Inflammatory Reaction by NMDA-Mediated Anti-inflammatory Function in MPTP-Treated Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2020 |
Chronic Infiltration of T Lymphocytes into the Brain in a Non-human Primate Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopaminergic N | 2020 |
Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; DEAD-box RNA Helicases; | 2020 |
Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Blood- | 2020 |
Gait Deficits and Loss of Striatal Tyrosine Hydroxlase/Trk-B are Restored Following 7,8-Dihydroxyflavone Treatment in a Progressive MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Flav | 2020 |
The Effect of Low-Intensity Transcranial Ultrasound Stimulation on Behavior in a Mouse Model of Parkinson's Disease Induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Disease Models, Anim | 2020 |
Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; | 2020 |
Lanthionine ketimine ester improves outcome in an MPTP-induced mouse model of Parkinson's disease via suppressions of CRMP2 phosphorylation and microglial activation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids, Sulfur; Animals; Disease Models, Animal; | 2020 |
BMAL1 regulation of microglia-mediated neuroinflammation in MPTP-induced Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; ARNTL Transcription Factors; Disease Models, | 2020 |
Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disabled Persons; Disease Models, | 2020 |
NLRP3 inflammasome and glia maturation factor coordinately regulate neuroinflammation and neuronal loss in MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cells, Cultured; Disease Models, A | 2020 |
Bruceine D elevates Nrf2 activation to restrain Parkinson's disease in mice through suppressing oxidative stress and inflammatory response.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2020 |
A Mouse Model of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Induced Parkinson Disease Shows that 2-Aminoquinoline Targets JNK Phosphorylation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Aminoquinolines; Animals; | 2020 |
TAT-tagging of VIP exerts positive allosteric modulation of the PAC1 receptor and enhances VIP neuroprotective effect in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Allosteric Regulation; Animals; Cell Survival; Cell-Pe | 2020 |
Transcriptomic Profiling of Circular RNA in Different Brain Regions of Parkinson's Disease in a Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Computational Biology; Disease Models, | 2020 |
Glyphosate exposure exacerbates the dopaminergic neurotoxicity in the mouse brain after repeated administration of MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Dopa | 2020 |
Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson's disease through AKT/mTOR pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Clioquinol; Disease Models, Animal; Haplorhin | 2020 |
Down-regulation of DJ-1 Augments Neuroinflammation via Nrf2/Trx1/NLRP3 Axis in MPTP-induced Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Down-Regulation; Mice | 2020 |
Editorial for the Special Issue "Animal Models of Parkinson's Disease and Related Disorders".
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Early Diagnosis; Huma | 2020 |
Neuroprotective Effect of Chlorogenic Acid on Mitochondrial Dysfunction-Mediated Apoptotic Death of DA Neurons in a Parkinsonian Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Apoptosis; Behavior, Animal; Ch | 2020 |
Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior | 2020 |
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior | 2020 |
3-Pyridinylboronic acid normalizes the effects of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure in zebrafish embryos.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Boronic Acids; Disease Models, Animal; Mice; | 2022 |
Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Lactobacillus plantar | 2020 |
The insect molting hormone 20-hydroxyecdysone protects dopaminergic neurons against MPTP-induced neurotoxicity in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2020 |
Papaverine inhibits α-synuclein aggregation by modulating neuroinflammation and matrix metalloproteinase-3 expression in the subacute MPTP/P mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Astrocytes; Disease Models, | 2020 |
Synergistic effect of electric stimulation and mesenchymal stem cells against Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Cell Proliferation; | 2020 |
Preparation and Neuroprotective Activity of Glucuronomannan Oligosaccharides in an MPTP-Induced Parkinson's Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apoptosis; Apoptosis Re | 2020 |
Docosahexaenoic acid-acylated astaxanthin ester exhibits superior performance over non-esterified astaxanthin in preventing behavioral deficits coupled with apoptosis in MPTP-induced mice with Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Brain; Disease Models, Animal; Doc | 2020 |
Molecular Regulatory Mechanism and Toxicology of Neurodegenerative Processes in MPTP/Probenecid-Induced Progressive Parkinson's Disease Mice Model Revealed by Transcriptome.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Gen | 2021 |
Pepper component 7-ethoxy-4-methylcoumarin, a novel dopamine D2 receptor agonist, ameliorates experimental Parkinson's disease in mice and Caenorhabditis elegans.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Genetically Modified; Behavior, Anim | 2021 |
Functional Crosstalk between CB and TRPV1 Receptors Protects Nigrostriatal Dopaminergic Neurons in the MPTP Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Capsaicin; Disease Models, Animal; Dopaminerg | 2020 |
Functional validation of a human GLUD2 variant in a murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Transport System X-AG; Animals; Brain-Deriv | 2020 |
Korean Red Ginseng Regulates Intestinal Tight Junction and Inflammation in the Colon of a Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Colon; Disease Models, Anima | 2020 |
Therapeutic Potential of Repeated Intravenous Transplantation of Human Adipose-Derived Stem Cells in Subchronic MPTP-Induced Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intravenous; Animals; Disease Models, | 2020 |
2-Hydroxy-4-Methylbenzoic Anhydride Inhibits Neuroinflammation in Cellular and Experimental Animal Models of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Benzoates; Cell Surviva | 2020 |
Human Amniotic Epithelial Cells Alleviate a Mouse Model of Parkinson's Disease Mainly by Neuroprotective, Anti-Oxidative and Anti-Inflammatory Factors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2021 |
Ellagic Acid Prevents Dopamine Neuron Degeneration from Oxidative Stress and Neuroinflammation in MPTP Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2020 |
Changes in Striatal Medium Spiny Neuron Morphology Resulting from Dopamine Depletion Are Reversible.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Axons; Corpus Striatum; Dendritic Spines; Dis | 2020 |
Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Catec | 2021 |
Brain Selective Estrogen Treatment Protects Dopaminergic Neurons and Preserves Behavioral Function in MPTP-induced Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Corpus Striatum; Disease Models, Anima | 2021 |
D
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Bromocriptine; C | 2021 |
Blood Exosomes Have Neuroprotective Effects in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopaminergic N | 2020 |
DNA Methyltransferase 1 Is Dysregulated in Parkinson's Disease via Mediation of miR-17.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Line, Tumor; Disease Models, Animal; DNA | 2021 |
Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2021 |
Korean red ginseng suppresses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced inflammation in the substantia nigra and colon.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Colon; Disease Models, Animal; Dopaminergic N | 2021 |
Neuroprotective and Anti-Inflammatory Effects of Evernic Acid in an MPTP-Induced Parkinson's Disease Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Apoptosis; Astrocyt | 2021 |
Depression Induced by Chronic Unpredictable Mild Stress Increases Susceptibility to Parkinson's Disease in Mice via Neuroinflammation Mediated by P2X7 Receptor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Depression; Disease Models, Animal; Mice; Mic | 2021 |
Simvastatin Prevents Neurodegeneration in the MPTP Mouse Model of Parkinson's Disease via Inhibition of A1 Reactive Astrocytes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Disease Models, Animal; Dopaminer | 2021 |
G-CSF reduces loss of dopaminergic neurons by inhibiting TNF-α and IL-1β in mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2023 |
Transcranial Ultrasound Stimulation Suppresses Neuroinflammation in a Chronic Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2021 |
Protective effects of prucalopride in MPTP-induced Parkinson's disease mice: Neurochemistry, motor function and gut barrier.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzofurans; Body Weight; Disease Models, Ani | 2021 |
Inhibition of long non-coding RNA HOXA11-AS against neuroinflammation in Parkinson's disease model via targeting miR-124-3p mediated FSTL1/NF-κB axis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Disease Models, Animal; Dopaminerg | 2021 |
The association of enteric neuropathy with gut phenotypes in acute and progressive models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Cell Count; Chronic Disease; C | 2021 |
Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2021 |
A New Tool to Study Parkinsonism in the Context of Aging: MPTP Intoxication in a Natural Model of Multimorbidity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2021 |
Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2021 |
Generation of Mitochondrial Toxin Rodent Models of Parkinson's Disease Using 6-OHDA , MPTP , and Rotenone.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Male; Mice; | 2021 |
The neuroprotective effects of isoquercitrin purified from apple pomace by high-speed countercurrent chromatography in the MPTP acute mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Countercurrent Distribution; Disea | 2021 |
Citicoline improved cardiovascular function in animal model of dysautonomia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Pressure; Cardiovascular Diseases; Cyti | 2021 |
Epigenetic mechanisms involved in the neuroprotective effect of scorpion extract in a Parkinson's disease murine model based on multi-omics approach.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Epigenesis, Genetic; | 2021 |
The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Glucagon-Like Peptide | 2021 |
Thioredoxin-1 regulates calcium homeostasis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calcium; Disease Models, Animal; Homeostasis; | 2021 |
Brain-derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Cognitive | 2021 |
Silibinin attenuates motor dysfunction in a mouse model of Parkinson's disease by suppression of oxidative stress and neuroinflammation along with promotion of mitophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2021 |
PEP-1-GLRX1 Reduces Dopaminergic Neuronal Cell Loss by Modulating MAPK and Apoptosis Signaling in Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Cell | 2021 |
microRNA-106b-containing extracellular vesicles affect autophagy of neurons by regulating CDKN2B in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Autophagy; Cells, Cultured; Cyclin | 2021 |
Behavioral characterization in MPTP/p mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2021 |
Neuropeptide-S affects cognitive impairment and depression-like behavior on MPTP induced experimental mouse model of Parkinson’s disease
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cognition; Depression; Disease Models, Animal | 2021 |
[Macrophage migration inhibitory factor meditates MPP+/MPTP-induced NLRP3 inflammasome activation in microglia cells].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Disease Models, | 2021 |
Partial depletion and repopulation of microglia have different effects in the acute MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminopyridines; Animals; Behavior, Animal; Cyclooxygen | 2021 |
4,4'-Dimethoxychalcone regulates redox homeostasis by targeting riboflavin metabolism in Parkinson's disease therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2021 |
Morphine attenuates neurotoxic effects of MPTP in zebrafish embryos by regulating oxidant/antioxidant balance and acetylcholinesterase activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholinesterase; Analgesics, Opioid; Animals; Ant | 2022 |
GSK-3 mediates nuclear translocation of p62/SQSTM1 in MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cell Nucleus; Disease Models, Anim | 2021 |
Neuroprotective effects of 2,4-dinitrophenol in an acute model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,4-Dinitrophenol; Animals; Cell Death; Dinitrophenols | 2017 |
Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Cell Line; Disea | 2017 |
Dysfunction of mitochondrial Lon protease and identification of oxidized protein in mouse brain following exposure to MPTP: Implications for Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aconitate Hydratase; Animals; Cell Death; Disease Mode | 2017 |
Effect of dental pulp stem cells in MPTP-induced old-aged mice model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Behavior, Animal; Cell Differentiation | 2017 |
Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Arabidopsis Proteins; C | 2017 |
Pre-clinical therapeutic development of a series of metalloporphyrins for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antioxidants; Antiparki | 2017 |
Effects of a combination treatment of KD5040 and
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cyclic AMP Response Element-Binding Pr | 2017 |
Rolipram improves facilitation of contextual fear extinction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cyclic AMP; Cyclic AMP Resp | 2017 |
MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2018 |
Analogues of desferrioxamine B designed to attenuate iron-mediated neurodegeneration: synthesis, characterisation and activity in the MPTP-mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Ascorbic Acid; Benzothiazoles; | 2017 |
Neuroprotective effects of total flavonoid fraction of the Epimedium koreanum Nakai extract on dopaminergic neurons: In vivo and in vitro.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Cell L | 2017 |
Complete Comparison Display (CCD) evaluation of ethanol extracts of Centella asiatica and Withania somnifera shows that they can non-synergistically ameliorate biochemical and behavioural damages in MPTP induced Parkinson's model of mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Bioma | 2017 |
Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Calcium Channel Blockers; Calcium | 2017 |
Treadmill exercise produces neuroprotective effects in a murine model of Parkinson's disease by regulating the TLR2/MyD88/NF-κB signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Corpus Striatum; Disease Mod | 2017 |
Not all boronic acids with a five-membered cycle induce tremor, neuronal damage and decreased dopamine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Boronic Acids; Brain; Chromatography, High Pr | 2017 |
2',3'-Dideoxycytidine Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cells, Cultured; Disease Models, | 2017 |
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astroc | 2017 |
Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Biomarkers; Callithrix; Dis | 2017 |
Electroacupuncture Promotes Recovery of Motor Function and Reduces Dopaminergic Neuron Degeneration in Rodent Models of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Brain-Derived Neurotrophic Factor; | 2017 |
Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Aged, 80 and over; Animals; Cell Prolifer | 2017 |
[The effect of neurotoxin MPTP administration to mice on the proteomic profile of brain isatin-binding proteins].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Carrier Proteins; Disease Models, Anim | 2017 |
Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Chemistry; Disease Mo | 2017 |
[Effect of Shouwu Shudi Yin on dopaminegic neurons in MPTP induced Parkinson's disease mouse model].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2016 |
Objectively measuring effects of electro-acupuncture in parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Animals; Apomorphine; Corpus Stri | 2018 |
Physical Exercise Modulates L-DOPA-Regulated Molecular Pathways in the MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Gene | 2018 |
Role of ethanolic extract of Bacopa monnieri against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced mice model via inhibition of apoptotic pathways of dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Bacopa; Disease Models, Animal; Do | 2017 |
Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Diffusion Tensor Imaging; Disease Mode | 2018 |
Mild hyperbaric oxygen inhibits the decrease of dopaminergic neurons in the substantia nigra of mice with MPTP-induced Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2018 |
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzene Derivatives; Disease Models, Animal; | 2018 |
Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; B | 2018 |
MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's disease by targeting Nlrp3.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytokines; Disease Models, Animal; Gene Expre | 2018 |
(-)-Epigallocatechin-3-gallate modulates peripheral immunity in the MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catechin; Disease Models, Animal; Dopaminergi | 2018 |
The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP-treated common marmoset model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Banisteriopsis; Callith | 2018 |
Whole-Transcriptome Analysis of Mouse Models with MPTP-Induced Early Stages of Parkinson's Disease Reveals Stage-Specific Response of Transcriptome and a Possible Role of Myelin-Linked Genes in Neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cluster Analysis; Disease Models, Animal; Exo | 2018 |
TREM2 overexpression attenuates neuroinflammation and protects dopaminergic neurons in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adenoviridae; Animals; | 2018 |
Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Disease Mode | 2018 |
Naringenin Decreases α-Synuclein Expression and Neuroinflammation in MPTP-Induced Parkinson's Disease Model in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Anti-Inflammatory Agents; Cy | 2018 |
In vivo GluCEST MRI: Reproducibility, background contribution and source of glutamate changes in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biological Transport; Disease Models, Animal; | 2018 |
Peripheral Administration of Tetanus Toxin Hc Fragment Prevents MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2018 |
Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Glucose; Body Weight; Cytokines; Diseas | 2018 |
Pharmacological Inhibition of Necroptosis Protects from Dopaminergic Neuronal Cell Death in Parkinson's Disease Models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cell Differentiation; Disease Mode | 2018 |
Astrocytic JWA deletion exacerbates dopaminergic neurodegeneration by decreasing glutamate transporters in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Transport System X-AG; Animals; Astrocytes; | 2018 |
Oligo-Porphyran Ameliorates Neurobehavioral Deficits in Parkinsonian Mice by Regulating the PI3K/Akt/Bcl-2 Pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Behavior, Animal; Brain; Disease M | 2018 |
Regulatable Lentiviral Hematopoietic Stem Cell Gene Therapy in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Differentiation; Corpus Striatum; Diseas | 2018 |
Targeted deletion of the aquaglyceroporin AQP9 is protective in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aquaporins; Disease Models, Animal; Dopaminer | 2018 |
Neural Stem Cell Grafts Promote Astroglia-Driven Neurorestoration in the Aged Parkinsonian Brain via Wnt/β-Catenin Signaling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Astrocytes; Brain; Cell Death; Cell Di | 2018 |
TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arginase; Cell Line; Cell Polarity; Cytokines | 2018 |
Synthesis and biological evaluation of clovamide analogues as potent anti-neuroinflammatory agents in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Cell Line; Disease | 2018 |
Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gait; Hindlimb; Homeo | 2018 |
2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Astrocytes; Behavior, Animal | 2018 |
Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cell Line; Corpus Striatum; | 2018 |
MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Death; Disease Models, | 2019 |
PPARß/δ agonist alleviates NLRP3 inflammasome-mediated neuroinflammation in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2019 |
JNK-mediated microglial DICER degradation potentiates inflammatory responses to induce dopaminergic neuron loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Cells, Cultured; Cytokines; | 2018 |
Effect of Zishenpingchan granule prepared from Chinese medicinal substances on the c-Jun N-terminal protein kinase pathway in mice\
with Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cyclooxygenase 2; Disease Models, | 2017 |
Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP/p mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cells, Cultured; Chromatography, High Pressur | 2018 |
Acute Restraint Stress Augments 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neurotoxicity via Increased Toxin Uptake into the Brain in C57BL/6 Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 2018 |
Telmisartan Ameliorates Astroglial and Dopaminergic Functions in a Mouse Model of Chronic Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiotensin II Type 1 Receptor Blockers; Animals; Astr | 2018 |
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Delayed-Action Preparations; | 2018 |
1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Choline O-Acetyltransferase; Disease Models, | 2018 |
Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson's disease animal model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Annexin A2; Astrocytes; Calcium-Binding Prote | 2018 |
Cell-penetrating artificial mitochondria-targeting peptide-conjugated metallothionein 1A alleviates mitochondrial damage in Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Sequence; Animals; Cell Death; Cell Line, T | 2018 |
Upgraded Methodology for the Development of Early Diagnosis of Parkinson's Disease Based on Searching Blood Markers in Patients and Experimental Models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Case-Control Studies; Catecholami | 2019 |
Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age of Onset; Animals; Callithrix; Circadian Rhythm; D | 2018 |
Modulation of mitochondrial phenotypes by endurance exercise contributes to neuroprotection against a MPTP-induced animal model of PD.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Disease Models, Animal; Exercise T | 2018 |
Neuroprotective effect of crocin on substantia nigra in MPTP-induced Parkinson's disease model of mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Carotenoids; Disease Models, Anima | 2019 |
Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Ente | 2018 |
Comparative evaluation of extract of Bacopa monnieri and Mucuna pruriens as neuroprotectant in MPTP model of Parkinson’s disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bacopa; Disease Models, Animal; Mice; Mice, I | 2016 |
Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Cutaneous; Animals; Apoptosis; Corpus | 2018 |
Proanthocyanidins exert a neuroprotective effect via ROS/JNK signaling in MPTP‑induced Parkinson's disease models in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cell Proliferation; Cell Survival; | 2018 |
Reduction of HIP2 expression causes motor function impairment and increased vulnerability to dopaminergic degeneration in Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Dopa | 2018 |
Anodal transcranial direct current stimulation prevents methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity by modulating autophagy in an in vivo mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy; Biomarkers; Brain-Derived Neurotro | 2018 |
Genetic suppression of collapsin response mediator protein 2 phosphorylation improves outcome in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2019 |
A non-human primate model for stable chronic Parkinson's disease induced by MPTP administration based on individual behavioral quantification.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Disease Models, Anim | 2019 |
Nicotine promotes neuron survival and partially protects from Parkinson's disease by suppressing SIRT6.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Animals, Newborn; Ap | 2018 |
Mitigation Effects of a Novel Herbal Medicine, Hepad, on Neuroinflammation, Neuroapoptosis, and Neuro-Oxidation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Apoptosis; Cell Line; C | 2018 |
Neuroprotective effects of Astilbin on MPTP-induced Parkinson's disease mice: Glial reaction, α-synuclein expression and oxidative stress.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Astrocytes; Disease Models, | 2019 |
Effect of NAC treatment and physical activity on neuroinflammation in subchronic Parkinsonism; is physical activity essential?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcysteine; Analysis of Variance; Animals; Calcium | 2018 |
Counteracting neuroinflammation in experimental Parkinson's disease favors recovery of function: effects of Er-NPCs administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Coculture Techniques; Corpus Striatum; Cytoki | 2018 |
Bone loss in MPTP mouse model of Parkinson's disease is triggered by decreased osteoblastogenesis and increased osteoclastogenesis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bone Resorption; Cancellous Bone; Cell Line, | 2019 |
Admixing MPTP-resistant and MPTP-vulnerable mice enhances striatal field potentials and calbindin-D28K expression to avert motor behaviour deficits.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calbindin 1; Corpus Striatum; Disease Models, | 2019 |
TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson's diseases in vivo model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cytokines; Disease Models, A | 2019 |
EriB targeted inhibition of microglia activity attenuates MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Nucleus; Cy | 2018 |
Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy; Behavior, Animal; Cognition; Corpu | 2019 |
Lactoferrin ameliorates dopaminergic neurodegeneration and motor deficits in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Behavior, Animal; Cell Line; Disea | 2019 |
5-(3,4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson's disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells aga
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Humans; Inflam | 2019 |
The toxin MPTP generates similar cognitive and locomotor deficits in hTau and tau knock-out mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Alzheimer Disease; Animals; Brain; Co | 2019 |
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Female; Locomotion; M | 2019 |
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Glycogen Synthase Kin | 2019 |
Norfluoxetine Prevents Degeneration of Dopamine Neurons by Inhibiting Microglia-Derived Oxidative Stress in an MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2018 |
A simple method to study motor and non-motor behaviors in adult zebrafish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Behavioral Research; Diseas | 2019 |
Apelin-13 protects dopaminergic neurons in MPTP-induced Parkinson's disease model mice through inhibiting endoplasmic reticulum stress and promoting autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Apelin; Autophagy; Beclin-1; | 2019 |
Reduced VMAT2 expression exacerbates the hyposmia in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2019 |
Hippocampal damage and white matter lesions contribute to cognitive impairment in MPTP-lesioned mice with chronic cerebral hypoperfusion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Brain; Brain Ischemia; Carotid Ste | 2019 |
Acupuncture Inhibits the Increase in Alpha-Synuclein by Modulating SGK1 in an MPTP Induced Parkinsonism Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; alpha-Synuclein; Animals; Chronic | 2019 |
Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Choli | 2019 |
MicroRNA-124 regulates the expression of p62/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Autophagy; Cell Line; Cell Line, T | 2019 |
Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytochrome P-450 CYP2D6; Disease Models, Anim | 2019 |
Telomerase gene therapy ameliorates the effects of neurodegeneration associated to short telomeres in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dependovirus; Disease Models, Animal; | 2019 |
Impairment of Nrf2- and Nitrergic-Mediated Gastrointestinal Motility in an MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; | 2019 |
MicroRNA-190 alleviates neuronal damage and inhibits neuroinflammation via Nlrp3 in MPTP-induced Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Brain; Cell Line, Tumor; Disease M | 2019 |
Kir6.1/K-ATP channel on astrocytes protects against dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease via promoting mitophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Astrocytes; Corpus St | 2019 |
Role of microtubule-associated protein 6 glycosylated with Gal-(β-1,3)-GalNAc in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, Affinity; Disease Models, Ani | 2019 |
miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antagomirs; Disease Models, Animal; Dopamine; | 2019 |
Angiogenin in Parkinson disease models: role of Akt phosphorylation and evaluation of AAV-mediated angiogenin expression in MPTP treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Cell Line, Tumor; Dependovirus; D | 2013 |
Endurance exercise training protects against the upregulation of nitric oxide in the striatum of MPTP/probenecid mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Male | 2013 |
Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Case-Control Studies; Ceruloplasmin; De | 2013 |
Neuronal loss in the caudal intralaminar thalamic nuclei in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholinesterase; Animals; Apoptosis; Calbindin 1; | 2014 |
Neuroprotective effects of puerarin on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease model in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2014 |
Photobiomodulation preserves behaviour and midbrain dopaminergic cells from MPTP toxicity: evidence from two mouse strains.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Disease Models, Animal; | 2013 |
Conditional disruption of calpain in the CNS alters dendrite morphology, impairs LTP, and promotes neuronal survival following injury.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; alpha-Amino-3-hydroxy-5-methyl-4-isoxazol | 2013 |
Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Analysis of Variance; Anim | 2013 |
Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; | 2013 |
Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adoptive Transfer; Animals; CD4-Positive T-Lymphocytes | 2013 |
Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Corpus Striatum; | 2014 |
Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood-Brain Barrier; Brain; Corpus Striatum; | 2013 |
Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Circadian Rhythm; Cognition | 2013 |
Reduced cholinergic olfactory centrifugal inputs in patients with neurodegenerative disorders and MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Alzheimer Disease; Animals; C | 2013 |
Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 2013 |
Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Corpus Striatum; | 2013 |
Cerebral metabonomics study on Parkinson's disease mice treated with extract of Acanthopanax senticosus harms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Disease Models, Animal; Dopamine; | 2013 |
Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-2-Associated X Protein; Disease Models, A | 2013 |
[Changes of glucose in the brains of monkeys with MPTP induced Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Fluorodeoxyglu | 2013 |
Dopamine receptor 3 might be an essential molecule in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Disease Models, Animal; | 2013 |
Neuroprotection by tetrahydroxystilbene glucoside in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis Regulatory Proteins; Ataxia; Behavi | 2013 |
Saffron pre-treatment offers neuroprotection to Nigral and retinal dopaminergic cells of MPTP-Treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Crocus; Disease Models, Animal; Dopaminergic | 2013 |
Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiogenesis Inducing Agents; Animals; Becaplermin; Ce | 2011 |
Imaging of superoxide generation in the dopaminergic area of the brain in Parkinson's disease, using mito-TEMPO.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Cyclic N-Oxides; Disease Models | 2013 |
Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acyclic Monoterpenes; | 2013 |
Olfaction in three genetic and two MPTP-induced Parkinson's disease mouse models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; alpha-Synuclein; Animals; | 2013 |
Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antioxidants; Be | 2014 |
Comparison of the neuroprotective potential of Mucuna pruriens seed extract with estrogen in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Estrogens; | 2014 |
Effects of the root bark of Paeonia suffruticosa on mitochondria-mediated neuroprotection in an MPTP-induced model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Disease | 2014 |
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Disease Models, | 2014 |
Parkinson's disease, lights and melanocytes: looking beyond the retina.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Female; Light; Male; | 2014 |
PEP-1-HO-1 prevents MPTP-induced degeneration of dopaminergic neurons in a Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cell Line, Tumor; Disease Models, | 2014 |
Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Disease Models, Animal; Dopamine; | 2014 |
Neuroprotective effects of mesenchymal stem cells through autophagy modulation in a parkinsonian model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; | 2014 |
Neuroprotective effects of tetramethylpyrazine against dopaminergic neuron injury in a rat model of Parkinson's disease induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Caspas | 2014 |
Human neural stem cells survive long term in the midbrain of dopamine-depleted monkeys after GDNF overexpression and project neurites toward an appropriate target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Line; Cell Lineage; Cell Shape; Cell Sur | 2014 |
Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Astrocytes; Chemistry, Pharmace | 2014 |
The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Blood-Brain Barrier; Brain; | 2014 |
Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calpain; Cell Death; Cells, Cultured; Cyclin- | 2014 |
In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Chromatography, High Pressure Liq | 2014 |
Protective effect of chinonin in MPTP-induced C57BL/6 mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2014 |
Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechol O-Methyltransf | 2014 |
Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cells, Cultured; Chaperonin 60; C | 2014 |
Impaired nerve conduction velocity in MPTP-treated mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2015 |
Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carboxylic Acids; Disease M | 2014 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; | 2015 |
[P38 MAPK signaling pathway regulates nuclear factor-κB and inducible nitric oxide synthase expressions in the substantia nigra in a mouse model of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Imidazoles; MAP Kinas | 2014 |
PRDX6 Exacerbates Dopaminergic Neurodegeneration in a MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Behavior, Animal; Cells, Cultured | 2015 |
Effect of monocrotophos, an organophosphorus insecticide, on the striatal dopaminergic system in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Mo | 2016 |
(1)H NMR-based metabolomics study on a goldfish model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2014 |
A novel compound VSC2 has anti-inflammatory and antioxidant properties in microglia and in Parkinson's disease animal model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptor Proteins, Signal Transducing; Animals; Anti-In | 2015 |
Protective effects of PEP-1-Catalase on stress-induced cellular toxicity and MPTP-induced Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Death; Cell Line; Cell Survival; | 2015 |
Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2014 |
Targeted toxicants to dopaminergic neuronal cell death.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Death; Dise | 2015 |
Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Disease Models, Animal; Dopaminergic N | 2014 |
Attenuation of neuroinflammatory responses and behavioral deficits by Ligusticum officinale (Makino) Kitag in stimulated microglia and MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Behavior, Animal; C | 2015 |
Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2015 |
Possible role of GABA-B receptor modulation in MPTP induced Parkinson's disease in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Baclofen; Cerebral Cortex; Corpus Striatum; C | 2015 |
MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Ag | 2015 |
Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Genetically Modified; Disease Models | 2015 |
Anti-neuroinflammatory effects of DPTP, a novel synthetic clovamide derivative in in vitro and in vivo model of neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Line; Cells, Cultured; Disease Mo | 2015 |
Parkinson Disease: Diffusion MR Imaging to Detect Nigrostriatal Pathway Loss in a Marmoset Model Treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Corpus Striatum; Diffusion Magnet | 2015 |
The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Amyotrophic Lateral Sclerosis; Animal | 2015 |
[Moving activity and wakefulness-sleep cycle changes in a mouse MPTP model of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Cerebral Cortex; Circadian Rhythm | 2014 |
Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Abietanes; Animals; Anti-Inflammatory Agents; Ants; Ce | 2015 |
Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Benzeneacetamides; Disease | 2015 |
Neuroprotective effects of 5-(4-hydroxy-3-dimethoxybenzylidene)-thiazolidinone in MPTP induced Parkinsonism model in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Benzylidene Compounds; Cell | 2015 |
Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-κB-dependent inflammation process in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Cell Line, Tumor; | 2015 |
Apoptotic Mediators are Upregulated in the Skeletal Muscle of Chronic/Progressive Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Apoptosis Regulatory Proteins; Cas | 2015 |
DJ-1-dependent protective activity of DJ-1-binding compound no. 23 against neuronal cell death in MPTP-treated mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzamides; Brain; Cell Death; Disease Models | 2015 |
Ameliorative effects of baicalein in MPTP-induced mouse model of Parkinson's disease: A microarray study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Proliferation; Disease Models, Animal; D | 2015 |
Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Cells, Cultured; Cerebral C | 2015 |
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arrestins; Behavior, Animal; beta-Arrestins; | 2015 |
Transcranial Direct Current Stimulation Ameliorates Behavioral Deficits and Reduces Oxidative Stress in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Glut | 2015 |
Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease | 2015 |
Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2015 |
Neuroprotective effects of ginkgetin against neuroinjury in Parkinson's disease model induced by MPTP via chelating iron.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antigens, CD; Ap | 2015 |
Pain perception in acute model mice of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Corpus Striatum; Disease Models, | 2015 |
A dysfunction of CD4+ T lymphocytes in peripheral immune system of Parkinson's disease model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; CD4-Positive T-Lymphocytes; Cell Differentiat | 2014 |
Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/β-catenin dependent pathways in a mice model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals | 2015 |
Ginsenoside Rg1 Ameliorates Motor Function in an Animal Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2015 |
Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease.
Topics: 1-Deoxynojirimycin; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Count; Cells, | 2015 |
Chronic MPTP treatment produces hyperactivity in male mice which is not alleviated by concurrent trehalose treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Hyp | 2015 |
Nrf2-ARE signals mediated the anti-oxidative action of electroacupuncture in an MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electroacupuncture; M | 2015 |
Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Basal Ganglia; Catalepsy; Disease | 2015 |
MPTP activates ASK1-p38 MAPK signaling pathway through TNF-dependent Trx1 oxidation in parkinsonism mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antibodies, Neutralizing; Corpus Striatum; Di | 2015 |
Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Caspase 3; Disease Mode | 2015 |
Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anisoles; Astrocytes; Cell Death; Disease Mod | 2015 |
Neuroprotective effects of 3-O-demethylswertipunicoside against MPTP-induced Parkinson's disease in vivo and its antioxidant properties in vitro.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biphenyl Comp | 2015 |
Transiently impaired neurogenesis in MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Bromodeoxyuridine; Calcium-Binding | 2015 |
Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arachidonic Acids; Benzodioxoles; Brain; Cell | 2015 |
Zingerone activates VMAT2 during MPP(+) -induced Cell Death.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Corpus Striatum; Disease Models, | 2015 |
Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/α-synuclein aggregation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Autophagy; Cyclin-Dependent | 2015 |
14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 14-3-3 Proteins; Adenoviridae; Analysis of Variance; A | 2015 |
Executive function deficits and glutamatergic protein alterations in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Brain; Cognition Disord | 2015 |
Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Sequence; Animals; Cyclin-Dependent Kinase | 2015 |
Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Caspas | 2015 |
Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Callithrix; Disease Models, | 2016 |
Silibinin suppresses astroglial activation in a mouse model of acute Parkinson's disease by modulating the ERK and JNK signaling pathways.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Antioxidants; Astrocytes; C | 2015 |
Dopaminergic lesioning impairs adult hippocampal neurogenesis by distinct modification of α-synuclein.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Bromodeoxyuridine; Cell Coun | 2016 |
Bee Venom Phospholipase A2, a Novel Foxp3+ Regulatory T Cell Inducer, Protects Dopaminergic Neurons by Modulating Neuroinflammatory Responses in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bee Venoms; Dinoprostone; Disease Models, Ani | 2015 |
Near-infrared light is neuroprotective in a monkey model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Inf | 2016 |
Neurobehavioral Anomalies in the Pitx3/ak Murine Model of Parkinson's Disease and MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Disease Models, Anim | 2016 |
Chronic and progressive Parkinson's disease MPTP model in adult and aged mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Aging; Animals; Catecholamines; Chronic D | 2016 |
Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adaptive Immunity; Ana | 2016 |
Anti-apoptotic effect of modified Chunsimyeolda-tang, a traditional Korean herbal formula, on MPTP-induced neuronal cell death in a Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apoptosis; bcl-2-Associ | 2015 |
Neuroprotective effects of piperine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkaloids; Animals; Anti-Inflammatory Agents; Apoptosi | 2015 |
Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Blood-Brain Barrier; Cell Li | 2016 |
Design and evaluation of mucoadhesive microemulsion for neuroprotective effect of ibuprofen following intranasal route in the MPTP mice model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adhesives; Administration, Intranasal; Animals; Corpus | 2016 |
Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Anti-Inflammatory Agents; Di | 2016 |
Aquaporin-4 mediates communication between astrocyte and microglia: Implications of neuroinflammation in experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aquaporin 4; Astrocytes; Cell Communication; | 2016 |
Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood-Brain Barrier; Brain; Disease Models, A | 2016 |
TLR4 signaling mediates AP-1 activation in an MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Behavior, Animal; Disease Models, | 2016 |
Alteration of nuclear factor-kappaB pathway promote neuroinflammation depending on the functions of estrogen receptors in substantia nigra after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Calcium-Binding Proteins; Cell Co | 2016 |
Inhibition of p38 pathway-dependent MPTP-induced dopaminergic neurodegeneration in estrogen receptor alpha knockout mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2016 |
Presymptomatic MPTP Mice Show Neurotrophic S100B/mRAGE Striatal Levels.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aldehydes; Animals; Corpus Striatum; Disease Models, A | 2016 |
Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Chronic Disease; Dis | 2016 |
Estrogen receptors modulate striatal metabotropic receptor type 5 in intact and MPTP male mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Corpus Str | 2016 |
In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Cell Death; Disease | 2016 |
Gene dysregulation is restored in the Parkinson's disease MPTP neurotoxic mice model upon treatment of the therapeutic drug Cu(II)(atsm).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calcium Signaling; Coordination Complexes; Di | 2016 |
Ceftriaxone prevents the neurodegeneration and decreased neurogenesis seen in a Parkinson's disease rat model: An immunohistochemical and MRI study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Brain; Brain Mapping; B | 2016 |
[Effect of Baichanting Compound on Dopamine Contents in Parkinson's Disease Model Mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Drugs, Chin | 2016 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease in zebrafish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Disease Models, Anim | 2016 |
Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Doco | 2016 |
Long Non-coding RNA HOTAIR Promotes Parkinson's Disease Induced by MPTP Through up-regulating the Expression of LRRK2.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Count; Cell Line, Tumor; Disease | 2016 |
Hericium erinaceus mycelium and its isolated erinacine A protection from MPTP-induced neurotoxicity through the ER stress, triggering an apoptosis cascade.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Agaricales; Animals; Apoptosis; Behavior, Animal; Brai | 2016 |
Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Disease Models, Animal; Dopaminer | 2016 |
Individual and Familial Susceptibility to MPTP in a Common Marmoset Model for Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Corpus Striatum; Disease Models, | 2016 |
Physical exercise counteracts MPTP-induced changes in neural precursor cell proliferation in the hippocampus and restores spatial learning but not memory performance in the water maze.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Bromodeoxyuri | 2016 |
MPTP neurotoxicity is highly concordant between the sexes among BXD recombinant inbred mouse strains.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2016 |
Aging-related 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurochemial and behavioral deficits and redox dysfunction: improvement by AK-7.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Behavior Rating Scale; Benzamides; Cor | 2016 |
Non-invasive, neuron-specific gene therapy by focused ultrasound-induced blood-brain barrier opening in Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; DNA; Dopamine; | 2016 |
Neuroprotective and anti-inflammatory effects of morin in a murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Anti-Inflammatory Agents; A | 2016 |
The Essential Role of Drp1 and Its Regulation by S-Nitrosylation of Parkin in Dopaminergic Neurodegeneration: Implications for Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2016 |
Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antigens, CD; Cell Line, Transformed; Disease | 2016 |
Resveratrol alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of α-synuclein via SIRT1-deacetylated LC3.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; alpha-Synuclein; Animals; Autophagy; Beha | 2016 |
Caspase-1 Deficiency Alleviates Dopaminergic Neuronal Death via Inhibiting Caspase-7/AIF Pathway in MPTP/p Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Chloromethyl Ketones; Animals; Apoptosis In | 2017 |
Near-infrared light treatment reduces astrogliosis in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Calcium-Binding Protein | 2016 |
Effects of a higher dose of near-infrared light on clinical signs and neuroprotection in a monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2016 |
Inhibitory effect of thiacremonone on MPTP-induced dopaminergic neurodegeneration through inhibition of p38 activation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Astrocytes; Behavio | 2016 |
Beta-asarone protects against MPTP-induced Parkinson's disease via regulating long non-coding RNA MALAT1 and inhibiting α-synuclein protein expression.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Allylbenzene Derivatives; alpha-Synuclein; Animals; An | 2016 |
Therapeutic effects of paeonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetophenones; Animals; Behavior, Animal; Brain-Derive | 2016 |
CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood-Brain Barrier; Cytokines; Disease Model | 2016 |
Subthalamic, not striatal, activity correlates with basal ganglia downstream activity in normal and parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Basal Ganglia; Brain Waves | 2016 |
Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals | 2017 |
Protective role of 6-Hydroxy-1-H-Indazole in an MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2016 |
A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2016 |
Antioxidant-Rich Fraction of Urtica dioica Mediated Rescue of Striatal Mito-Oxidative Damage in MPTP-Induced Behavioral, Cellular, and Neurochemical Alterations in Rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Behavior, Animal; Corpus Striat | 2017 |
δ-Aminolevulinate Dehydratase Activity is Stimulated in a MPTP Mouse Model of Parkinson's Disease: Correlation with Myeloperoxidase Activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Male; Mice, Inbred C5 | 2017 |
FAF1 mediates regulated necrosis through PARP1 activation upon oxidative stress leading to dopaminergic neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptor Proteins, Signal Transducing; Animals; Apoptos | 2016 |
α-lipoic acid exerts neuroprotective effects on neuronal cells by upregulating the expression of PCNA via the P53 pathway in neurodegenerative conditions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electron Transport Co | 2016 |
Effects of high-frequency stimulation of the internal pallidal segment on neuronal activity in the thalamus in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Deep Brain Stimulation; Di | 2016 |
Continuous MPTP intoxication in the Göttingen minipig results in chronic parkinsonian deficits.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Diseas | 2016 |
Mulberry fruit ameliorates Parkinson's-disease-related pathology by reducing α-synuclein and ubiquitin levels in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Corpus Striatu | 2017 |
Respiratory chain inhibition: one more feature to propose MPTP intoxication as a Leigh syndrome model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electron Transport; E | 2016 |
Proteomic Analysis of the Effect of Korean Red Ginseng in the Striatum of a Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blotting, Western; Corpus Striatum; Disease M | 2016 |
Puerarin prevents inflammation and apoptosis in the neurocytes of a murine Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Caspas | 2016 |
Effect of L-pGlu-(1-benzyl)-l-His-l-Pro-NH
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Ischemia; Catalepsy; Cell Death; Diseas | 2016 |
ASIC1a Deficient Mice Show Unaltered Neurodegeneration in the Subacute MPTP Model of Parkinson Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acid Sensing Ion Channels; Animals; Catecholamines; Di | 2016 |
Hederagenin and α-hederin promote degradation of proteins in neurodegenerative diseases and improve motor deficits in MPTP-mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenylate Kinase; alpha-Synuclein; Animals; Autophagy; | 2017 |
Rho kinase II interference by small hairpin RNA ameliorates 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine‑induced parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Biomarkers; Disease Models, | 2016 |
The behavioural and neuroprotective outcomes when 670nm and 810nm near infrared light are applied together in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2017 |
Injury-stimulated Sonic hedgehog expression in microglia contributes to neuroinflammatory response in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cells, Cultured; Disease Models, Animal; Hedg | 2017 |
Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antidepressive Agents; Disease Models, Animal | 2018 |
Gynostemma pentaphyllum Ethanolic Extract Protects Against Memory Deficits in an MPTP-Lesioned Mouse Model of Parkinson's Disease Treated with L-DOPA.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclic AMP Response Ele | 2017 |
The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2017 |
Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dendrites; Disease Models, Animal; Dopaminerg | 2017 |
Isobavachalcone Attenuates MPTP-Induced Parkinson's Disease in Mice by Inhibition of Microglial Activation through NF-κB Pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biomarkers; Cell Line; Chalcones; | 2017 |
Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amidohydrolases; Animals; Benzamides; Carbamates; Dise | 2019 |
Nesfatin-1 protects dopaminergic neurons against MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Calci | 2017 |
Activin A Inhibits MPTP and LPS-Induced Increases in Inflammatory Cell Populations and Loss of Dopamine Neurons in the Mouse Midbrain In Vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Activins; Animals; Cell Survival; Disease Models, Anim | 2017 |
Regulation of glutamate transporter trafficking by Nedd4-2 in a Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Amino Acid Transport Syst | 2017 |
Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Brain; Cell Count; Cholesterol; C | 2017 |
Rapamycin upregulates glutamate transporter and IL-6 expression in astrocytes in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Transport System X-AG; Animals; Astrocytes; | 2017 |
Chronic mild stress augments MPTP induced neurotoxicity in a murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Pharmaceutic; Animals; Body Weight; Brain-D | 2017 |
Early upregulation of 18-kDa translocator protein in response to acute neurodegenerative damage in TREM2-deficient mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Carrier Proteins; Disease Mode | 2017 |
Neuroprotective properties of icariin in MPTP-induced mouse model of Parkinson's disease: Involvement of PI3K/Akt and MEK/ERK signaling pathways.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromones; Corpus Striatum; Disease Models, A | 2017 |
The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; alpha-Synuclein; Animals; Autophagy; Cell | 2017 |
Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biphenyl Compounds; Corpus Striatum; Disease | 2017 |
Pramipexole restores depressed transmission in the ventral hippocampus following MPTP-lesion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzothiazoles; Dextroamphetamine; Disease Mo | 2017 |
The Cleavage Effect of Mesenchymal Stem Cell and Its Derived Matrix Metalloproteinase-2 on Extracellular α-Synuclein Aggregates in Parkinsonian Models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cell Line; Cell Survival; Cu | 2017 |
Expression of Cbl-interacting protein of 85 kDa in MPTP mouse model of Parkinson's disease and 1-methyl-4-phenyl-pyridinium ion-treated dopaminergic SH-SY5Y cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Adaptor Proteins, Signal | 2008 |
Development of a stable, early stage unilateral model of Parkinson's disease in middle-aged rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Animals; Disease Models, Animal; Drug Adm | 2008 |
A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Brain; Disease Models, | 2008 |
Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Caspase 3; Chi-Square D | 2008 |
Amiloride is neuroprotective in an MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acid Sensing Ion Channels; Acidosis, Lactic; Amiloride | 2008 |
Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Axons; Disease Models, Anima | 2008 |
Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson's-like disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Central Nervous System; Disease Models, Anima | 2008 |
Molecular imaging reveals a correlation between 2'-CH3-MPTP-induced neonatal neurotoxicity and dopaminergic neurodegeneration in adult transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Animals, Newborn; Brain; Disease Model | 2008 |
Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptation, Physiological; Analysis of Variance; Anima | 2008 |
Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Pharmaceutic; Animals; Brain; Chromatograph | 2008 |
Deep brain stimulation reduces neuronal entropy in the MPTP-primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Deep Brain Stimulation; Di | 2008 |
Significant effect of dimethylsulfoniopropionate on Parkinson's disease of senescence-accelerated mice induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Alzheimer Disea | 2008 |
Differential effects of the dopamine neurotoxin MPTP in animals with a partial deletion of the GDNF receptor, GFR alpha1, gene.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Count; Cell Survival; Disease Mod | 2008 |
Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Benza | 2008 |
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antip | 2008 |
Enhanced susceptibility to MPTP neurotoxicity in magnesium-deficient C57BL/6N mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Causality; Corpus Striatum; Disease Models, A | 2009 |
Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Analysis of Variance; Animals; Cell Death; Corp | 2008 |
Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: protective role of S-allylcysteine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Basal Ganglia; Behavior, Animal | 2008 |
Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Benzothiazoles; Brain; | 2008 |
Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the HALLWAY task.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Behavioral Sciences; Biomec | 2009 |
Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Corpus | 2009 |
Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Enteric Nervous Syste | 2009 |
Transplantation of embryonic stem cell-derived dopaminergic neurons in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Survival; Disease Mode | 2009 |
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not elicit long-lasting increases in cyclooxygenase-2 expression in dopaminergic neurons of monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Count; Cyclooxygenase | 2009 |
Effect of estradiol on striatal dopamine activity of female hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Biogenic Amines; Chromatogra | 2009 |
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix | 2009 |
Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Ataxia; Disease Models, Animal; | 2009 |
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Infarction; Cell Death; Cell Hypoxia; C | 2009 |
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disea | 2009 |
Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkaline Phosphatase; Animals; Astrocytes; Base Sequen | 2009 |
Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-2-Associated X Protein; Cell Survival; Ce | 2009 |
Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Analysis of Variance; Animals; Autoradiog | 2009 |
Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Female; Genetic Thera | 2009 |
Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; CD4-Positive T-Lymphocytes; CD8-Positi | 2009 |
Zocor Forte (simvastatin) has a neuroprotective effect against LPS striatal dopaminergic terminals injury, whereas against MPP+ does not.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 2009 |
Pyrethroid and organophosphate insecticide exposure in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease: an immunohistochemical analysis of tyrosine hydroxylase and glial fibrillary acidic protein in dorsolateral striatu
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chlorpyrifos; Disease Models, Animal; Drug Co | 2009 |
MPTP intoxication in mice: a useful model of Leigh syndrome to study mitochondrial diseases in childhood.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Basal Ganglia Diseases; Diseas | 2009 |
New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antibodies; Antiparkins | 2011 |
Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Callithrix; Disease Models, | 2009 |
Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Animals, Newborn; Cells | 2009 |
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; C | 2009 |
Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Corpus Striatum; Disease Mod | 2009 |
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2'-Deoxyguanosine; alpha-Synuclein; Analysis | 2009 |
WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzoxazines; Cannabinoid Receptor Agonists; | 2009 |
Primate adult brain cell autotransplantation, a pilot study in asymptomatic MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Cell Communication; Cell Mov | 2009 |
Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholine; Aging; Animals; Axons; Cell Death; Dise | 2009 |
JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anthracenes; Cell Death; Cyclooxygenase 2; Di | 2009 |
Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cyclooxygenase 2; Disease Models, Animal; DNA | 2009 |
Quantification of Paraquat, MPTP, and MPP+ in brain tissue using microwave-assisted solvent extraction (MASE) and high-performance liquid chromatography-mass spectrometry.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chromatography, High Pressure Liquid; | 2009 |
Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Analysis of Variance; Anim | 2010 |
Elevated interleukin-1beta induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine aggravating dopaminergic neurodegeneration in old male mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Aging; Animals; Biomarkers; Cytokines; Di | 2009 |
Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Corpus Str | 2009 |
Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Biogenic Monoamines; Brain; | 2009 |
Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chronic Disease; Disease Mo | 2009 |
Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Age Factors; Animals; Cell Line; Disease | 2009 |
Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopamine Pl | 2009 |
Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; ATP Binding Cassette Tr | 2009 |
Altered AMPA receptor expression with treadmill exercise in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Corpus Striatum; Disease Model | 2010 |
Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Hydrogen; L | 2009 |
Effects of pergolide mesilate on metallothionein mRNAs expression in a mouse model for Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Brain; Disease Models, Animal; | 2009 |
Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomechanical Phenomena; Chromatography, High | 2010 |
Oxidants induce alternative splicing of alpha-synuclein: Implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; alpha-Synuclein; Alternative Splici | 2010 |
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Cell Survival; Disease Models, Animal; | 2009 |
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiograph | 2010 |
Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzamides; Brain; Disease Models, Animal; En | 2010 |
Small peptide inhibitor of JNKs protects against MPTP-induced nigral dopaminergic injury via inhibiting the JNK-signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptor Proteins, Signal Transducing; Animals; Apoptos | 2010 |
Gene expression profile of acupuncture treatment in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Animals; Biomarkers; Databases, G | 2010 |
Neuroprotective effects of bee venom pharmaceutical acupuncture in acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Acute Disease; Animals; Bee Venom | 2010 |
Nest building performance following MPTP toxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Mo | 2010 |
[Neuroprotective effects and mechanisms of Chuanxiong Chatiao pulvis against MPTP-induced dopaminergic neurotoxicity in mice model of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Drugs, Chin | 2009 |
Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiency.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Glial Cell | 2009 |
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Death; Cycloheximi | 2010 |
[Effection of Qing-Xuan tablets on behavior pattern and striatal TNF-alpha of Parkinson model mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Mo | 2009 |
Exercise protects against MPTP-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytoprotection; Disease Models, Animal; Femal | 2010 |
Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cerebral Cortex; Corpus | 2010 |
Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cells, Cultured; Chronic Disease; Corp | 2010 |
Neuroprotective and neurotoxic phenotypes of activated microglia in neonatal mice with respective MPTP- and ethanol-induced brain injury.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Brain Injuries; Corpus Stri | 2010 |
Social odor recognition: a novel behavioral model for cognitive dysfunction in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Disease Models, Animal; | 2010 |
Detection of MPTP-induced substantia nigra hyperechogenicity in Rhesus monkeys by transcranial ultrasound.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Female; Humans; Macac | 2010 |
Dopaminergic cells in the periaqueductal grey matter of MPTP-treated monkeys and mice; patterns of survival and effect of deep brain stimulation and lesion of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Cell Survival; Deep Brain Stimula | 2010 |
Nicotine- and caffeine-mediated changes in gene expression patterns of MPTP-lesioned mouse striatum: Implications in neuroprotection mechanism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Base Sequence; Caffeine; Disease M | 2010 |
Ethyl pyruvate has a neuroprotective effect through activation of extracellular signal-regulated kinase in Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apop | 2010 |
Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Castration; Disease Models, Animal; Drug Tole | 2010 |
Post-MPTP treatment with granulocyte colony-stimulating factor improves nigrostriatal function in the mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Mo | 2010 |
Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2009 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease M | 2010 |
Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; C | 2010 |
Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Bezafibrat | 2010 |
VTA neurons show a potentially protective transcriptional response to MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytoprotection; Disease Models, Animal; Gene | 2010 |
Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2010 |
Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Behavior, Animal; Brain; Corticoster | 2010 |
Objective and quantitative evaluation of motor function in a monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Mapping; Carbon Radioisotopes; C | 2010 |
[Experimental modeling of functional deficiency of the nigrostriatal dopaminergic system in mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Axons; Corpus Striatum; Disease Models, Anima | 2010 |
Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Birth | 2010 |
Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Depre | 2010 |
Endurance exercise training promotes angiogenesis in the brain of chronic/progressive mouse model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antigens, CD34; Blood Vessels; Chronic Diseas | 2010 |
Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Mo | 2010 |
Dopaminergic cell damage and vulnerability to MPTP in Pink1 knockdown zebrafish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gene Knockdown Techni | 2010 |
Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Caspa | 2010 |
Neuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxicity in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Caspase 3; Cell | 2010 |
[Modeling of preclinical and early clinical stages of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2010 |
Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Analysis of Varianc | 2010 |
Computational physiology of the basal ganglia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Basal Ganglia; Chlorocebus | 2010 |
Elevation of oxidized DJ-1 in the brain and erythrocytes of Parkinson disease model animals.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Catecholamines; Chromatography, High P | 2010 |
[Oxidative processes and lipid metabolism in the experimental induced Parkinsonian syndrome].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Lipid Metabolism; Lip | 2010 |
[Optimization of counting process of dopaminergic neurons in substantia nigra of parkinsonian mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Disease Models, Animal; Dopamine; | 2010 |
Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cells, Cultured; Cytoprotection; Disease Mode | 2010 |
The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Area Under Curve; Benzoxazoles; Callithrix; D | 2010 |
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Brain-Derived Neurotrophic Factor; Corp | 2010 |
Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspase 3; Disease Models, Animal; | 2010 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease M | 2010 |
Assessment of metabolic changes in the striatum of a MPTP-intoxicated canine model: in vivo ¹H-MRS study of an animal model for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Choline; Corpus Striatum; Crea | 2011 |
Primary motor cortex of the parkinsonian monkey: differential effects on the spontaneous activity of pyramidal tract-type neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Analysis of Variance; Animals; Brai | 2011 |
Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Inhalation; Animals; Apoptosis; Base S | 2011 |
The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Docosahexaenoic Acids | 2010 |
A neuroprotective role for angiogenin in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cell Line, Tumor; Cytoprotection; | 2011 |
Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Corp | 2010 |
Modeling the motor striatum under Deep Brain Stimulation in normal and MPTP conditions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Algorithms; Animals; Basal Ganglia; Corpus Striatum; D | 2010 |
Modeling the effects of Deep Brain Stimulation on sensorimotor cortex in normal and MPTP conditions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Algorithms; Animals; Cerebral Cortex; Deep Brain Stimu | 2010 |
Polygalae radix inhibits toxin-induced neuronal death in the Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Brain; Caspase 3; Cell Death; D | 2011 |
The effect of docosahexaenoic Acid on visual evoked potentials in a mouse model of Parkinson's disease: the role of cyclooxygenase-2 and nuclear factor kappa-B.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Caspase 3; Cyclooxygena | 2011 |
[Effects of subchronic hemantane administration on dopamine and serotonin receptors in intact and MPP+-treated rat brain ex vivo].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Corpus Striatum; Disease Models, | 2010 |
Novel role of aquaporin-4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aquaporin 4; CD4 Antigens; Cells, Cultured; C | 2011 |
Low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor-κB reporter mice prior to loss of dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Astrocytes; Cell Death; | 2011 |
Bee venom reduces neuroinflammation in the MPTP-induced model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bee | 2011 |
Effect of intermittent washout periods on progressive lesioning of the nigrostriatal pathway with 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dise | 2011 |
Protective effects of synthetic kynurenines on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Cytosol; Disease Models, Ani | 2011 |
Mitochondrial permeability transition pore component cyclophilin D distinguishes nigrostriatal dopaminergic death paradigms in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; | 2012 |
Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclohexanols; Disease | 2011 |
The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Dopa | 2011 |
Molecular imaging of cell death in an experimental model of Parkinson's disease with a novel apoptosis-targeting peptide.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Apoptosis; Brain; Cell Count; Dis | 2012 |
Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dihydroxyphenylalanine; Dise | 2011 |
Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cells, Cultured; Coculture Techniques; Corpus | 2011 |
Involvement of the Fc gamma receptor in a chronic N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of dopaminergic loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Disease Models, Animal; DNA-Bindi | 2011 |
Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Brain; Brain Mapping; C | 2011 |
Endogenous morphine-like compound immunoreactivity increases in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; alpha-Methyltyrosine; Analysis of Variance; Anim | 2011 |
Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Analysis of Variance; Animals; bcl-2- | 2011 |
Neuroprotective effect of kaempferol against a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Ataxia; Corpus Striatum; Diseas | 2011 |
[Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Antiparkinson Agents; Disease Mod | 2011 |
Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Activity Cycles; Animals; Behavior, Animal; Cognition; | 2011 |
SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Aniline Compounds; Animals; Brai | 2011 |
Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Linolenic Acid; | 2011 |
Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Line; Disease Models, Animal; Fem | 2012 |
Asiaticoside: attenuation of neurotoxicity induced by MPTP in a rat model of Parkinsonism via maintaining redox balance and up-regulating the ratio of Bcl-2/Bax.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; bcl-2-Associated X Protein; Cor | 2012 |
Subthalamo-pallidal interactions underlying parkinsonian neuronal oscillations in the primate basal ganglia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antiparkinson Agents; Basa | 2011 |
Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Fema | 2012 |
Acupuncture enhances the synaptic dopamine availability to improve motor function in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Points; Acupuncture Therapy; Animals; Beha | 2011 |
The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Apolipoproteins E; Biog | 2012 |
Dangguijakyak-san protects dopamine neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity under postmenopausal conditions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-2-Associated X Protein; Behavior, Animal; | 2012 |
Harpagoside attenuates MPTP/MPP⁺ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antibodies; Axons; Cells, Cultured; Corpus St | 2012 |
Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Count; Corpus Stri | 2012 |
Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Brain; Disease Models, | 2012 |
Experimental modeling of preclinical and clinical stages of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopaminergic N | 2011 |
The translational value of the MPTP non-human primate model of Parkinsonism for deep brain stimulation research.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Deep Brain Stimulation; Disease Models, Anima | 2011 |
Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Age Factors; Animals; Anim | 2012 |
Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease involves cross talk between inflammatory and Wnt/β-catenin signaling pathways: functional consequences for neuropr
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; beta Catenin; Cells, Cultured; Coculture Tech | 2012 |
Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Angiotensin II Type 1 Receptor B | 2012 |
No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Binding Sites; Corpus Striat | 2012 |
MRI/SPECT-based diagnosis and CT-guided high-intensity focused-ultrasound treatment system in MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; High-Intensity Focuse | 2013 |
Protective effect of extract of Acanthopanax senticosus Harms on dopaminergic neurons in Parkinson's disease mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Caspase 3; Chromatog | 2012 |
Pegylated granulocyte colony-stimulating factor conveys long-term neuroprotection and improves functional outcome in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Chroma | 2012 |
Evidence of oligodendrogliosis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2013 |
MPTP-induced model of Parkinson's disease in heat shock protein 70.1 knockout mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2012 |
Mesenchymal stem cells augment neurogenesis in the subventricular zone and enhance differentiation of neural precursor cells into dopaminergic neurons in the substantia nigra of a parkinsonian model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromodeoxyuridine; Cell Proliferation; Cells, | 2012 |
Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Beha | 2012 |
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; | 2013 |
Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Apoptosis; bcl-2-Associated X P | 2013 |
Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Age Factors; Aging; An | 2012 |
Docosahexaenoic acid provides protective mechanism in bilaterally MPTP-lesioned rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Docosahexaenoic Acids | 2012 |
Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-Associated Death Protein; Cell Death; Dis | 2012 |
Dopaminergic neurons from midbrain-specified human embryonic stem cell-derived neural stem cells engrafted in a monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Transplantation; Disease Models, Animal; | 2012 |
Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Agmatine; Analysis of Vari | 2012 |
The neuroprotective effect of overexpression of calbindin-D(28k) in an animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Blotting, Western; Calbindi | 2013 |
LLDT-67 attenuates MPTP-induced neurotoxicity in mice by up-regulating NGF expression.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Astrocytes; Cells, Cultured | 2012 |
Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Brain; Calcium-Binding | 2012 |
Neuro-protective effects of bee venom by suppression of neuroinflammatory responses in a mouse model of Parkinson's disease: role of regulatory T cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bee Venoms; Disease Models, Animal; Dopaminer | 2012 |
PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Callithrix; Disease | 2012 |
The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chemokine CX3CL1; Corpus Striatum; Disease Mo | 2012 |
Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Dopa | 2013 |
Acorus gramineus inhibits microglia mediated neuroinflammation and prevents neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acorus; Animals; Anti-Inflammatory Agents; Cell Line; | 2012 |
Physical activity and environmental enrichment regulate the generation of neural precursors in the adult mouse substantia nigra in a dopamine-dependent manner.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2',3'-Cyclic-Nucleotide Phosphodiesterases; Adult Stem | 2012 |
Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Corpus Striatum; Diseas | 2012 |
S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Case-Control Studies; Cell Line; Diseas | 2012 |
PEP-1-ribosomal protein S3 protects dopaminergic neurons in an MPTP-induced Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2013 |
Evaluation of TorsinA as a target for Parkinson disease therapy in mouse models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; alpha-Synuclein; Animals; Disease Models | 2012 |
Acetylcholinesterase deficiency decreases apoptosis in dopaminergic neurons in the neurotoxin model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcholinesterase; Alk | 2013 |
Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; C | 2013 |
The MPTP/probenecid model of progressive Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chromatography, High Pressu | 2013 |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antioxidants; Antiparkinson Agent | 2013 |
Lithium's gene expression profile, relevance to neuroprotection A cDNA microarray study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gene Expression Regul | 2013 |
Da-Bu-Yin-Wan and Qian-Zheng-San, two traditional Chinese herbal formulas, up-regulate the expression of mitochondrial subunit NADH dehydrogenase 1 synergistically in the mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Biogenic Monoamines; Cerebr | 2013 |
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; | 2002 |
GABA-opioid interactions in the globus pallidus: [D-Ala2]-Met-enkephalinamide attenuates potassium-evoked GABA release after nigrostriatal lesion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cats; Disease Models, Anima | 2002 |
Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antiparkinson Agents; Brom | 2002 |
Effect of tomato intake on striatal monoamine level in a mouse model of experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Monoamines; Body Weight; Carotenoids | 2002 |
Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Corpus Striatum; Disease Models, | 2002 |
A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; DNA; Electrophoretic | 2002 |
Neuroimmunophilin ligand V-10,367 is neuroprotective after 24-hour delayed administration in a mouse model of diffuse traumatic brain injury.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Body Weight; Brain Inju | 2002 |
Role of nitric oxide synthase against MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; C | 2002 |
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Diben | 2002 |
Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Diseas | 2002 |
Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dose-Resp | 2002 |
Activation of the c-Jun N terminal kinase pathway in an animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; JNK | 2002 |
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, | 2003 |
Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Cell Count; Cell Death; Disease Models | 2003 |
Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Evaluation Studies as | 2003 |
Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Binding, Competitive; C | 2003 |
Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Brain; Cats; Choline; Corpus S | 2003 |
Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Death; Cell | 2003 |
Stimulation of the subthalamic nucleus changes the firing pattern of pallidal neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Behavior, Animal; Disease | 2003 |
Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Chronic Disease; Corpus Striat | 2003 |
NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Base Sequence; Disease Models, Animal; DNA Pr | 2003 |
LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Ac | 2003 |
Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Corpus Striatum; Disease Model | 2003 |
Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Aged; Aged, 80 and over; Animals; Behavi | 2003 |
Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Disease Models, Anim | 2003 |
Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dose-Respon | 2003 |
Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catechols; Disease Models, Animal; Macaca mul | 2003 |
Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2003 |
Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disea | 2003 |
Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Cell Death; Clorgyline; Disease | 2003 |
Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Ditiocarb; Dopamine; | 2003 |
Circadian determinations of cortisol, prolactin and melatonin in chronic methyl-phenyl-tetrahydropyridine-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Circadian Rhythm; Disease Models, | 2003 |
Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2003 |
Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Carotid Arteries; Cor | 2003 |
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2003 |
Primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Corpus Striatum; Disease Models, Anima | 2003 |
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Antiparkinson Agents | 2003 |
Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Animals; Blotting, Western; Chromatograp | 2003 |
MPP+ induces the endoplasmic reticulum stress response in rabbit brain involving activation of the ATF-6 and NF-kappaB signaling pathways.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Activating Transcription Factor 6; Animals; Basal Gang | 2003 |
Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Disease Mo | 2003 |
Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Caber | 2003 |
Depressed contractile function and adrenergic responsiveness of cardiac myocytes in an experimental model of Parkinson disease, the MPTP-treated mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Caffeine; Calcium; Cell Size; | 2004 |
MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Count; Corpus Striatum | 2004 |
Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Clinical Trials as Topic; Corpus | 2004 |
Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 2004 |
Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptation, Physiological; alpha7 Nicotinic Acetylchol | 2004 |
Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dose | 2004 |
Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspase Inhibitors; Caspases; Casp | 2004 |
Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Animals; Cell Death; Corpus Striatum; Di | 2004 |
Deep brain stimulation for Parkinson's disease: potential risk of tissue damage associated with external stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electric Stimulation; | 2004 |
Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Cell Count; Cerebral Cortex; | 2004 |
Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cyclic AMP-Dependent Protein Kinases; Disease | 2004 |
Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biomarkers; Calbindins; Corpus St | 2004 |
Immunization of rats with conjugates of dopamine and serotonin with bovine serum albumin prevents the development of experimental MPTP-induced depressive syndrome (electrophysiological parameters).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antibodies; Depression; | 2004 |
Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzopyrans; Brain; Callithrix; Disease Model | 2004 |
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adoptive Transfer; Animals; Coat Protein Complex I; Co | 2004 |
Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Female; Gene E | 2004 |
Selective recovery of striatal 125I-alpha-conotoxinmii nicotinic receptors after nigrostriatal damage in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Azetidines; Bridged Bicyclo Compounds, Hetero | 2004 |
Olfactory impairment and Parkinson's disease-like symptoms observed in the common marmoset following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Corpus Striatum; Disease Models, | 2004 |
Neuroprotective effects of Bak Foong Pill in 1-methyl-4-phenyl-1,2,3,6-tetrahyrdropyridine (MPTP)-induced Parkinson's disease model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Base Sequence; Disease Models, Animal; DNA Pr | 2004 |
Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Methyltyrosine; | 2004 |
Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Blotting, Western; | 2004 |
Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Cycle; Cell Death; Chronic Disease; Cyto | 2004 |
The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenocorticotropic Hormone; Animals; Anxiety; Disease | 2004 |
Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Disease Models, Animal; Dopami | 2004 |
Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allyl Compounds; Anima | 2004 |
An application of a new planar positron imaging system (PPIS) in a small animal: MPTP-induced parkinsonism in mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Brain; Disease Models, Animal; | 2004 |
Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disab | 2004 |
Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biological Transport; Cell Count; | 2004 |
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 2005 |
Vigilance states in a parkinsonian model, the MPTP mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arousal; Circadian Rhythm; Disease Models, An | 2004 |
Striatal preprotachykinin gene expression reflects parkinsonian signs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cats; Corpus Striatum; Dise | 2004 |
Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apoptosis; Behavior, Animal; Dep | 2005 |
Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Brain-Derived Neurot | 2004 |
The neurotoxicology of hard foraging and fat-melts.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Fats; Hunger; | 2004 |
Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Corpus Striatum; Disease Models, Anima | 2004 |
Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Brain-Derived Neurotrophic Factor; Dis | 2005 |
Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Cell Differentiation; Cell Line; | 2005 |
Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Survival; C | 2005 |
Chronic implantation of deep brain stimulation leads in animal models of neurological disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Brain; Brain Mapping; Deep | 2005 |
Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Apomorphine; Catechin; Disea | 2004 |
Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chronic Disease; Corpus Striatum; Cytoprotect | 2005 |
Immunization with myelin oligodendrocyte glycoprotein and complete Freund adjuvant partially protects dopaminergic neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage in mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Corpus | 2005 |
Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Disease Mo | 2005 |
Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cognition Disorders; Denervation; Disease Mod | 2005 |
Temporal evolution of mouse striatal gene expression following MPTP injury.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Corpus Striatum; Diseas | 2005 |
A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Calbindins; Callithrix; Cor | 2005 |
Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Anima | 2005 |
Selective glial cell line-derived neurotrophic factor production in adult dopaminergic carotid body cells in situ and after intrastriatal transplantation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Analysis of Variance; Animals; Animals, N | 2005 |
Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caloric Restriction; Corpus Striatum; Disease | 2005 |
In mice, production of plasma IL-1 and IL-6 in response to MPTP is related to behavioral lateralization.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Corpus | 2005 |
Cellular distribution of interleukin-1alpha-immunoreactivity after MPTP intoxication in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biomarkers; Corpus Striatum; Dise | 2005 |
MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Apoptosis; Bl | 2005 |
Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Analysis of Variance; Animals; Brai | 2005 |
Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Mo | 2005 |
Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acetates; Animals; Die | 2004 |
Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; B | 2005 |
Changes in cytoskeletal gene expression linked to MPTP-treatment in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Cyclic AMP; Cytoskeletal Pro | 2005 |
Norharman-induced motoric impairment in mice: neurodegeneration and glial activation in substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Carbolines; Caspase 3; Caspases; D | 2006 |
CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Apoptosis; Axotomy; Behavio | 2005 |
Unraveling substantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Disease Models, Animal; Dise | 2005 |
Differential survival patterns among midbrain dopaminergic cells of MPTP-treated monkeys and 6OHDA-lesioned rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Cell Survival; Disease Mod | 2005 |
Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzoquinones; Blotting, Western; Brain; Cell | 2005 |
Cell survival patterns in the pedunculopontine tegmental nucleus of methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys and 6OHDA-lesioned rats: evidence for differences to idiopathic Parkinson disease patients?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Survival; Disease Mode | 2005 |
MTH1, an oxidized purine nucleoside triphosphatase, protects the dopamine neurons from oxidative damage in nucleic acids caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; DNA | 2006 |
Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Aged, 80 and over; Animals; Astrocytes; C | 2006 |
Down-regulation of metabotropic glutamate receptor 1alpha in globus pallidus and substantia nigra of parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Behavior, Animal; Benzoate | 2005 |
Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Proliferation; Disease Models, Animal; D | 2006 |
Cerebellar neurotransmission in attention-deficit/hyperactivity disorder: does dopamine neurotransmission occur in the cerebellar vermis?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2006 |
Pramipexole protects against MPTP toxicity in non-human primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antioxidants; Benzothia | 2006 |
Lesions in monkey globus pallidus externus exacerbate parkinsonian symptoms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Analysis of Variance; Animals; Apom | 2006 |
Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Chorea; Disease Models, Animal; F | 2006 |
Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Blotting, Western; Disease Models, | 2006 |
In vivo complementation of complex I by the yeast Ndi1 enzyme. Possible application for treatment of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dependovirus; Disease Models, Animal; Electro | 2006 |
Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Basal Ganglia; Cell Cou | 2006 |
Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Nor | 2006 |
Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Aging; Animals; Brain; Cell Death; Corpus | 2006 |
Use-dependent behavioral and neurochemical asymmetry in MPTP mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Chemistry; Corpus Str | 2007 |
Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Apoptotic Protease-Activating Fact | 2006 |
Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood-Brain Barrier; Cell Count; Disease Mode | 2006 |
Can a single subunit yeast NADH dehydrogenase (Ndi1) remedy diseases caused by respiratory complex I defects?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electron Transport Co | 2006 |
Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Amines; Cattle; Cell-Free System; Co | 2006 |
Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Count; Cyclic GMP; | 2006 |
Wld(S) mice are protected against the Parkinsonian mimetic MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Blotting, Western; Brai | 2006 |
Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Dieldrin; Disease Models, A | 2006 |
The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Behavior, Animal; | 2006 |
MPTP treatment impairs tyrosine hydroxylase immunopositive fibers not only in the striatum, but also in the amygdala.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amygdala; Animals; Axons; Corpus Striatum; Disease Mod | 2005 |
Ebselen effects on MPTP-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Azoles; Brain; Cell Line, Tumor | 2006 |
Evidence of apoptosis in the subventricular zone and rostral migratory stream in the MPTP mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspase 3; Caspases; Cell Count; C | 2006 |
In vivo modulation of the Parkinsonian phenotype by Nrf2.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antineoplastic Agents; Autoradiography; Cocai | 2006 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine | 2006 |
Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dopamine | 2006 |
Changes in the neuronal activity in the pedunculopontine nucleus in chronic MPTP-treated primates: an in situ hybridization study of cytochrome oxidase subunit I, choline acetyl transferase and substance P mRNA expression.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholine; Animals; Biomarkers; Choline O-Acetyltr | 2007 |
Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Cell Death; Cell Lin | 2007 |
Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Basal Ganglia Disease | 2007 |
Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acetylcholinesterase; | 2006 |
Effects of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Attention; Behavior, An | 2006 |
Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Corpus Striatum; Diseas | 2007 |
Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; | 2007 |
Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Chemokine CCL2; Chemokines; C | 2007 |
Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Animals; Disease Models, Animal; Dopamine | 2007 |
Neuroprotection in Parkinson models varies with toxin administration protocol.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antigens, Nuclear; Axons; Benzothiazoles; Bio | 2006 |
CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adoptive Transfer; Animals; Antineoplastic Combined Ch | 2007 |
SPECT imaging, immunohistochemical and behavioural correlations in the primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Disea | 2007 |
Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acyl Coenzyme A; Analysis of Variance; Animals; Bezafi | 2007 |
Pre-training to find a hidden platform in the Morris water maze can compensate for a deficit to find a cued platform in a rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptation, Physiological; Analysis of Variance; Anima | 2007 |
Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Anesthetics, Combined; Animals; Biogenic Monoamines; C | 2007 |
Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Survival; Chemokines; Corpus Stri | 2007 |
Protocol for the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Model | 2007 |
Estimation of D2-like receptor occupancy by dopamine in the putamen of hemiparkinsonian Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Kine | 2008 |
Manganese does not alter the severe neurotoxicity of MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2007 |
Effect of acute administration of hydroalcohol extract of Ilex paraguariensis St Hilaire (Aquifoliaceae) in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Hydroxyl Radical; Ile | 2007 |
'Rejuvenation' protects neurons in mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Antiparkinson Agents; Calcium; Calcium | 2007 |
Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Factor Xa; | 2007 |
Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Azetidines; Behavior, A | 2007 |
Taurine fails to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Corpus Striatum; Disease Models, Anima | 2008 |
[Effect of phosphorylated c-Jun expression on COX-2 expression in the substantia nigra of MPTP mouse model of subacute Parkinson disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anthracenes; Blotting, Western; Cell Death; C | 2007 |
Endurance exercise promotes cardiorespiratory rehabilitation without neurorestoration in the chronic mouse model of parkinsonism with severe neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Calorimetry, Indirect; Citr | 2007 |
Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Inhala | 2007 |
Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cyclooxygenase 2; Disease Models, Animal; Dru | 2007 |
Changes in the rates of the tricarboxylic acid (TCA) cycle and glutamine synthesis in the monkey brain with hemiparkinsonism induced by intracarotid infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): studies by non-invasive 13C-magnetic reso
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Brain; Carbon Isotopes; Citric | 2007 |
Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Disea | 2008 |
Paraquat: the red herring of Parkinson's disease research.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Humans; Molecu | 2007 |
Alteration in the differentiation-related molecular expression in the subventricular zone in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Biomarkers; Caspases; Caspases | 2008 |
Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Disease Mo | 2007 |
Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animal Feed; Animals; Coenzymes; Disease Models, Anima | 2008 |
Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-X Protein; Disease Models, Animal; Dopami | 2008 |
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Disease Models, Animal; Diseas | 2007 |
A model of MPTP-induced Parkinson's disease in the goldfish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acclimatization; Animals; Brain; Disease Models, Anima | 2007 |
Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2008 |
Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Benzhydryl Compounds; Biomarke | 2008 |
Visualization of monoaminergic neurons and neurotoxicity of MPTP in live transgenic zebrafish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Genetically Modified; Biogenic Monoa | 2008 |
Low-pass filter properties of basal ganglia cortical muscle loops in the normal and MPTP primate model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Behavior, Animal; Brain Ma | 2008 |
Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cystamine; Disease Models, Animal; Dru | 2008 |
Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Cytoprotectio | 2008 |
Quantitative gene expression profiling of mouse brain regions reveals differential transcripts conserved in human and affected in disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Conserved Sequence; Databases, Genetic | 2008 |
Proteasome inhibitor does not enhance MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cysteine Proteinase Inhibitors; Disease Model | 2008 |
Pallidal burst activity during therapeutic deep brain stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Behavior, Animal; Deep Bra | 2008 |
PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Disease Models, Animal; | 2008 |
Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype in mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Caffeine; Central Nervo | 2008 |
Globus pallidus plays a critical role in neurotrophic factor induced functional improvements in hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2008 |
Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Curcumin; Dis | 2008 |
Striatal histone modifications in models of levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; Animals; Chromatin; Chromosome Aberration | 2008 |
Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2008 |
Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Analysis of Variance; Aniline Compo | 2008 |
[Changes of amino acids neurotransmitters in striatum of hemi-parkinsonian rhesus monkey after high frequency stimulation of subthalamic nucleus].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Chromatography, High Pressure Li | 2007 |
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Disease Models, Anima | 1983 |
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects locomotor activity without producing a nigrostriatal lesion in the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Corpus Striatum; De | 1984 |
Monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Animals; Cats; Disease Models, Animal; Haplorhi | 1983 |
Trail of ironies to Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Haplorhini; Humans; P | 1984 |
Street drugs yield primate Parkinson's model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Animals; Disease Models, Animal; Humans; Illici | 1983 |
Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Diseases; Disease | 1984 |
Alteration of corticotropin-releasing factor immunoreactivity in MPTP-treated rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amygdala; Animals; Corticotropin-Releasing Hormone; Di | 1995 |
Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Autoradiography; Callit | 1995 |
Behavioral involvement of central dopamine D1 and D2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Disease Models | 1995 |
Adrenal medulla and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Carbidopa; Catecholamines; D | 1994 |
[An animal model of peptic ulcer induced by destruction of dopaminergic neurons].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Drug Administration R | 1994 |
Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; A | 1994 |
N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromocriptine; Disease Models, Animal; Domina | 1994 |
Parkinsonism induced with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cats: behavioral, biochemical and pathological studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Catecholamines; Cats; Disea | 1993 |
N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Diz | 1993 |
Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1993 |
[The characteristics of a parkinsonian syndrome induced in an experiment by a deficiency of nigrostriatal dopamine and by stimulation of the cholinergic neurons of the caudate nucleus].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcholine; Animals; C | 1993 |
Development of a model for Parkinson's disease in sheep using unilateral intracarotid injection of MPTP via slow continuous infusion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Carotid Arteries; Ca | 1994 |
Immunological changes in the MPTP-induced Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antibody-Producing Cells; Cell Migration Inhi | 1993 |
Developing a stable bilateral model of parkinsonism in rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Carotid Arteries; Disease Models, | 1993 |
[The effect of parlodel on development of depressive syndrome in rats, caused by administering 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Bromocriptine; Depressive D | 1995 |
GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 1995 |
ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 1996 |
[Intrathecal infusion of brain-derived neurotrophic factor protects nigral dopaminergic neurons from degenerative changes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced monkey parkinsonian model].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Cricetinae | 1995 |
Biochemical evaluations in skeletal muscles of primates with MPTP Parkinson-like syndrome.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electron Transport Co | 1995 |
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; C | 1995 |
No NO prevents parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Enzyme Inhi | 1996 |
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Model | 1996 |
Synthesis and muscarinic activities of 3-(pyrazolyl)-1,2,5,6-tetrahydropyridine derivatives.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Analysis of Variance; Animals; Bind | 1996 |
Alterations in pallidal neuronal responses to peripheral sensory and striatal stimulation in symptomatic and recovered parkinsonian cats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Afferent Pathways; Animals; Behavior, Animal; Brain Ch | 1995 |
Dopamine D1 receptor desensitization profile in MPTP-lesioned primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Benzopyrans; Disease Models, Anim | 1996 |
High frequency stimulation of the internal Globus Pallidus (GPi) simultaneously improves parkinsonian symptoms and reduces the firing frequency of GPi neurons in the MPTP-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Globus Pallidus; Maca | 1996 |
Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cells, Cultured; Chickens; | 1997 |
Presymptomatic revelation of experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Kyn | 1997 |
In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acridine Orange; Animals; Apoptosis; Cats; Cell Nucleu | 1997 |
Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzophenones; Catechol O-Methyltransferase; | 1997 |
Selective full dopamine D1-like (SKF-82958) and D2-like (N-0923) agonist combination in the MPTP monkey model of hemiparkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Disease Models, Animal; Dopamin | 1997 |
Mitochondrial toxins in models of neurodegenerative diseases. I: In vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Azides; Brain; Disease Models, Animal; Dopami | 1997 |
Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Corpus Striatum; Disease Model | 1997 |
Kinetics of nigral degeneration in a chronic model of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Death; Chronic Dis | 1997 |
A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cell Count; Chronic Dis | 1997 |
Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflamma | 1997 |
Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Brain; Catalase; Disease Models | 1997 |
Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 1998 |
Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Benzofurans; Brain Tissue Tr | 1998 |
Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Cell Death; Corpus Striatum; Denervati | 1998 |
A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 1998 |
Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Disease Models, Animal; Dopamine; | 1998 |
The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Corpus Striatu | 1998 |
[Behaviour after transplantation of brain cells into monkey models of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Fet | 1997 |
Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Behavior, Animal; Disease Mo | 1998 |
Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; B | 1998 |
[Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Cutaneous; Aged; Animals; Antiparkinso | 1998 |
Protective effect of talipexole on MPTP-treated planarian, a unique parkinsonian worm model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Azepines; Brain; Disease Models, Animal; Dopa | 1998 |
Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Carbon Radioisotopes; Corpus Striatum; | 1998 |
Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Benzopyrans; Callithrix; Disease | 1999 |
Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Biomarkers; Cocaine; Disease Models, An | 1999 |
Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiotensin-Converting Enzyme Inhibitors; Animals; Cor | 1999 |
A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biological Availability; Body Weight; Circadi | 1999 |
Convection-enhanced selective excitotoxic ablation of the neurons of the globus pallidus internus for treatment of parkinsonism in nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Albumins; Animals; Antiparkinson Agents; Disease Model | 1999 |
Apomorphine protects against MPTP-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; A | 1999 |
Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease | 1999 |
The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Antagonists; Animals; Antiparkinson Agents; | 1999 |
A new video/computer method to measure the amount of overall movement in experimental animals (two-dimensional object-difference method).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Callithrix; Computer Storage Dev | 1999 |
Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflamma | 1999 |
Differential regulation of striatal dopamine D(1) and D(2) receptors in acute and chronic parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Benzazepines; Chronic Disease; | 1999 |
Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Disease Models, | 1999 |
Pesticide study aids Parkinson research.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Insecticides; | 1999 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chlorocebus aethiops; Disea | 2000 |
Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disea | 2000 |
The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 2000 |
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Carbidopa; | 2000 |
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodiazepines; Dioxoles; Disease Models, An | 2000 |
Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus S | 2000 |
The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Disease M | 2000 |
Autoradiographic analysis of N-methyl-D-aspartate receptor binding in monkey brain: effects of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine and levodopa treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain Chemistry; Disease Mod | 2000 |
Dopamine-receptor stimulation: biobehavioral and biochemical consequences.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease | 2000 |
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Antigens, CD; Dihydroxyphenylalanine; | 2000 |
Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Biological Clocks; Chloroc | 2000 |
Activity of pallidal and striatal tonically active neurons is correlated in mptp-treated monkeys but not in normal monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Biological Clocks; Chloroc | 2001 |
Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Prote | 2001 |
Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Brain; Disease Models, Anima | 2001 |
Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2001 |
cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Gene Expres | 2000 |
Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzoates; Brain-Derived Neurotrophic Factor; | 2001 |
Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; beta-Synuclein; Cell Line; C | 2001 |
Neuroprotective aspects of a novel MAO-B inhibitor PF9601N.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2000 |
Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Base Sequence; bcl-2-Associated X Protein; Di | 2001 |
Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspase 8; Caspase 9; Caspases; Di | 2001 |
Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Binding, Competitive; Catecholam | 2001 |
Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspase 3; Caspases; Disease Model | 2001 |
Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Benzoates; Cocaine; Corpus Str | 2001 |
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caffeine; Cat | 2001 |
Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Cognition Disorders; Corpus | 2001 |
Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Binding Sites; Binding, Comp | 2001 |
Evidence for target-specific outgrowth from subpopulations of grafted human dopamine neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Tissue Transplantation; Disease Models, | 2001 |
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiograp | 2001 |
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Drug Ther | 2001 |
Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior | 2001 |
Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Axons; Brain; Cell Death; Chro | 2001 |
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Callithrix; Disease Models, Anim | 2001 |
Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding, Competitive; Corpus Striatum; Diseas | 2001 |
Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; BH3 Interacting Domain Death Agonist Protein; | 2001 |
Novel observations with FDOPA-PET imaging after early nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dihydroxyphenylalanine; Dise | 2001 |
Effects of transient focal inactivation of the basal ganglia in parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Behavior, Animal; Disease | 2002 |
Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Callithrix; Disease Models, | 2002 |
Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Dependo | 2002 |
Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alanine; Animals; Apomorphine; Autoradiography; Bindin | 2002 |
[Treatment of neurodegenerative diseases: new perspectives].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Corpus Striatum; De | 2001 |
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Bacterial Agents; Astrocytes; Corpus Str | 2002 |
Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antineoplastic A | 2002 |
The distribution of copper, zinc- and manganese-superoxide dismutase, and glutathione peroxidase messenger ribonucleic acid in rat basal ganglia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Copper; Disease Models, Animal | 2002 |
Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; alpha-Synuclein; Amphetamine; Animals; Behavior | 2002 |
Method for culturing postnatal substantia nigra as an in vitro model of experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Cell Survival; Chimera; Coc | 2002 |
Enhanced synchrony among primary motor cortex neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Arm; Biomechanical Phenome | 2002 |
[The effect of amiridin on the MPTP-induced Parkinson-like syndrome in monkeys].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Behavior, Animal; Cholineste | 1992 |
Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Disease Mod | 1992 |
Disappearance of circadian rhythms in Parkinson's disease model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in dogs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aldosterone; Animals; Circadian Rhythm; Disease Models | 1992 |
Dopamine fiber detection by [11C]-CFT and PET in a primate model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cocaine; Disease Models, Animal; Dopamine; Im | 1992 |
A parkinsonian syndrome induced in the goldfish by the neurotoxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Gold | 1992 |
MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Caudate Nucleus; | 1992 |
Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Par
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 1991 |
MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Corpus Striatum; Disease Models, Anima | 1990 |
Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1991 |
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Ac | 1991 |
Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Tissue Transplantatio | 1991 |
Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Atropine; Clonidine; Disease Models, Animal; | 1991 |
Hemiparkinsonism in monkeys following unilateral common carotid artery infusion of MPTP. A study of behavior, biochemistry and histology.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carotid Arteries; Disease Models, Animal; Fem | 1991 |
Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Brain; | 1990 |
Gangliosides prevent MPTP toxicity in mice--an immunocytochemical study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gangliosides; Male; M | 1990 |
Chronic low-dose MPTP in nonhuman primates: a possible model for attention deficit disorder.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Attention; Attention Deficit Disorder with Hy | 1991 |
Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; C | 1991 |
[Recovery of nigrostriatal and mesolimbic dopaminergic system following administration of ganglioside in MPTP-treated mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Fibers; Age Factors; Animals; Corpus Striat | 1990 |
[Experimental research on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian animal models in the rhesus monkey and C57 black mouse].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Disease Models, Animal; Dopa | 1990 |
MAO-B and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Platelets; Disease Models, Animal; Huma | 1990 |
Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Body Weight; Corpus Striatum; Di | 1990 |
Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Tissue Transplantation; Caudate Nucleus | 1990 |
Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Apomorphine; Behavior, Anima | 1990 |
CCK-8S inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Indu | 1990 |
Role of reactive oxygen species in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Line; Cell Survival; Disease Models, Ani | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Callitrichinae; Cholecystoki | 1986 |
The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucle | 1985 |
A sheep model for MPTP induced Parkinson-like symptoms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Disease M | 1989 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not destroy nigrostriatal neurons in the scorbutic guinea pig.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Ascorbic Acid | 1985 |
Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chlorocebus aethiops; Disease Models, Animal; | 1986 |
Timing of levodopa therapy: evidence from MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Levodopa; Macaca fasc | 1987 |
MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Diseas | 1987 |
An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callitrichinae; Cell Count; Disease Models, A | 1987 |
Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Carotid Arteries; Corpus Str | 1986 |
Saccadic eye movement deficits in the MPTP monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Eye Movements; gamma- | 1986 |
Nigral and adrenal grafts in parkinsonism: recent basic and clinical studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Caudate Nucleus; Chromaffin | 1987 |
The potential use of vitamin E and selenium in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Hydroxydopami | 1986 |
The MPTP story: an introduction.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Haplorhini; Humans; P | 1986 |
Pathophysiology and biochemical mechanisms involved in MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Disease M | 1987 |
L-deprenyl in prevention of MPTP induced depletion of striatal enkephalins in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Enke | 1988 |
Study on MPTP-induced parkinsonian animal model in rhesus monkey and the mechanism of MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Macaca mulatta; Male; | 1988 |
[A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carbidopa; Disease Models, | 1985 |
MPTP in mice: treatment, distribution and possible source of contamination.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Environmental Exposur | 1988 |
Amine fluorescence histochemical investigation of the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced parkinsonian mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 1988 |
The partial dopamine receptor agonist terguride in the MPTP-induced hemiparkinsonian monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Ergolines; Female; Li | 1988 |
A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Equ | 1988 |
Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Deoxy Sugars; Deoxyglucose; Di | 1986 |
Parkinson-like syndrome in nonhuman primates receiving a tetrahydropyridine derivative.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Atrophy; Brain; Disease Models, Animal; Femal | 1986 |
Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Brain; Brain Chemistry; Carbidop | 1986 |
[Experimental model of Parkinson disease induced by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Mice; Parkinson Disea | 1986 |
Recent research advances in Parkinson's disease: Part I.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Levodopa; Par | 1986 |
"In vivo" visualization by positron emission tomography of the progressive striatal dopamine receptor damage occurring in MPTP-intoxicated non-human primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromine; Corpus Striatum; Disease Models, Ani | 1986 |
Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 1986 |
Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Deoxyglucose; Disease | 1987 |
Similarity and dissimilarity of MPTP models to Parkinson's disease: importance of juvenile parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Animals; Disease Models, Animal; Humans; Parkin | 1987 |
Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Indu | 1987 |
The use of the MPTP-treated mouse as an animal model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1987 |
Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1987 |
Alterations of the muscarinic cholinergic (mACh) receptors in the striatum of the MPTP-induced parkinsonian model in mice: in vitro quantitative autoradiographical analysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Corpus Striatum; Disease Mod | 1987 |
Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Corpus Striatum; Disease Mod | 1985 |
New amphibian models for the study of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain Chemistry; | 1985 |
MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electromyography; Mac | 1985 |
A simple quantitative bradykinesia test in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Disease Models, Animal; Dopa | 1985 |